



National Comprehensive
Cancer Network®

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic

Version 1.2020 — December 4, 2019

NCCN.org

Continue



National
Comprehensive
Cancer
Network®

NCCN Guidelines Version 1.2020

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic

[NCCN Guidelines Index](#)

[Table of Contents](#)

[Discussion](#)

***Mary B. Daly, MD, PhD/Chair** † Δ
Fox Chase Cancer Center

***Robert Pilarski, MS, LGC/Vice-chair** Δ
The Ohio State University Comprehensive
Cancer Center - James Cancer Hospital
and Solove Research Institute

Michael P. Berry, MD ¶
St. Jude Children's Research Hospital/
The University of Tennessee
Health Science Center

Saundra S. Buys, MD ‡ † †
Huntsman Cancer Institute
at the University of Utah

Patricia Dickson, MD Δ
Siteman Cancer Center at Barnes-
Jewish Hospital and Washington
University School of Medicine

Susan M. Domchek, MD †
Abramson Cancer Center
at the University of Pennsylvania

Ahmed Elkhanany, MD †
O'Neal Comprehensive Cancer Center at
UAB

Susan Friedman, DVM ¥
FORCE: Facing Our Risk of Cancer
Empowered

Judy E. Garber, MD, MPH †
Dana-Farber/Brigham and
Women's Cancer Center

Michael Goggins, MD ✎
The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins

Mollie L. Hutton, MS, CGC Δ
Roswell Park Comprehensive Cancer Center

Seema Khan, MD ¶
Robert H. Lurie Comprehensive Cancer
Center of Northwestern University

Catherine Klein, MD † †
University of Colorado Cancer Center

Wendy Kohlmann, MS, CGC Δ
Huntsman Cancer Institute
at the University of Utah

Allison W. Kurian, MD, MSc † † Δ
Stanford Cancer Institute

Christine Laronga, MD ¶
Moffitt Cancer Center

Jennifer K. Litton, MD †
The University of Texas
MD Anderson Cancer Center

Julie S. Mak, MS, LCGC Δ
UCSF Helen Diller Family
Comprehensive Cancer Center

Carolyn S. Menendez, MD ¶ Δ
Duke Cancer Institute

Sofia D. Merajver, MD, PhD ‡ † †
University of Michigan
Rogel Cancer Center

Barbara S. Norquist, MD Ω
Fred Hutchinson Cancer Research Center/
Seattle Cancer Care Alliance

Kenneth Offit, MD † † Δ
Memorial Sloan Kettering Cancer Center

Tuya Pal, MD Δ
Vanderbilt-Ingram Cancer Center

Holly J. Pederson, MD Δ
Case Comprehensive Cancer Center/
University Hospitals Seidman Cancer Center
and Cleveland Clinic Taussig Cancer Institute

Gwen Reiser, MS, CGC Δ
Fred & Pamela Buffett Cancer Center

Kristen Mahoney Shannon, MS, CGC † Δ
Massachusetts General Hospital
Cancer Center

Kala Visvanathan, MD, MHS † †
The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins

Jeffrey N. Weitzel, MD † ‡ Δ
City of Hope National Medical Center

Myra J. Wick, MD, PhD Ω Δ
Mayo Clinic Cancer Center

Kari B. Wisinski, MD †
University of Wisconsin
Carbone Cancer Center

Matthew B. Yurgelun, MD † †
Dana-Farber/Brigham and
Women's Cancer Center

¶ Breast surgical oncology
Δ Cancer/Medical genetics
✎ Gastroenterology
Ω Gynecologic oncology/Gynecology
‡ Hematology/Hematology oncology
† Internal medicine
† Medical oncology
¥ Patient advocacy
*Discussion Writing Committee Member

Continue

NCCN
Susan Darlow, PhD
Mary Dwyer, MS

[NCCN Guidelines Panel Disclosures](#)



National
Comprehensive
Cancer
Network®

NCCN Guidelines Version 1.2020

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic

[NCCN Guidelines Index](#)

[Table of Contents](#)

[Discussion](#)

[NCCN Genetic/Familial High-Risk Assessment Panel Members](#)

[Summary of the Guidelines Updates](#)

[Approach to Cancer History \(EVAL-1\)](#)

[Principles of Cancer Risk Assessment and Counseling \(EVAL-A\)](#)

[Pedigree: First-, Second-, and Third-Degree Relatives of Proband \(EVAL-B\)](#)

Hereditary Testing Criteria

[Testing Criteria for High-Penetrance Breast and Ovarian Cancer Susceptibility Genes \(CRIT-1\)](#)

[Testing Criteria for Pancreatic Cancer Susceptibility Genes \(CRIT-3\)](#)

[Testing Criteria for Li-Fraumeni Syndrome \(CRIT-4\)](#)

[Testing Criteria for Cowden Syndrome/PTEN Hamartoma Tumor Syndrome \(CRIT-5\)](#)

Genetic Testing Process

[Testing Criteria Met \(GENE-1\)](#)

[Cancer Risk Management Based on Genetic Test Results \(GENE-A\)](#)

Management/Screening

[BRCA Pathogenic/Likely Pathogenic Variant-Positive Management \(BRCA-A\)](#)

[Pancreatic Cancer Screening \(PANC-A\)](#)

[Li-Fraumeni Syndrome Management in Adults \(LIFR-A\)](#)

[Cowden Syndrome/PHTS Management \(COWD-A\)](#)

Clinical Trials: NCCN believes that the best management for any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN Member Institutions, [click here: nccn.org/clinical_trials/member_institutions.aspx](#).

NCCN Categories of Evidence and Consensus: All recommendations are category 2A unless otherwise indicated.

See [NCCN Categories of Evidence and Consensus](#).

The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2019.



Updates in Version 1.2020 of the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic from Version 3.2019 include:

Global

- The name of the Guidelines has changed to "NCCN Guidelines for Genetic Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic."
- Criteria for Further Genetic Risk Evaluation section was removed from the Guidelines.

Breast, Ovarian and/or Pancreatic Cancer Genetic Assessment

EVAL-1

- Approach to Cancer History page is new.

EVAL-A

- Principles of Cancer Risk Assessment and Counseling section was extensively revised.

Hereditary Cancer Testing Criteria

- All testing criteria have been moved into a new section titled, "Hereditary Cancer Testing Criteria."

CRIT-1 and CRIT-2

- **BRCA1/2 Testing Criteria** has been revised as, "Testing Criteria for High-Penetrance Breast and/or Ovarian Cancer Susceptibility Genes."
 - ▶ The criteria were extensively revised and reorganized into three sections
 - ◇ Testing is clinically indicated in the following scenarios
 - ◇ Testing may be considered in the following scenarios
 - ◇ There is a low probability (<2.5%) that testing will have findings of documented clinical utility in the following scenarios

CRIT-3

- Testing Criteria for Pancreatic Cancer Susceptibility Genes is new.

CRIT-4

- Testing Criteria for Li-Fraumeni Syndrome
 - ▶ 4th bullet was added, "Affected individual with pathogenic/likely pathogenic variant identified on tumor genomic testing that may have implications if also identified on germline testing" with a corresponding footnote, "This should prompt a careful evaluation of personal and family history of the individual to determine the yield of germline sequencing. Somatic TP53 pathogenic/likely pathogenic variants are common in many tumor types in absence of a germline pathogenic/likely pathogenic variant."
 - ▶ Footnote was removed, "TP53 testing can be ordered alone, concurrently with BRCA1/2 testing, and/or other gene testing or as a follow-up test after negative BRCA1/2 testing."

CRIT-5

- Testing Criteria for Cowden Syndrome/PTEN Hamartoma Tumor Syndrome
 - ▶ 6th bullet was added, "PTEN pathogenic/likely pathogenic variant detected by tumor profiling on any tumor type in the absence of germline analysis." with a corresponding footnote, "This should prompt a careful evaluation of personal and family history of the individual to determine the yield of germline sequencing. Somatic PTEN pathogenic/likely pathogenic variants are common in many tumor types in absence of germline pathogenic/likely pathogenic variant."

Genetic Testing Process

- A new section titled, "Genetic Testing Process," was created, which includes an algorithm for all hereditary testing criteria for "Testing criteria met" and tables for "Cancer Risk Management Based on Genetic Test Results."

GENE-1

- Testing Criteria Met, Genetic Testing
 - ▶ "Multi-gene testing, if appropriate" was removed and replaced with "Consider comprehensive testing of patient *with multi-gene panel* or if unaffected, *attempt, if possible, to test family member with highest likelihood of a pathogenic/likely pathogenic variant before testing an unaffected individual.*"
 - ▶ Footnote e was added, "Patients meeting Cowden syndrome clinical diagnostic criteria (see COWD-A 1 of 3) should be managed as pathogenic/likely pathogenic variant carriers."

GENE-A

- Cancer Risk Management Based on Genetic Test Results
 - ▶ "Female" was added to "breast cancer" as appropriate.
 - ▶ Genes associated with pancreatic cancer were added to the table, with links to PANC-A as appropriate.

GENE-A 1 of 5

- ATM
 - ▶ Ovarian Cancer Risk and Management was revised by adding, "Evidence insufficient; manage based on family history."
 - ▶ Comments section revised, "...~~Insufficient evidence to recommend against radiation therapy.~~ *ATM mutation should not lead to a recommendation to avoid radiation therapy at this time. See Discussion for information regarding the c.7271T>G variant.*"
- BARD1, Breast Cancer Risk and Management, "including triple negative" was added.
- BRIP1, Breast Cancer Risk and Management was revised from "Unknown or insufficient evidence" to "Potential increase in female breast cancer (including triple negative) risk with insufficient evidence for risk management."

[Continued](#)



Updates in Version 1.2020 of the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic from Version 3.2019 include:

Genetic Testing Process (continued)

GENE-A 2 of 5

- CDH1, comments section was added.
- CDKN2A was added to the table.
- MSH2, MLH1, MSH6, PMS2, EPCAM, comments section was added.

GENE-A 3 of 5

- NBN
 - ▶ Breast Cancer Risk and Management was revised, "Increased risk of female breast cancer *for individuals with 657del5 variant*."
 - ▶ Ovarian Cancer Risk and Management was revised from, "Unknown or insufficient evidence for ovarian cancer risk" to "Potential increase in ovarian cancer risk, RRSO: Evidence insufficient; manage based on family history."
 - ▶ Comments section was revised.

PALB2

- ▶ Breast Cancer Risk and Management, RRM was revised from, "Evidence insufficient, manage based on family history" to "Discuss option of risk-reducing mastectomy."
- ▶ Ovarian Cancer Risk and Management was revised from "Unknown or insufficient evidence for ovarian cancer risk" to "Potential increase in ovarian cancer risk, RRSO: Evidence insufficient; manage based on family history."

GENE-A 4 of 5

- RAD51C and RAD51D, Breast cancer risk and management was revised from "Unknown or insufficient evidence for breast cancer risk" to "Potential increase in triple-negative female breast cancer risk with insufficient evidence for risk management."

GENE-A 5 of 5

- Footnote f was added, "Screening and risk-reduction management is extrapolated from BRCA1/2 data based on levels of risk."

BRCA Pathogenic/Likely Pathogenic Variant-Positive Management

BRCA-A 1 of 2

- Women
 - ▶ 5th bullet, 1st sub-bullet was revised, "... management of menopausal symptoms, ~~possible short-term~~ hormone replacement therapy, and related medical issues."
 - ▶ 6th bullet was revised by adding, "Women who undergo hysterectomy at the time of RRSO are candidates for estrogen alone hormone replacement therapy, which is associated with a decreased risk of breast cancer compared to combined estrogen and progesterone, which is required when the uterus is left in situ (Chlebowski R, Rohan T, Manson J, et al. *JAMA Oncol* 2015;1:296-305)."

BRCA-A 2 of 2

- Men
 - ▶ 3rd bullet, starting age for prostate cancer screening was changed from 45 y to 40 y.
- Men and Women
 - ▶ 2nd bullet was revised, "No specific screening guidelines exist for ~~pancreatic cancer and melanoma, but general melanoma risk management is appropriate, such as annual full-body skin examination and minimizing UV exposure but screening may be individualized based on cancers observed in the family.~~
 - ▶ 3rd bullet was added, "For pancreatic cancer screening recommendations, see PANC-A."

Pancreatic Cancer Screening

PANC-A

- Pancreatic cancer screening section is new.

Li-Fraumeni Syndrome Management

LIFR-A 2 of 2

- Other Aspects of Managing LFS
 - ▶ 9th bullet was added, "There is controversy over how to manage cancer risk in incidental TP53 carriers who do not meet classic LFS criteria; some data suggest lower cancer risks in TP53 pathogenic/likely pathogenic carriers who do not have a family history consistent with LFS."
- Testing Considerations section is new.

Cowden Syndrome/PTEN Hamartoma Tumor Syndrome Management

COWD-A 2 of 3

- Women
 - ▶ 4th bullet was revised by adding, "Discuss option of risk-reducing mastectomy *in women with pathogenic/likely pathogenic variants identified. For those with clinical Cowden syndrome, consideration of risk-reducing surgery should be based on family history.*"
 - ▶ 5th bullet was revised by adding, "For endometrial cancer screening, *consider starting by age 35 y.*"

COWD A 3 of 3

- Men and Women
 - ▶ 2nd bullet was revised, "Annual thyroid ultrasound starting ~~at age 7 y at time of CS/PHTS diagnosis, including in childhood.~~
 - ▶ 5th bullet was revised from, "Dermatologic management may be indicated for some patients" to "There may be an increased risk of melanoma, and the prevalence of other skin characteristics with Cowden syndrome may independently make routine dermatology evaluations of value. Annual dermatology examinations are recommended."



APPROACH TO CANCER HISTORY (For all patients, [see Principles of Cancer Risk Assessment and Counseling \[EVAL-A\]](#).)

• Personal or family history

- ▶ Breast and/or ovarian cancer → [See Testing Criteria for High-Penetrance Breast and/or Ovarian Cancer Susceptibility Genes \(CRIT-1\)](#)
 - ▶ Pancreatic cancer → [See Testing Criteria for Pancreatic Cancer Susceptibility Genes \(CRIT-3\)](#)
 - ▶ Prostate cancer → [See Testing Criteria for High-Penetrance Breast and/or Ovarian Cancer Susceptibility Genes \(CRIT-1\)](#)
 - ▶ Colorectal cancer → [See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal](#)
- #### • Specific cancer syndromes
- ▶ Li-Fraumeni syndrome → [See Testing Criteria for Li-Fraumeni Syndrome \(CRIT-4\)](#)
 - ▶ Cowden syndrome/PTEN hamartoma tumor syndrome → [See Testing Criteria for Cowden Syndrome/PTEN Hamartoma Tumor Syndrome \(CRIT-5\)](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



PRINCIPLES OF CANCER RISK ASSESSMENT AND COUNSELING

- The decision to offer genetic testing involves three related stages: 1) pre-test counseling done prior to ordering testing; 2) consideration of the most appropriate tests to order; and 3) post-test counseling done when results are disclosed.¹⁻⁵ It is recommended that a genetic counselor, medical geneticist, oncologist, surgeon, oncology nurse, or other health professional with expertise and experience in cancer genetics be involved at each stage whenever possible. Testing should be considered in appropriate high-risk individuals where it is likely to impact the risk management and/or treatment of the tested individuals and/or their at-risk family members.

Pre-test counseling includes the following elements:

- Evaluation of patient's needs and concerns regarding:
 - Knowledge of genetic testing for cancer risk, including benefits, risks, and limitations
 - Goals for cancer family risk assessment
- Detailed family history including:
 - Collection of a comprehensive family history
 - ◊ Assessing family history; close blood relatives include first-, second-, and third-degree relatives on each side of the family, particularly around individuals with a diagnosis of cancer ([See EVAL-B](#))
 - ◊ Types of cancer, bilaterality, age at diagnosis, subtype, and pathology report confirmation
 - ◊ Ethnicity (specifically Ashkenazi Jewish ancestry)
- Detailed medical and surgical history including:
 - Documentation of prior genetic testing results for patients and their family members
 - Personal cancer history (eg, age, histology, laterality)
 - Pathology reports of primary cancers and/or benign lesions (eg, breast biopsies)
 - Carcinogen exposure (eg, history of radiation therapy)
 - Reproductive history
 - Hormone or oral contraceptive use
 - History of risk-reducing surgeries
- Focused physical exam (conducted by qualified clinician):
 - Cowden syndrome/PTEN hamartoma tumor syndrome (PHTS) specific: dermatologic,^a including oral mucosa, head circumference, and thyroid (enlarged or nodular on palpation)
- Generation of a differential diagnosis and educating the patient on inheritance patterns, penetrance, variable expressivity, and the possibility of genetic heterogeneity
- Preparation for the possible outcomes of testing, including positive (pathogenic, likely pathogenic), negative, uncertain variants, and mosaic results
- Obtaining written informed consent, and documenting the informed consent in the patient's medical record
- Discuss possible management options if a mutation is identified (enhanced surveillance, risk-reducing agents, and risk-reducing surgery)
- Advise about possible inherited cancer risk to relatives, options for risk assessment, testing, and management.
- Cost of genetic testing
- Current legislation regarding genetic discrimination and the privacy of genetic information

[References on
EVAL-A 6 of 6](#)

^a For Cowden syndrome dermatologic manifestations, [see CRIT-5](#) and for Peutz-Jeghers syndrome (PJS) dermatologic manifestations, [see NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal](#).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)

**EVAL-A
1 OF 6**



PRINCIPLES OF CANCER RISK ASSESSMENT AND COUNSELING

Prior to genetic testing, the following should be taken into consideration:

- The probability of pathogenic/likely pathogenic variant detection associated with these criteria will vary based on family structure. Individuals with unknown or limited family history/structure, such as fewer than 2 female first- or second-degree relatives having lived beyond age 45 in either lineage, may have an underestimated probability of familial pathogenic/likely pathogenic variant detection. The estimated likelihood of pathogenic/likely pathogenic variant detection may be very low in families with a large number of unaffected female relatives or a large number of male relatives.
- Patients who have received an allogeneic bone marrow transplant or with active or recent hematologic malignancies should not have molecular genetic testing via blood or buccal samples (due to unreliable test results from contamination by donor DNA) until other technologies are available. If available, DNA should be extracted from a fibroblast culture. If this source of DNA is not possible, buccal samples can be considered, subject to the risk of donor DNA contamination.
- If more than one family member is affected with cancers highly associated with a particular inherited cancer susceptibility syndrome, consider initial testing of a family member with youngest age at diagnosis, bilateral disease, multiple primary cancers, or other cancers associated with the syndrome, or most closely related to the proband/patient. If there are no available family members with cancer that is a cardinal feature of the syndrome in question, consider testing first- or second-degree family members affected with other cancers thought to be related to the gene in question (eg, prostate or pancreas with *BRCA1/2*).
- Testing for unaffected family members when no affected member is available should be considered. Significant limitations of interpreting test results should be discussed.
- In children <18 y, genetic testing is generally not recommended when results would not impact medical management.⁶
- Likely pathogenic variants are usually clinically managed similarly to pathogenic variants.
- Choice of multi-gene testing, see [EVAL-A 3 of 6](#).

[References on
EVAL-A 6 of 6](#)

[Continued](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**PRINCIPLES OF CANCER RISK ASSESSMENT AND COUNSELING****• Choice of multi-gene testing**

- ▶ The introduction of multi-gene testing for hereditary forms of cancer has rapidly altered the clinical approach to hereditary cancer testing of at-risk patients and their families. Based on next-generation sequencing (NGS) technology, these tests simultaneously analyze a set of genes that are associated with a specific family cancer phenotype or multiple phenotypes.
- ▶ An individual's personal and/or family history may be explained by more than one inherited cancer syndrome; thus, phenotype-directed testing based on personal and family history through a multi-gene panel test may be more efficient and cost-effective and increase the yield of detecting a pathogenic/likely pathogenic variant in a gene that will impact medical management for the individual or his/her at-risk family members.
- ▶ There may also be a role for multi-gene testing in individuals who have tested negative for a single syndrome, but whose personal or family history remains suggestive of an inherited susceptibility.
- ▶ Rarely, some individuals may carry pathogenic/likely pathogenic germline variants in more than one cancer susceptibility gene; thus, consideration of a multigene panel for individuals already known to carry a single pathogenic/likely pathogenic germline variant from phenotype-directed testing may be considered on a case-by-case basis, based on the degree of suspicion for there being additional variants.
- ▶ Because commercially available tests differ in the specific genes analyzed, variant classification, and other factors, it is important to consider the indication for testing and expertise of the laboratory when choosing the specific laboratory and test panel.
- ▶ Multi-gene testing can include “intermediate” penetrant (moderate-risk) genes.^b For many of these genes, there are limited data on the degree of cancer risk, and there may currently be no clear guidelines on risk management for carriers of pathogenic/likely pathogenic variants. Not all genes included on available multi-gene tests are necessarily clinically actionable.
- ▶ It may be possible to refine risks associated with both moderate and high penetrance genes, taking into account the influence of gene/gene or gene/environment interactions. In addition, certain pathogenic/likely pathogenic variants in a gene may pose higher or lower risk than other pathogenic/likely pathogenic variants in that same gene. This information should be taken into consideration when assigning risks and management recommendations for individuals and their at-risk relatives.
- ▶ In many cases the information from testing for moderate penetrance genes does not change risk management compared to that based on family history alone.
- ▶ Pathogenic/likely pathogenic variants in many breast, ovarian, pancreatic, and prostate cancer susceptibility genes involved in DNA repair may be associated with rare autosomal recessive conditions, thus posing risks to offspring if the partner is also a carrier.
- ▶ As more genes are tested, there is an increased likelihood of finding variants of unknown significance (VUS), mosaicism, and clonal hematopoiesis of indeterminate potential (CHIP).
- ▶ Multigene panel testing increases the likelihood of finding pathogenic/likely pathogenic variants without clear clinical significance.
- ▶ Germline confirmatory testing should be done when a pathogenic variant is found on tumor genomic testing that has clinical implications if also identified in the germline.

[References on
EVAL-A 6 of 6](#)

^b Research is evolving, and gene carriers should be encouraged to participate in clinical trials or genetic registries. Carriers are also encouraged to recontact their genetics providers every few years for updates.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)

**EVAL-A
3 OF 6**

**PRINCIPLES OF CANCER RISK ASSESSMENT AND COUNSELING****Evaluating the Source of Genetic Testing Information**

- Prior to using any germline findings for medical management, it is important to establish whether the reported findings were obtained from a laboratory that is certified by the College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) to issue a report of germline findings directly to ordering health care providers. Some states (eg, New York) may have additional reporting requirements.
- Confirmatory germline testing through an appropriately certified laboratory is recommended when a potential pathogenic/likely pathogenic variant is identified through various data sources as noted below:
 - ▶ **Commercial entities providing ancestry** (and sometimes health) information typically do so through microarray-based single nucleotide polymorphism (SNP) testing that has not been validated for clinical use. Third-party software applications can be used by consumers to obtain an interpretation of the raw data provided by these companies. Raw data and third-party software are not able to provide information that is appropriate for medical management, as these services are not subject to quality-control processes and recent research suggests that the error rate is substantial.⁷
 - ▶ **Tumor testing** can be complementary to germline testing and can assist in interpretation of results. However:
 - ◊ Pathogenic/likely pathogenic variants reported by laboratories providing tumor-only profiling may be of somatic or germline origin. Although germline origin can sometimes be inferred with a high degree of confidence (eg, founder pathogenic/likely pathogenic variants in *BRCA1/2*), confirmatory testing is usually indicated for pathogenic/likely pathogenic variants with a reasonable clinical suspicion of being of germline origin (based on patient/family history or clinical characteristics and in some cases variant frequency).
 - ◊ However, somatic pathogenic/likely pathogenic variants are common in several genes with germline implications (eg, *TP53*, *STK11*, *PTEN*), and will rarely be indicative of a need for germline testing unless clinical/family history features suggest the possibility of a germline pathogenic/likely pathogenic variant.
 - ◊ Interpretation of tumor sequencing results may differ from the interpretation of this same change when present in the germline, for several reasons. Because tumor testing is designed to address treatment actionability, a variant that is interpreted as pathogenic or likely pathogenic in the germline may be interpreted as normal (and not reported) or a VUS in the tumor because it has no clear clinical implications. In addition, the sensitivity of most tumor testing is lower (particularly for intermediate-sized deletions and duplications) than most dedicated germline tests, and the filtering of tumor sequencing data may differ between tumor and germline testing labs. Thus, clinically indicated germline testing is still appropriate for patients meeting testing guidelines, regardless of tumor profiling results.
 - ▶ **Research**: Patients may have participated in research studies that include germline genomic analysis.⁸ In such cases, it is recommended to review the patient's findings with a genetics professional and/or the reporting laboratory to establish whether the original report was generated by an appropriately certified laboratory, or whether confirmatory testing is recommended.

[References on
EVAL-A 6 of 6](#)[Continued](#)**Note:** All recommendations are category 2A unless otherwise indicated.**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



PRINCIPLES OF CANCER RISK ASSESSMENT AND COUNSELING

Post-test counseling includes the following elements:

- Discussion of results and associated medical risks
- Interpretation of results in context of personal and family history of cancer
- Discussion of recommended medical management options
- Discuss and offer assistance with informing and testing at-risk family members.
- Discuss available resources such as high-risk clinics, disease-specific support groups, and research studies.
- For patients of reproductive age, advise about options for prenatal diagnosis and assisted reproduction, including pre-implantation genetic diagnosis. Discussion should include known risks, limitations, and benefits of these technologies. See [Discussion](#) for details.
- Biallelic pathogenic/likely pathogenic variants in some genes, included on gene panels, may be associated with rare autosomal recessive conditions, such as Fanconi anemia or constitutional mismatch repair deficiency ([See GENE-A](#)). Thus, for these genes, consideration should be given to carrier testing the partner for pathogenic/likely pathogenic variants in the same gene if it would inform reproductive decision-making and/or risk assessment and management.⁹
- Testing family members for a VUS should not be done for clinical purposes. Consider a referral to research studies that aim to define the functional impact of variants such as variant reclassification programs through clinical labs or registries.
- When genetic testing for inherited cancer is conducted by providers with limited expertise in genetics and/or without pre-test counseling, referral to a genetics health provider should be considered for the following situations:
 - ▶ Pathogenic/likely pathogenic variant identified
 - ▶ Negative results, yet family history remains suggestive of inherited disease
 - ▶ Any VUS result for which a provider considers using to guide management
 - ▶ A mosaic or possibly mosaic result
 - ▶ Discrepant interpretation of variants, including discordant results across laboratories
 - ▶ Interpretation of polygenic risk scores, particularly in instances in which it may impact patient care
 - ▶ Interpretation of pathogenic/likely pathogenic variants for patients tested through direct-to-consumer or consumer-initiated models

[References on
EVAL-A 6 of 6](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



PRINCIPLES OF CANCER RISK ASSESSMENT AND COUNSELING

References


- ¹Robson ME, Bradbury AR, Arun B, et al. American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. J Clin Oncol 2015;33:3660-3667.
- ²Berliner JL, Fay AM, Cummings SA, Burnett B, Tillmanns T. NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer. J Genet Couns 2013;22:155-163.
- ³American College of Obstetricians and Gynecologists; ACOG Committee on Practice Bulletins--Gynecology; ACOG Committee on Genetics; Society of Gynecologic Oncologists. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol 2009;113:957-966.
- ⁴Lancaster JM, Powell CB, Chen LM, Richardson DL; SGO Clinical Practice Committee. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 2015;136:3-7.
- ⁵Weitzel JN, Blazer KR, Macdonald DJ, Culver JO, Offit K. Genetics, genomics, and cancer risk assessment: State of the art and future directions in the era of personalized medicine. CA Cancer J Clin 2011;61:327-359.
- ⁶Committee on Bioethics; Committee on Genetics, and American College of Medical Genetics and; Genomic Social; Ethical; Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Pediatrics 2013;131:620-622.
- ⁷Tandy-Connor S, Guiltinan J, Krempely K, et al. False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care. Genet Med 2018;20:1515-1521.
- ⁸Green R, Berg J, Grody W, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013;15:565-574.
- ⁹Offit K, Levran O, Mullaney B, et al. Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst 2003;95:1548-1551.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



PEDIGREE: FIRST-, SECOND-, AND THIRD-DEGREE RELATIVES OF PROBAND^a



^aFirst-degree relatives: parents, siblings, and children;
second-degree relatives: grandparents, aunts, uncles, nieces, nephews, grandchildren, and half-siblings;
third-degree relatives: great-grandparents, great-aunts, great-uncles, great-grandchildren, first cousins, and half aunts and uncles.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 1.2020

Hereditary Cancer Testing Criteria

TESTING CRITERIA FOR HIGH-PENETRANCE BREAST AND/OR OVARIAN CANCER SUSCEPTIBILITY GENES

(This often includes *BRCA1*, *BRCA2*, *CDH1*, *PALB2*, *PTEN*, and *TP53* among others. See [GENE-A](#) for a more complete list.)^{a,b,c,d}

Testing is clinically indicated in the following scenarios:

1. Individuals with any blood relative with a known pathogenic/likely pathogenic variant in a cancer susceptibility gene
2. Individuals meeting the criteria below but with previous limited testing (eg, single gene and/or absent deletion duplication analysis) interested in pursuing multi-gene testing
3. **Personal history of cancer**
 - Breast cancer with at least one of the following:
 - Diagnosed at age ≤45 y; or
 - Diagnosed at age 46–50 y with:
 - ◊ Unknown or limited family history; or
 - ◊ A second breast cancer diagnosed at any age; or
 - ◊ ≥1 close blood relative^e with breast, ovarian, pancreatic, or high-grade (Gleason score ≥7) or intraductal prostate cancer at any age
 - Diagnosed at age ≤60 y with triple-negative breast cancer;
 - Diagnosed at any age with:
 - ◊ Ashkenazi Jewish ancestry; or
 - ◊ ≥1 close blood relative^e with breast cancer at age ≤50 y or ovarian, pancreatic, or metastatic or intraductal prostate cancer at any age; or
 - ◊ ≥3 total diagnoses of breast cancer in patient and/or close blood relatives^e
 - Diagnosed at any age with male breast cancer
 - Epithelial ovarian cancer^f (including fallopian tube cancer or peritoneal cancer) at any age
 - Exocrine pancreatic cancer at any age^g ([See CRIT-3](#))
 - Metastatic or intraductal prostate cancer at any age^h
 - High-grade (Gleason score ≥7) prostate cancer with:
 - Ashkenazi Jewish ancestry; or
 - ≥1 close relative^e with breast cancer at age ≤50 y or ovarian, pancreatic, or metastatic or intraductal prostate cancer at any age; or
 - ≥2 close relatives^e with breast or prostate cancer (any grade) at any age.
 - A mutation identified on tumor genomic testing that has clinical implications if also identified in the germline
 - To aid in systemic therapy decision-making, such as for HER2-negative metastatic breast cancerⁱ
4. **Family history of cancer**
 - An affected or unaffected individual with a first- or second-degree blood relative meeting any of the criteria listed above (except individuals who meet criteria only for systemic therapy decision-making)^j
 - An affected or unaffected individual who otherwise does not meet the criteria above but has a probability >5% of a *BRCA1/2* pathogenic variant based on prior probability models (eg, Tyrer-Cuzick, BRCAPro, PennII)^k

Criteria met → [See GENE-1](#)

If testing criteria not met, consider testing for other hereditary syndromes

If criteria for other hereditary syndromes not met, then cancer screening as per [NCCN Screening Guidelines](#)

[Continued on next page](#)

[Footnotes on CRIT-2](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 1.2020

Hereditary Cancer Testing Criteria

TESTING CRITERIA FOR HIGH-PENETRANCE BREAST AND/OR OVARIAN CANCER SUSCEPTIBILITY GENES (continued)
(This often includes *BRCA1*, *BRCA2*, *CDH1*, *PALB2*, *PTEN*, and *TP53* among others. See [GENE-A](#) for a more complete list.)^{a,b,c,d}

Testing may be considered in the following scenarios (with appropriate pre-test education and access to post-test management):

1. Bilateral breast cancer, first diagnosed between the ages of 50 and 65 y
2. An unaffected Ashkenazi Jewish individual^f
3. An affected or unaffected individual who otherwise does not meet any of the above criteria but with a 2.5%–5% probability of *BRCA1/2* pathogenic variant based on prior probability models (eg, Tyrer-Cuzick, BRCAPro, PennII)^b

There is a low probability (<2.5%) that testing will have findings of documented clinical utility in the following scenarios:

1. Women diagnosed with breast cancer at age >65 y, with no close relative^e with breast, ovarian, pancreatic, or prostate cancer
2. Men diagnosed with localized prostate cancer with Gleason Score <7 and no close relative^e with breast, ovarian, pancreatic, or prostate cancer

^a For further details regarding the nuances of genetic counseling and testing, see [EVAL-A](#).

^b Testing for pathogenic variants in other genes should take into consideration factors such as patient preferences, turnaround time, and insurance restrictions to particular labs (and thus particular panels). The prevalence of VUS increases with testing of additional genes. Individuals should have pre-test education on the challenges in managing pathogenic variants in genes associated with specific syndromes (eg, *CDH1* and *TP53* given their expanding clinical phenotypes) in the absence of a family history typical of such syndromes (does not apply for de novo pathogenic variants). Patients should also have pre-test education regarding the uncertain clinical utility of identifying certain pathogenic variants (eg, monoallelic *MUTYH*).

^c Meeting one or more of these criteria warrants further personalized risk assessment, genetic counseling, and often genetic testing and management.

^d For the purposes of these guidelines, invasive and ductal carcinoma in situ breast cancers should be included.

^e Close blood relatives include first-, second-, and third-degree relatives on the same side of the family. (See [EVAL-B](#).)

^f *BRCA*-related ovarian cancers are associated with epithelial, non-mucinous histology. Lynch syndrome can be associated with both non-mucinous and mucinous epithelial tumors. Be attentive for clinical evidence of Lynch syndrome (see [NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal](#)). Specific types of non-epithelial ovarian cancers and tumors can also be associated with other rare syndromes. Examples include an association between sex-cord tumors with annular tubules and PJS or Sertoli-Leydig tumors and DICER1-related disorders.

^g Approximately 2%–5% of unselected cases of pancreatic adenocarcinoma will have a *BRCA1/2* pathogenic/likely pathogenic variant. However, the disease is highly aggressive and the option to test the affected relative may not be available in the future. Thus, there may be significant benefit to family members in testing these patients near the time of diagnosis. In addition, increasing evidence suggests that identification of a *BRCA1/2* pathogenic/likely pathogenic variant may direct use of targeted therapies for patients with pancreatic cancer (See [NCCN Guidelines for Pancreatic Adenocarcinoma](#)). (Holter S, Borgida A, Dodd A, et al. J Clin Oncol 2015;33:3124-3129. Shindo K, Yu J, Suenaga M, et al. J Clin Oncol 2017;35:3382-3390. Golan T, Hammel P, Reni M, et al. N Engl J Med 2019;381:317-327.)

^h Metastatic prostate cancer is biopsy-proven and/or with radiographic evidence and includes distant metastasis and regional bed or nodes. It is not a biochemical recurrence only. Prostate cancer-specific mortality should be a surrogate for metastatic disease for family history purposes.

ⁱ Eg, PARP inhibitors for ovarian cancer, prostate cancer, pancreatic cancer, and metastatic HER2-negative breast cancer; platinum therapy for prostate cancer and pancreatic cancer. See the relevant [NCCN treatment guidelines](#) for further details.

^j This may be extended to an affected third-degree relative if related through two male relatives (eg, paternal grandfather's mother or sister). If the affected first-degree relative underwent genetic testing and is negative for detectable mutations and there is no other family history of cancer, there is a low probability that any finding will have documented clinical utility.

^k The approximate 5% threshold for probability of carrying *BRCA1/2* pathogenic variants is utilized because of availability of prior probability models; however, it is recognized that current model estimates vary substantially, and that different thresholds may be appropriate if other genes are included in the model utilized. If genes other than *BRCA1* and *BRCA2* are to be included in models evaluating the threshold for testing, the penetrance, clinical actionability, and phenotypic features of cancers associated with mutations in these genes should be considered. The panel encourages the development of validated models that include these parameters to determine eligibility and appropriateness for gene panel testing for inherited cancer risk. These models are only validated for *BRCA1/2*.

^l Testing for three founder mutations of *BRCA1/2* may be offered to unaffected men and women as early as age 18–25 years, who have one grandparent identified as of Ashkenazi Jewish ancestry, irrespective of cancer history in the family, as part of longitudinal studies. For those without access to longitudinal research studies, testing may be provided if there is access to pre-test education along with post-test counseling, additional genetic testing if indicated, and high-risk management. Testing should not be offered outside of a medical framework or clinical trial.

Note: All recommendations are category 2A unless otherwise indicated.


Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



TESTING CRITERIA FOR PANCREATIC CANCER SUSCEPTIBILITY GENES^a

DIAGNOSIS

TESTING CRITERIA



^a For further details regarding the nuances of genetic counseling and testing, [see EVAL-A](#).

^m Genes that are typically tested for pancreatic cancer risk include *ATM*, *BRCA1*, *BRCA2*, *CDKN2A*, most Lynch syndrome genes (*MLH1*, *MSH2*, *MSH6*, *EPCAM*), *PALB2*, *STK11*, and *TP53*.

ⁿ Pancreatic cancer risk is higher in individuals of Ashkenazi Jewish descent. Genetic testing of Ashkenazi Jewish patients with pancreatic cancer may have higher yield of mutations than of non-Ashkenazi Jewish patients.

^o Testing of first-degree relatives should only be done if it is impossible to test the individual who has pancreatic cancer. Some second-degree relatives may meet testing criteria based on additional family history.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 1.2020

Hereditary Cancer Testing Criteria

TESTING CRITERIA FOR LI-FRAUMENI SYNDROME^a

FOLLOW-UP

- Individual from a family with a known *TP53* pathogenic/likely pathogenic variant
- Classic Li-Fraumeni syndrome (LFS) criteria:^p
 - Combination of an individual diagnosed at age <45 y with a sarcoma^q
AND
A first-degree relative diagnosed at age <45 y with cancer
AND
An additional first- or second-degree relative in the same lineage with cancer diagnosed at age <45 y, or a sarcoma at any age
- Chompret criteria:^{r,s}
 - Individual with a tumor from LFS tumor spectrum (eg, soft tissue sarcoma, osteosarcoma, CNS tumor, breast cancer, adrenocortical carcinoma), before 46 y of age, AND at least one first- or second-degree relative with any of the aforementioned cancers (other than breast cancer if the proband has breast cancer) before the age of 56 y or with multiple primaries at any age
OR
 - Individual with multiple tumors (except multiple breast tumors), two of which belong to LFS tumor spectrum with the initial cancer occurring before the age of 46 y
OR
 - Individual with adrenocortical carcinoma, or choroid plexus carcinoma or rhabdomyosarcoma of embryonal anaplastic subtype, at any age of onset, regardless of family history
OR
 - Breast cancer before 31 y of age
- Affected individual with pathogenic/likely pathogenic variant identified on tumor genomic testing that may have implications if also identified on germline testing^t

LFS testing
criteria met

→ [See GENE-1](#)

If LFS testing
criteria not
met, consider
testing
for other
hereditary
syndromes, if
appropriate

→ Individualized
recommendations
according to
personal and
family history

^a For further details regarding the nuances of genetic counseling and testing, [see EVAL-A](#).

^p Li FP, Fraumeni JF, Jr., Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. *Cancer Res* 1988;48:5358-5362.

^q To date, there have been no reports of Ewing sarcoma, GIST, desmoid tumor, or angiosarcoma in *TP53* pathogenic/likely pathogenic variant carriers.

^r Chompret A, Abel A, Stoppa-Lyonnet D, et al. Sensitivity and predictive value of criteria for p53 germline mutation screening. *J Med Genet* 2001;38:43-47.

^s Bougeard G, Renaux-Petel M, Flaman JM, et al. Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. *J Clin Oncol* 2015;33:2345-2352.

^t This should prompt a careful evaluation of personal and family history of the individual to determine the yield of germline sequencing. Somatic *TP53* pathogenic/likely pathogenic variants are common in many tumor types in absence of a germline pathogenic/likely pathogenic variant.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 1.2020

Hereditary Cancer Testing Criteria

TESTING CRITERIA FOR COWDEN SYNDROME (CS)/PTEN HAMARTOMA TUMOR SYNDROME (PHTS)^{a,u,v,w}

- Individual from a family with a known *PTEN* pathogenic/likely pathogenic variant
- Individual with a personal history of Bannayan-Riley-Ruvalcaba syndrome (BRRS)
- Individual meeting clinical diagnostic criteria^x for CS/PHTS
- Individual not meeting clinical diagnostic criteria^x for CS/PHTS with a personal history of:
 - ▶ Adult Lhermitte-Duclos disease (cerebellar tumors); or
 - ▶ Autism spectrum disorder and macrocephaly; or
 - ▶ Two or more biopsy-proven trichilemmomas; or
 - ▶ Two or more major criteria (one must be macrocephaly); or
 - ▶ Three major criteria, without macrocephaly; or
 - ▶ One major and ≥3 minor criteria;^y or
 - ▶ ≥4 minor criteria

Major criteria:

- Breast cancer
- Endometrial cancer
- Follicular thyroid cancer
- Multiple GI hamartomas or ganglioneuromas^{aa}
- Macrocephaly (megalcephaly) (ie, ≥97%, 58 cm in adult women, 60 cm in adult men)^{bb}
- Macular pigmentation of glans penis
- Mucocutaneous lesions^{cc}
 - ▶ One biopsy-proven trichilemmoma
 - ▶ Multiple palmoplantar keratoses
 - ▶ Multifocal or extensive oral mucosal papillomatosis
 - ▶ Multiple cutaneous facial papules (often verrucous)

^a For further details regarding the nuances of genetic counseling and testing, [see EVAL-A](#).

^u These are testing criteria; clinical diagnostic criteria can be found on [COWD-A](#).

^v If two criteria involve the same structure/organ/tissue, both may be included as criteria.


^w Current evidence does not support testing for succinate dehydrogenase (*SDH*) gene pathogenic/likely pathogenic variants in patients with PHTS. (Am J Hum Genet 2011;88:674-675).

^x Pilarski R, Burt R, Kohlmann W, et al. Cowden syndrome and the PTEN hamartoma tumor syndrome: Systematic review and revised diagnostic criteria. J Natl Cancer Inst 2013;105:1607-1616. [See COWD-A](#).

- At-risk individual with a relative with a clinical diagnosis of CS/PHTS or BRRS for whom testing has not been performed
 - ▶ The at-risk individual must have the following:
 - ◇ Any one major criterion or
 - ◇ Two minor criteria
- *PTEN* pathogenic/likely pathogenic variant detected by tumor profiling on any tumor type in the absence of germline analysis^z

Minor criteria:^{dd}

- Autism spectrum disorder
- Colon cancer
- ≥3 esophageal glycogenic acanthoses
- Lipomas
- Intellectual disability (ie, IQ ≤75)
- Papillary or follicular variant of papillary thyroid cancer



FOLLOW-UP

→ [See GENE-1](#)

→ Individualized recommendations according to personal and family history

- Thyroid structural lesions (eg, adenoma, nodule(s), goiter)
- Renal cell carcinoma
- Single GI hamartoma or ganglioneuroma
- Testicular lipomatosis
- Vascular anomalies (including multiple intracranial developmental venous anomalies)

^y If an individual has two or more major criteria, such as breast cancer and non-medullary thyroid cancer, but does not have macrocephaly, one of the major criteria may be included as one of the three minor criteria to meet testing criteria.

^z This should prompt a careful evaluation of personal and family history of the individual to determine the yield of germline sequencing. Somatic *PTEN* pathogenic/likely pathogenic variants are common in many tumor types in absence of germline pathogenic/likely pathogenic variant.

^{aa} Multiple polyp types are often seen in patients with PHTS, and less commonly may include adenomas, hyperplastic polyps, and other histologies.

^{bb} Roche AF, Mukherjee D, Guo SM, Moore WM. Head circumference reference data: Birth to 18 years. Pediatrics 1987;79:706-712.

^{cc} The literature available on mucocutaneous lesions is not adequate to accurately specify the number or extent of mucocutaneous lesions required to be a major criterion for CS/PHTS. Clinical judgment should be used.

^{dd} Insufficient evidence exists in the literature to include fibrocystic disease of the breast, fibromas, and uterine fibroids as diagnostic criteria.


Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 1.2020

Genetic Testing Process



^a For further details regarding the nuances of genetic counseling and testing, [see EVAL-A](#).

^b If of Ashkenazi Jewish descent, in addition to the specific familial pathogenic/likely pathogenic variant, test for all three founder pathogenic/likely pathogenic variants.

^c Additional testing may be indicated if there is also a significant family history of cancer on the side of the family without the known pathogenic/likely pathogenic variant.

^d If no pathogenic/likely pathogenic variant is found, consider testing another family member with next highest likelihood of having a pathogenic/likely pathogenic variant.

^e Patients meeting Cowden syndrome clinical diagnostic criteria ([see COWD-A 1 of 3](#)) should be managed as pathogenic/likely pathogenic variant carriers.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 1.2020

Genetic Testing Process

CANCER RISK MANAGEMENT BASED ON GENETIC TEST RESULTS^{a-e}

The inclusion of a gene in this table below does not imply the endorsement either for or against multi-gene testing for moderate-penetrance genes.

Gene	Breast Cancer Risk and Management	Ovarian Cancer Risk and Management	Other Cancer Risks and Management
<i>ATM</i>	Increased risk of female breast cancer^f <ul style="list-style-type: none"> Screening: Annual mammogram with consideration of tomosynthesis and consider breast MRI with contrast starting at age 40 y^{g,h} RRM: Evidence insufficient, manage based on family history 	Potential increase in ovarian cancer risk <ul style="list-style-type: none"> RRSO: Evidence insufficient; manage based on family history 	<ul style="list-style-type: none"> Pancreatic <ul style="list-style-type: none"> ▶ See PANC-A Unknown or insufficient evidence for prostate cancer
Comments: Counsel for risk of autosomal recessive condition in offspring. ATM mutation should not lead to a recommendation to avoid radiation therapy at this time. See Discussion for information regarding the c.7271T>G variant.			
<i>BARD1</i>	Potential increase in female breast cancer (including triple negative) risk with insufficient evidence for risk management	Unknown or insufficient evidence for ovarian cancer risk	Unknown or insufficient evidence for other cancers
<i>BRCA1</i>	Increased risk of breast cancer <ul style="list-style-type: none"> See BRCA Pathogenic Variant-Positive Management 	Increased risk of ovarian cancer <ul style="list-style-type: none"> See BRCA Pathogenic Variant-Positive Management 	Pancreatic, Prostate <ul style="list-style-type: none"> See BRCA Pathogenic Variant-Positive Management
<i>BRCA2</i>	Increased risk of breast cancer <ul style="list-style-type: none"> See BRCA Pathogenic Variant-Positive Management 	Increased risk of ovarian cancer <ul style="list-style-type: none"> See BRCA Pathogenic Variant-Positive Management 	Pancreatic, Prostate, Melanoma <ul style="list-style-type: none"> See BRCA Pathogenic Variant-Positive Management
Comment: Counsel for risk of autosomal recessive condition in offspring.			
<i>BRIP1</i>	Potential increase in female breast cancer (including triple negative) risk with insufficient evidence for risk management	Increased risk of ovarian cancer <ul style="list-style-type: none"> Consider RRSO at 45–50 y 	Unknown or insufficient evidence for other cancers
Comments: Counsel for risk of autosomal recessive condition in offspring. Based on estimates from available studies, the lifetime risk of ovarian cancer in carriers of pathogenic/likely pathogenic variants in <i>BRIP1</i> appears to be sufficient to justify consideration of risk-reducing salpingo-oophorectomy. The current evidence is insufficient to make a firm recommendation as to the optimal age for this procedure. Based on the current, limited evidence base, a discussion about surgery should be held around age 45–50 y or earlier based on a specific family history of an earlier onset of ovarian cancer.			

RRM: Risk-reducing mastectomy

RRSO: Risk-reducing salpingo-oophorectomy

[Continued](#)

[Footnotes on GENE-A 5 of 5](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 1.2020

Genetic Testing Process

CANCER RISK MANAGEMENT BASED ON GENETIC TEST RESULTS^{a-e}

The inclusion of a gene in this table below does not imply the endorsement either for or against multi-gene testing for moderate-penetrance genes.

Gene	Breast Cancer Risk and Management	Ovarian Cancer Risk and Management	Other Cancer Risks and Management
CDH1	Increased risk of female lobular breast cancer^f <ul style="list-style-type: none">Screening: Annual mammogram with consideration of tomosynthesis and consider breast MRI with contrast starting at age 30 y^{g,h}RRM: Evidence insufficient, manage based on family history	No increased risk of ovarian cancer	Diffuse gastric cancer <ul style="list-style-type: none">See NCCN Guidelines for Gastric Cancer: Principles of Genetic Risk Assessment for Gastric Cancer
	Comments: There is controversy over how to manage gastric cancer risk in individuals with pathogenic/likely pathogenic variants in <i>CDH1</i> in the absence of a family history of gastric cancer. However, one small study found that >50% of such individuals had gastric cancer identified at the time of risk-reducing total gastrectomy (Jacobs MF, et al. Gastroenterology 2019;157:87-96). Cleft lip with or without cleft palate has been associated with <i>CDH1</i> pathogenic/likely pathogenic variants (Frebourg T, et al. J Med Genet 2006;43:138-142).		
CDKN2A	No increased risk of breast cancer	No increased risk of ovarian cancer	Increased risk of pancreatic cancer <ul style="list-style-type: none">See PANC-A
CHEK2	Increased risk of female breast cancer^f <ul style="list-style-type: none">Screening: Annual mammogram with consideration of tomosynthesis and consider breast MRI with contrast starting at age 40 y^{g,h}RRM: Evidence insufficient, manage based on family history	No increased risk of ovarian cancer	Colon <ul style="list-style-type: none">See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal
	Comments: Risk data are based only on frameshift pathogenic/likely pathogenic variants. The risks for most missense variants are unclear but for some pathogenic/likely pathogenic variants, such as Ile157Thr, the risk for breast cancer appears to be lower. Management should be based on best estimates of cancer risk for the specific pathogenic/likely pathogenic variant.		
MSH2, MLH1, MSH6, PMS2, EPCAM ⁱ	Unknown or insufficient evidence for breast cancer risk^g <ul style="list-style-type: none">Manage based on family history	Increased risk of ovarian cancer <ul style="list-style-type: none">See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal	Colon, Uterine, Others <ul style="list-style-type: none">See NCCN Guidelines for Genetic/Familial High-Risk Assessment: ColorectalPancreatic (insufficient evidence for PMS2)See PANC-A
	Comment: Counsel for risk of autosomal recessive condition in offspring.		

RRM: Risk-reducing mastectomy

[Continued](#)

[Footnotes on GENE-A 5 of 5](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 1.2020

Genetic Testing Process

CANCER RISK MANAGEMENT BASED ON GENETIC TEST RESULTS^{a-e}

The inclusion of a gene in this table below does not imply the endorsement either for or against multi-gene testing for moderate-penetrance genes.

Gene	Breast Cancer Risk and Management	Ovarian Cancer Risk and Management	Other Cancer Risks and Management
NBN	Increased risk of female breast cancer for individuals with 657del5 variant^f <ul style="list-style-type: none"> Screening: Annual mammogram with consideration of tomosynthesis and consider breast MRI with contrast starting at age 40 y^{g,h} RRM: Evidence insufficient, manage based on family history 	Potential increase in ovarian cancer risk, <ul style="list-style-type: none"> RRSO: Evidence insufficient; manage based on family history 	Unknown or insufficient evidence for other cancers
	Comments: Current data suggest that breast cancer risks are not increased for pathogenic/likely pathogenic variants other than 657del5. Counsel for risk of autosomal recessive condition in children.		
NF1	Increased risk of female breast cancer^f <ul style="list-style-type: none"> Screening: Annual mammogram with consideration of tomosynthesis starting at age 30 y and consider breast MRI with contrast from ages 30–50 y^{g,h} RRM: Evidence insufficient, manage based on family history 	No increased risk of ovarian cancer	<ul style="list-style-type: none"> Malignant peripheral nerve sheath tumors, GIST, others Recommend referral to <i>NF1</i> specialist for evaluation and management
	Comments: At this time, there are no data to suggest an increased breast cancer risk after age 50 y. Screening recommendations only apply to individuals with a clinical diagnosis of NF. Consider possibility of false-positive MRI results due to presence of breast neurofibromas.		
PALB2	Increased risk of female breast cancer^f <ul style="list-style-type: none"> Screening: Annual mammogram with consideration of tomosynthesis and breast MRI with contrast at 30 y^{g,h} RRM: Discuss option of risk-reducing mastectomy 	Potential increase in ovarian cancer risk <ul style="list-style-type: none"> RRSO: Evidence insufficient; manage based on family history 	<ul style="list-style-type: none"> Pancreatic <ul style="list-style-type: none"> ▶ See PANC-A Unknown or insufficient evidence for other cancers
	Comments: Counsel for risk of autosomal recessive condition in offspring.		
PTEN	Increased risk of female breast cancer <ul style="list-style-type: none"> ▶ See Cowden Syndrome Management 	No increased risk of ovarian cancer	See Cowden Syndrome Management

RRM: Risk-reducing mastectomy

RRSO: Risk-reducing salpingo-oophorectomy

[Continued](#)

[Footnotes on GENE-A 5 of 5](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 1.2020

Genetic Testing Process

CANCER RISK MANAGEMENT BASED ON GENETIC TEST RESULTS^{a-e}

The inclusion of a gene in this table below does not imply the endorsement either for or against multi-gene testing for moderate-penetrance genes.

Gene	Breast Cancer Risk and Management	Ovarian Cancer Risk and Management	Other Cancer Risks and Management
RAD51C	Potential increase in triple-negative female breast cancer risk with insufficient evidence for risk management	Increased risk of ovarian cancer • Consider RRSO at 45–50 y	N/A
	Comments: Counsel for risk of autosomal recessive condition in offspring. Based on estimates from available studies, the lifetime risk of ovarian cancer in carriers of pathogenic/likely pathogenic variants in <i>RAD51C</i> appears to be sufficient to justify consideration of RRSO. The current evidence is insufficient to make a firm recommendation as to the optimal age for this procedure. Based on the current, limited evidence base, a discussion about surgery should be held around age 45–50 y or earlier based on a specific family history of an earlier onset ovarian cancer.		
RAD51D	Potential increase in triple-negative female breast cancer risk with insufficient evidence for risk management	Increased risk of ovarian cancer • Consider RRSO at 45–50 y	N/A
	Comments: Based on estimates from available studies, the lifetime risk of ovarian cancer in carriers of pathogenic/likely pathogenic variants in <i>RAD51D</i> appears to be sufficient to justify consideration of RRSO. The current evidence is insufficient to make a firm recommendation as to the optimal age for this procedure. Based on the current, limited evidence base, a discussion about surgery should be held around age 45–50 y or earlier based on a specific family history of an earlier onset ovarian cancer.		
STK11	Increased risk of female breast cancer • Screening: See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal - Peutz-Jeghers syndrome • RRM: Evidence insufficient, manage based on family history	Increased risk of non-epithelial ovarian tumors • See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal - Peutz-Jeghers syndrome	• See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal - Peutz-Jeghers syndrome • Pancreatic , see PANC-A
TP53	Increased risk of female breast cancer • See Li-Fraumeni Syndrome Management	No increased risk of ovarian cancer	• See Li-Fraumeni Syndrome Management • Pancreatic , see PANC-A

RRM: Risk-reducing mastectomy

RRSO: Risk-reducing salpingo-oophorectomy

[Footnotes on GENE-A 5 of 5](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



FOOTNOTES/REFERENCES FOR TABLES

- ^a Tung N, Domchek SM, Stadler Z, et al. Counselling framework for moderate-penetrance cancer-susceptibility mutations. *Nat Rev Clin Oncol* 2017;13:581-588. [See Discussion](#) for further details regarding the rationale for different starting ages for breast screening.
- ^b Couch FJ, Shimelis H, Hu C, et al. Associations between cancer predisposition testing panel genes and breast cancer. *JAMA Oncol* 2017;3:1190-1196.
- ^c Lilyquist J, LaDuca H, Polley E, et al. Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls. *Gynecol Oncol* 2017;147:375-380.
- ^d Kurian A, Hughes E, Handorf E, et al. Breast and ovarian cancer penetrance estimates derived from germline multiple-gene sequencing results in women. *Precis Oncol* 2017;1:1-12.
- ^e The following genes and others are found on some of the panels, but there is insufficient evidence to make *any* recommendations for breast MRI, RRSO, or *RRM*; *FANCC*, *MRE11A*, or *MUTYH* heterozygotes; or *RECQL4*, *RAD50*, *RINT1*, *SLX4*, *SMARCA4*, or *XRCC2*.
- ^f Screening and risk-reduction management is extrapolated from *BRCA1/2* data based on levels of risk.
- ^g May be modified based on family history (typically beginning screening 5–10 years earlier than the youngest diagnosis in the family but not later than stated in the table) or specific gene pathogenic/likely pathogenic variant.
- ^h For women with pathogenic/likely pathogenic variants who are treated for breast cancer and have not had bilateral mastectomy, screening should continue as described.
- ⁱ Recent data have demonstrated no significant association between pathogenic/likely pathogenic germline *PMS2* variants and risks of Lynch syndrome cancers beyond colorectal and endometrial cancer (Ten Broeke SW, et al. *J Clin Oncol*;36:2961-2968). This study did not specifically evaluate pancreatic cancer in *PMS2* carriers, but we should note that it is currently unclear if individuals with germline *PMS2* variants have increased risk of pancreatic cancer, even though it is a Lynch syndrome gene. There are no data to quantify the strength of association between *EPCAM* and pancreatic cancer, but *EPCAM* is generally thought to have the same cancer risks/penetrance as *MSH2*, given that pathogenic/likely pathogenic germline alterations in *EPCAM* induce constitutional silencing of *MSH2*.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 1.2020

BRCA-Pathogenic/Likely Pathogenic Variant - Positive Management

BRCA PATHOGENIC/LIKELY PATHOGENIC VARIANT-POSITIVE MANAGEMENT

WOMEN

- Breast awareness^a starting at age 18 y.
- Clinical breast exam, every 6–12 mo,^b starting at age 25 y.
- Breast screening^{c,d}
 - ▶ Age 25–29 y, annual breast MRI^e screening with contrast^f (or mammogram with consideration of tomosynthesis, only if MRI is unavailable) or individualized based on family history if a breast cancer diagnosis before age 30 is present.
 - ▶ Age 30–75 y, annual mammogram with consideration of tomosynthesis and breast MRI^e screening with contrast.
 - ▶ Age >75 y, management should be considered on an individual basis.
 - ▶ For women with a *BRCA* pathogenic/likely pathogenic variant who are treated for breast cancer and have not had a bilateral mastectomy, screening with annual mammogram with consideration of tomosynthesis and breast MRI should continue as described above.
- Discuss option of risk-reducing mastectomy
 - ▶ Counseling should include a discussion regarding degree of protection, reconstruction options, and risks. In addition, the family history and residual breast cancer risk with age and life expectancy should be considered during counseling.
- Recommend risk-reducing salpingo-oophorectomy (RRSO),^g typically between 35 and 40 y, and upon completion of child bearing. Because ovarian cancer onset in patients with *BRCA2* pathogenic/likely pathogenic variants is an average of 8–10 years later than in patients with *BRCA1* pathogenic/likely pathogenic variants, it is reasonable to delay RRSO for management of ovarian cancer risk until age 40–45 y in patients with *BRCA2* pathogenic/likely pathogenic variants unless age at diagnosis in the family warrants earlier age for consideration of prophylactic surgery. See Risk-Reducing Salpingo-Oophorectomy (RRSO) Protocol in [NCCN Guidelines for Ovarian Cancer](#) - Principles of Surgery.
 - ▶ Counseling includes a discussion of reproductive desires, extent of cancer risk, degree of protection for breast and ovarian cancer, management of menopausal symptoms, hormone replacement therapy, and related medical issues.
 - ▶ Salpingectomy alone is not the standard of care for risk reduction, although clinical trials of interval salpingectomy and delayed oophorectomy are ongoing. The concern for risk-reducing salpingectomy alone is that women are still at risk for developing ovarian cancer. In addition, in premenopausal women, oophorectomy likely reduces the risk of developing breast cancer but the magnitude is uncertain and may be gene-specific.
- Limited data suggest that there may be a slightly increased risk of serous uterine cancer among women with a *BRCA1* pathogenic/likely pathogenic variant. The clinical significance of these findings is unclear. Further evaluation of the risk of serous uterine cancer in the *BRCA* population needs to be undertaken. The provider and patient should discuss the risks and benefits of concurrent hysterectomy at the time of RRSO for women with a *BRCA1* pathogenic/likely pathogenic variant prior to surgery. Women who undergo hysterectomy at the time of RRSO are candidates for estrogen alone hormone replacement therapy, which is associated with a decreased risk of breast cancer compared to combined estrogen and progesterone, which is required when the uterus is left in situ (Chlebowski R, Rohan T, Manson J, et al. JAMA Oncol 2015;1:296-305).
- Address psychosocial and quality-of-life aspects of undergoing risk-reducing mastectomy and/or salpingo-oophorectomy.
- For those patients who have not elected RRSO, transvaginal ultrasound combined with serum CA-125 for ovarian cancer screening, although of uncertain benefit, may be considered at the clinician's discretion starting at age 30–35 y.
- Consider risk reduction agents as options for breast and ovarian cancer, including discussing risks and benefits ([See Discussion](#) for details). ([See NCCN Guidelines for Breast Cancer Risk Reduction](#)).
- Consider investigational imaging and screening studies, when available (eg, novel imaging technologies, more frequent screening intervals) in the context of a clinical trial.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Footnotes on
BRCA-A 2 of 2
Continued](#)

BRCA-A
1 OF 2



NCCN Guidelines Version 1.2020

BRCA-Pathogenic/Likely Pathogenic Variant - Positive Management

BRCA PATHOGENIC/LIKELY PATHOGENIC VARIANT-POSITIVE MANAGEMENT

MEN^h

- Breast self-exam training and education starting at age 35 y
- Clinical breast exam, every 12 mo, starting at age 35 y
- Starting at age 40 y: ([See Guidelines for Prostate Cancer Early Detection](#))
 - Recommend prostate cancer screening for *BRCA2* carriers
 - Consider prostate cancer screening for *BRCA1* carriers

MEN AND WOMEN

- Education regarding signs and symptoms of cancer(s), especially those associated with *BRCA* gene pathogenic/likely pathogenic variants.
- No specific screening guidelines exist for melanoma, but general melanoma risk management is appropriate, such as annual full-body skin examination and minimizing UV exposure.
- For pancreatic cancer screening recommendations, [see PANC-A](#).

RISK TO RELATIVES

- Advise about possible inherited cancer risk to relatives, options for risk assessment, and management.
- Recommend genetic counseling and consideration of genetic testing for at-risk relatives.

^a Women should be familiar with their breasts and promptly report changes to their health care provider. Periodic, consistent breast self exam (BSE) may facilitate breast self awareness. Premenopausal women may find BSE most informative when performed at the end of menses.

^b Randomized trials comparing clinical breast exam versus no screening have not been performed. Rationale for recommending clinical breast exam every 6–12 mo is the concern for interval breast cancers.

^c The appropriateness of imaging modalities and scheduling is still under study. Lowry KP, Lee JM, Kong CY, et al. Annual screening strategies in *BRCA1* and *BRCA2* gene mutation carriers: a comparative effectiveness analysis. *Cancer* 2012;118:2021-2030.

^d Lehman CD, Lee JM, DeMartini WB, et al. Screening MRI in women with a personal history of breast cancer. *J Natl Cancer Inst* 2016;108.

^e The criteria for high-quality breast MRI include a dedicated breast coil, the ability to perform biopsy under MRI guidance, radiologists experienced in breast MRI, and regional availability. Breast MRI is preferably performed on days 7–15 of a menstrual cycle for premenopausal women.

^f Breast MRI is preferred due to the theoretical risk of radiation exposure in pathogenic/likely pathogenic variant carriers.

^g Given the high rate of occult neoplasms, special attention should be given to sampling and pathologic review of the ovaries and fallopian tubes. ([See Discussion](#) for details.) [See the College of American Pathologists, Protocol for the Examination of Specimens from Patients with Carcinoma of the Ovary](#). [See NCCN Guidelines for Ovarian Cancer](#) for treatment of findings.

^h There are only limited data to support breast imaging in men.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



PANCREATIC CANCER SCREENING

- Emerging data have examined the efficacy of pancreatic cancer screening in select individuals at increased risk for exocrine pancreatic cancer. To date, most such studies have restricted pancreatic cancer screening to individuals with:
 1. A known pathogenic/likely pathogenic germline variant in a pancreatic cancer susceptibility gene (*ATM*, *BRCA1*, *BRCA2*, *CDKN2A*, *MLH1*, *MSH2*, *MSH6*, *EPCAM*, *PALB2*, *STK11*, *TP53*; [see GENE-A](#)) and a family history of pancreatic cancer (first-degree or second-degree relative) from the same side of the family as the germline pathogenic/likely pathogenic variant; or
 2. A family history of exocrine pancreatic cancer in ≥ 2 first-degree relatives from the same side of the family, even in the absence of a known pathogenic/likely pathogenic germline variant (many centers would enroll individuals with one affected first-degree relative and one second-degree relative); or
 3. A family history of exocrine pancreatic cancer in ≥ 3 first- and/or second-degree relatives from the same side of the family, even in the absence of a known pathogenic/likely pathogenic germline variant.
- These studies have typically started screening with contrast-enhanced MRI/magnetic resonance cholangiopancreatography (MRCP) and/or endoscopic ultrasound (EUS) in such high-risk individuals.
- Potential benefits of pancreatic cancer screening include a suggestion of downstaging, compared to historical data, in that 75%–90% of screen-detected pancreatic cancer has been surgically resectable at diagnosis (which is markedly higher than historical rates of resectability with pancreatic cancers detected due to symptoms).^{a,b} There has also been a suggestion of improved mortality compared to historical data, with one study demonstrating an 85% 3-year overall survival rate after screen-detected pancreatic cancer in high-risk individuals,¹ and another study demonstrating a 24% 5-year overall survival rate following screen-detected pancreatic cancer in individuals with germline c.67G>C *CDKN2A* variants.^b The Canto study also demonstrated 100% overall survival among 10 individuals with screen-detected precursor lesions (intraductal papillary mucinous neoplasms [IPMN] with high-grade dysplasia and/or high-grade pancreatic intraepithelial neoplasia [PanIN]) treated with surgical resection.
- Although evidence for downstaging has emerged in recent studies, longer-term studies are needed to determine if this downstaging translates to improved survival. Evidence from patients with sporadic forms of pancreatic ductal adenocarcinoma suggest that long-term survival is common for patients who present with stage I disease. Since many patients who undergo pancreatic surveillance have pancreatic abnormalities, mostly subcentimeter pancreatic cysts (42% of high-risk individuals in one study^c had at least one pancreatic mass/cyst and/or duct abnormality), there is potential for unnecessary interventions (such as fine-needle aspiration [FNA] and in some cases surgery). Although there is much more experience with evaluating and managing pancreatic cysts and other pancreatic imaging abnormalities, determination of the overall risk/benefits of pancreatic surveillance requires further study. Results of surveillance of high-risk individuals performed in tertiary care/high-volume centers under clinical trial settings may not be the same as those performed in routine clinical practice. Data are beginning to better define which screen-detected lesions in high-risk individuals should be considered to be at particularly high risk for neoplastic progression (eg, those with a solid pancreatic mass, those with pancreatic duct abnormalities, those with growing pancreatic cysts^a), but further data are needed to better define the threshold for surgical intervention and biopsy in high-risk individuals undergoing pancreatic cancer screening.

^a Canto MI, Almario JA, Schulick RD, et al. *Gastroenterology* 2018;155:740-751.

^b Vasen H, Ibrahim I, Ponce CG, et al. *J Clin Oncol* 2016;34:2010-2019.

^c Canto MI, Hruban RH, Fishman EK, et al. *Gastroenterology* 2012;142:796-804.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



PANCREATIC CANCER SCREENING

- For individuals considering pancreatic cancer screening, the panel recommends that screening be performed in experienced high-volume centers, ideally under research conditions. The panel recommends that such screening only take place after an in-depth discussion about the potential limitations to screening, including cost, the high incidence of pancreatic abnormalities, and uncertainties about the potential benefits of pancreatic cancer screening.
- The panel recommends that screening be considered using annual contrast-enhanced MRI/MRCP and/or EUS, with consideration of shorter screening intervals for individuals found to have worrisome abnormalities on screening. The panel emphasizes that most small cystic lesions found on screening will not warrant biopsy, surgical resection, or any other intervention.
- For all individuals with pathogenic/likely pathogenic germline variants in *STK11*
 - ▶ Consider pancreatic cancer screening beginning at age 30–35 years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family, whichever is earlier).
- For all individuals with pathogenic/likely pathogenic germline variants in *CDKN2A*
 - ▶ Consider pancreatic cancer screening beginning at age 40 years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family, whichever is earlier).
- For individuals with pathogenic/likely pathogenic germline variants in one of the other pancreatic cancer susceptibility genes (*ATM*, *BRCA1*, *BRCA2*, *MLH1*, *MSH2*, *MSH6*, *EPCAM*, *PALB2*, *TP53*), [see GENE-A](#).
 - ▶ Consider pancreatic cancer screening beginning at age 50 years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family, whichever is earlier) for individuals with exocrine pancreatic cancer in ≥1 first- or second-degree relatives from the same side of (or presumed to be from the same side of) the family as the identified pathogenic/likely pathogenic germline variant.^d
 - ▶ The panel does not currently recommend pancreatic cancer screening for carriers of mutations in genes other than *STK11* and *CDKN2A* in the absence of a close family history of exocrine pancreatic cancer.

Hereditary pancreatitis genes

- For individuals with pathogenic/likely pathogenic variants in *PRSS1* or other hereditary pancreatitis genes AND a clinical phenotype consistent with hereditary pancreatitis^e
 - ▶ Consider pancreatic cancer screening 20 years after onset of pancreatitis, or at age 40 years, whichever is earlier.

^d Abe T, Blackford A, Tamura K, et al. J Clin Oncol 2019;37:1070-1080.

^e The panel recognizes that patients with hereditary pancreatitis (sometimes caused by pathogenic germline variants in *PRSS1*, *SPINK1*, and other genes) have increased lifetime risks of pancreatic cancer. The clinical significance of pathogenic germline variants in these genes is unclear, when such variants are identified in individuals lacking a clinical history of pancreatitis. As such, the panel recommends germline testing for *PRSS1*, *SPINK1*, and other pancreatitis genes in individuals with a personal and/or family history of exocrine pancreatic cancer only if there is a personal and/or family history suggestive of hereditary pancreatitis.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



LI-FRAUMENI SYNDROME MANAGEMENT IN ADULTS

BREAST CANCER RISK FOR WOMEN

- Breast awareness^a starting at age 18 y.
- Clinical breast exam, every 6–12 mo, starting at age 20 y.^b
- Breast screening
 - ▶ Age 20–29^b y, annual breast MRI^c screening with contrast.^d
 - ▶ Age 30–75 y, annual breast MRI^c screening with contrast and mammogram with consideration of tomosynthesis.
 - ▶ Age >75 y, management should be considered on an individual basis.
 - ▶ For women with a *TP53* pathogenic/likely pathogenic variant who are treated for breast cancer, and who have not had a bilateral mastectomy, screening with annual breast MRI and mammogram with consideration of tomosynthesis should continue as described above.
- Discuss option of risk-reducing mastectomy
 - ▶ Counseling should include a discussion regarding degree of protection, reconstruction options, and risks. In addition, the family history and residual breast cancer risk with age and life expectancy should be considered during counseling.
- Address psychosocial and quality-of-life aspects of undergoing risk-reducing mastectomy.

OTHER CANCER RISKS

- Comprehensive physical exam including neurologic examination with high index of suspicion for rare cancers and second malignancies in cancer survivors every 6–12 mo.
- Colonoscopy and upper endoscopy every 2–5 y starting at 25 y or 5 y before the earliest known colon cancer in the family (whichever comes first).
- Annual dermatologic examination starting at 18 y.
- Annual whole body MRI^{e,f,g} (category 2B).
- Annual brain MRI (category 2B) may be performed as part of the whole body MRI or as a separate exam.

^a Women should be familiar with their breasts and promptly report changes to their health care provider. Periodic, consistent BSE may facilitate breast self awareness. Premenopausal women may find BSE most informative when performed at the end of menses.

^b Or at the age of the earliest diagnosed breast cancer in the family, if younger than age 20 y.

^c High-quality breast MRI limitations include having: a need for a dedicated breast coil, the ability to perform biopsy under MRI guidance by experienced radiologists in breast MRI, and regional availability. Breast MRI is preferably performed on days 7–15 of a menstrual cycle for premenopausal women.

^d Or mammogram with consideration of tomosynthesis, if MRI is unavailable. Breast MRI is preferred because of concerns regarding the risk of radiation exposure in pathogenic/likely pathogenic variant carriers.

^e Whole body MRI is not uniformly available. If whole body MRI is not available, then individuals with LFS are encouraged to participate in clinical trials or consider alternate comprehensive imaging methods. Other components of screening are being evaluated in protocols, including biochemical screening and regular blood screening for hematologic malignancies.

^f Ballinger M, Best A, Mai P, et al. Baseline surveillance in Li-Fraumeni syndrome using whole-body magnetic resonance imaging: a meta-analysis. *JAMA Oncol* 2017;3:1634-1639.

^g Screening through whole body MRI has been broadly demonstrated to be feasible and of potential utility in the early detection of cancer among classic LFS families, though it also results in the detection of false-positive findings and possible cancer overdiagnosis. Furthermore, screening utility has not been evaluated among those with a germline *TP53* pathogenic/likely pathogenic variant without a classic family history of LFS, who are increasingly identified through multi-gene panel tests.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

Continued

**LIFR-A
1 OF 2**



LI-FRAUMENI SYNDROME MANAGEMENT IN ADULTS

OTHER ASPECTS OF MANAGING LFS

- This screening and management of LFS is complex; it is preferred that individuals with LFS be followed at centers with expertise in the management of this syndrome.
- Because of the remarkable risk of additional primary neoplasms, screening may be considered for cancer survivors with LFS and a good prognosis from their prior tumor(s).
- Address limitations of screening for many cancers associated with LFS.
- Pediatricians should be apprised of the risk of childhood cancers in affected families and review screening recommendations for children with LFS.^h
- Therapeutic RT for cancer should be avoided when possible; diagnostic radiation should be minimized to the extent feasible without sacrificing accuracy.
- Provide additional surveillance based on family history of cancer.
- Provide education regarding signs and symptoms of cancer.
- Address psychosocial and quality-of-life aspects of the complex management of LFS.
- There is controversy over how to manage cancer risk in incidental *TP53* carriers who do not meet classic LFS criteria; some data suggest lower cancer risks in *TP53* pathogenic/likely pathogenic carriers who do not have a family history consistent with LFS.

REPRODUCTIVE OPTIONS

- For patients of reproductive age, advise about options for prenatal diagnosis and assisted reproduction including pre-implantation genetic diagnosis. Discussion should include known risks, limitations, and benefits of these technologies. [See Discussion](#) for details.

RISK TO RELATIVES

- Advise about possible inherited cancer risk to relatives, options for risk assessment, and management.
- Recommend genetic counseling and consideration of genetic testing for at-risk relatives.

TESTING CONSIDERATIONS

- Somatic *TP53* variants frequently confound germline testing results. Late post-zygotic aberrant clonal expansions (ACEs) containing a pathogenic *TP53* variant, limited to the hematologic compartment or to a tumor, may be detected in the blood or saliva through germline testing, particularly using NGS technology. The phenomenon of ACE is well described and is most often due to CHIP, which can be demonstrated in healthy populations at increasing frequency with increasing age (Jaiswal S, et al. *N Engl J Med* 2014;371:2488-2498; Genovese G, et al. *N Engl J Med* 2014;371:2477-2487). This finding has important clinical implications regarding potential application of unwarranted clinical interventions. Further, the finding of clonal hematopoiesis itself may portend adverse clinical outcomes, such as the development of hematologic neoplasia and increased non-hematologic mortality.
- Blood and/or saliva is an unsuitable source of DNA for germline testing for cases with a history of hematologic abnormalities. Careful examination of the patient's complete blood count (CBC) and peripheral blood smear may be warranted in all cases reporting the discovery of a *TP53* pathogenic/likely pathogenic variant, and testing of non-lymphoid ancillary tissues may help to delineate bona fide mosaic involvement of different germ layers (Weitzel J, et al. *Genet Med* 2018;20:809-816).

^h For additional information on the management of children with LFS, see Kratz C, Achatz M, Brugières L, et al. *Clin Cancer Res* 2017;23:e38-e45.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 1.2020

Cowden Syndrome/PTEN Hamartoma Tumor Syndrome Management

REVISED CLINICAL DIAGNOSTIC CRITERIA FOR PTEN HAMARTOMA TUMOR SYNDROME^a

MAJOR CRITERIA:

- Breast cancer
- Endometrial cancer (epithelial)
- Thyroid cancer (follicular)
- GI hamartomas (including ganglioneuromas, but excluding hyperplastic polyps; ≥3)
- Lhermitte-Duclos disease (adult)
- Macrocephaly (≥97th percentile: 58 cm for females, 60 cm for males)
- Macular pigmentation of the glans penis
- Multiple mucocutaneous lesions (any of the following):
 - ▶ Multiple trichilemmomas (≥3, at least one biopsy proven)
 - ▶ Acral keratoses (≥3 palmoplantar keratotic pits and/or acral hyperkeratotic papules)
 - ▶ Mucocutaneous neuromas (≥3)
 - ▶ Oral papillomas (particularly on tongue and gingiva), multiple (≥3) OR biopsy proven OR dermatologist diagnosed

MINOR CRITERIA:

- Autism spectrum disorder
- Colon cancer
- Esophageal glycogenic acanthoses (≥3)
- Lipomas (≥3)
- Intellectual disability (ie, IQ ≤75)
- Renal cell carcinoma
- Testicular lipomatosis
- Thyroid cancer (papillary or follicular variant of papillary)
- Thyroid structural lesions (eg, adenoma, multinodular goiter)
- Vascular anomalies/malformations (including multiple intracranial developmental venous anomalies)

Operational diagnosis in an individual (either of the following):

1. Three or more major criteria, but one must include macrocephaly, Lhermitte-Duclos disease, or GI hamartomas; or
2. Two major and three minor criteria.

Operational diagnosis in a family where one individual meets revised PTEN hamartoma tumor syndrome clinical diagnostic criteria or has a *PTEN* pathogenic/likely pathogenic variant:

1. Any two major criteria with or without minor criteria; or
2. One major and two minor criteria; or
3. Three minor criteria.

^a Pilarski R, Burt R, Kohlman W, et al. Cowden syndrome and the PTEN hamartoma tumor syndrome: Systematic review and revised diagnostic criteria. J Natl Cancer Inst 2013;105:1607-1616.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 1.2020

Cowden Syndrome/PTEN Hamartoma Tumor Syndrome Management

COWDEN SYNDROME/PHTS MANAGEMENT

WOMEN

- Breast awareness^b starting at age 18 y.
- Clinical breast exam, every 6–12 mo, starting at age 25 y or 5–10 y before the earliest known breast cancer in the family (whichever comes first).
- Breast screening
 - ▶ Annual mammography with consideration of tomosynthesis and breast MRI screening with contrast starting at age 30–35 y or 5–10 y before the earliest known breast cancer in the family (whichever comes first).^{c,d}
 - ▶ Age >75 y, management should be considered on an individual basis.
 - ▶ For women with a *PTEN* pathogenic/likely pathogenic variant who are treated for breast cancer, and have not had a bilateral mastectomy, screening with annual mammogram with consideration of tomosynthesis and breast MRI should continue as described above.
- Discuss option of risk-reducing mastectomy in women with pathogenic/likely pathogenic variants identified. For those with clinical Cowden syndrome, consideration of risk-reducing surgery should be based on family history.
 - ▶ Counseling should include a discussion regarding degree of protection, reconstruction options, and risks. In addition, the family history and residual breast cancer risk with age and life expectancy should be considered during counseling.
- For endometrial cancer screening,^e consider starting by age 35 y.
 - ▶ Encourage patient education and prompt response to symptoms (eg, abnormal bleeding). Patients are encouraged to keep a calendar in order to identify irregularities in their menstrual cycle.
 - ▶ Because endometrial cancer can often be detected early based on symptoms, women should be educated regarding the importance of prompt reporting and evaluation of any abnormal uterine bleeding or postmenopausal bleeding. The evaluation of these symptoms should include endometrial biopsy.
 - ▶ Endometrial cancer screening does not have proven benefit in women with CS/PHTS. However, endometrial biopsy is both highly sensitive and highly specific as a diagnostic procedure. Screening via endometrial biopsy every 1 to 2 years can be considered.
 - ▶ Transvaginal ultrasound to screen for endometrial cancer in postmenopausal women has not been shown to be sufficiently sensitive or specific as to support a positive recommendation, but may be considered at the clinician's discretion. Transvaginal ultrasound is not recommended as a screening tool in premenopausal women due to the wide range of endometrial stripe thickness throughout the normal menstrual cycle.
- Discuss option of hysterectomy^f upon completion of childbearing and counsel regarding degree of protection, extent of cancer risk, and reproductive desires.
- Address psychosocial and quality-of-life aspects of undergoing risk-reducing mastectomy and/or hysterectomy.

^b Women should be familiar with their breasts and promptly report changes to their health care provider. Periodic, consistent BSE may facilitate breast self awareness. Premenopausal women may find BSE most informative when performed at the end of menses.

^c The appropriateness of imaging modalities and scheduling is still under study.

^d High-quality breast MRI limitations include having: a need for a dedicated breast coil, the ability to perform biopsy under MRI guidance by experienced radiologists in breast MRI, and regional availability. Breast MRI is preferably performed on days 7–15 of a menstrual cycle for premenopausal women.

^e There are limited data regarding the lifetime risk of endometrial cancer in CS/PHTS. Surveillance screening and surgical intervention should be on an individual basis.

^f Oophorectomy is not indicated for CS/PHTS alone but may be indicated for other reasons.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)

COWD-A
2 OF 3



NCCN Guidelines Version 1.2020

Cowden Syndrome/PTEN Hamartoma Tumor Syndrome Management

COWDEN SYNDROME/PHTS MANAGEMENT

MEN AND WOMEN

- Annual comprehensive physical exam starting at age 18 y or 5 y before the youngest age of diagnosis of a component cancer in the family (whichever comes first), with particular attention to thyroid exam.
- Annual thyroid ultrasound starting at age 7 y.
- Colonoscopy, starting at age 35 y unless symptomatic or if close relative with colon cancer before age 40 y, then start 5–10 y before the earliest known colon cancer in the family. Colonoscopy should be done every 5 y or more frequently if patient is symptomatic or polyps are found.
- Consider renal ultrasound starting at age 40 y, then every 1–2 y.
- There may be an increased risk of melanoma, and the prevalence of other skin characteristics with Cowden syndrome may independently make routine dermatology evaluations of value. Annual dermatology recommendations are recommended.
- Consider psychomotor assessment in children at diagnosis and brain MRI if there are symptoms.
- Education regarding the signs and symptoms of cancer.

RISK TO RELATIVES

- Advise about possible inherited cancer risk to relatives, options for risk assessment, and management.
- Recommend genetic counseling and consideration of genetic testing for at-risk relatives.

REPRODUCTIVE OPTIONS

- For women of reproductive age, advise about options for prenatal diagnosis and assisted reproduction including pre-implantation genetic diagnosis. Discussion should include known risks, limitations, and benefits of these technologies. [See Discussion](#) for details.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Categories of Evidence and Consensus

Category 1	Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
Category 2A	Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
Category 2B	Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.
Category 3	Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise indicated.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



Discussion

This discussion is being updated to correspond with the newly updated algorithm. Last updated 01/18/19

Table of Contents

Overview	MS-2
Literature Search Criteria and Guidelines Update Methodology	MS-3
Genetic Risk Assessment and Counseling	MS-3
Formal Risk Assessment	MS-4
Evaluation of Patient's Needs and Concerns	MS-4
Detailed Family History	MS-5
Medical and Surgical History	MS-5
Focused Physical Examination	MS-6
Genetic Counseling	MS-6
Genetic Testing	MS-7
Multi-Gene Testing	MS-10
Hereditary Breast or Breast/Ovarian Cancer Syndromes	MS-11
BRCA-Related Breast/Ovarian Cancer Syndrome	MS-12
NCCN Recommendations	MS-18
Risk Assessment, Counseling, and Management	MS-19
Li-Fraumeni Syndrome	MS-29
Risk Assessment, Counseling, and Management	MS-32
Cowden Syndrome/ <i>PTEN</i> Hamartoma Tumor Syndrome	MS-34
Risk Assessment, Counseling, and Management	MS-37
Other Pathogenic/Likely Pathogenic Variants Associated with Breast/Ovarian Cancer	MS-41
ATM	MS-42
BARD1	MS-42
BRIP1	MS-43
CDH1	MS-43
CHEK2	MS-43
MLH1, MSH2, MSH6, PMS2, EPCAM	MS-44
NBN	MS-45
NF1	MS-45
PALB2	MS-46
RAD51C and RAD51D	MS-46
STK11	MS-47

Table 1. Glossary of Relevant Genetic Terms (from the National Cancer Institute [NCI])	MS-48
Table 2. Genetic Test Results to Determine the Presence of a Cancer-Predisposing Gene	MS-49
Table 3. Pathogenic/Likely Pathogenic Variants Associated with Autosomal Recessive Condition	MS-50
References	MS-51



Overview

All cancers develop as a result of mutations in certain genes, such as those involved in the regulation of cell growth and/or DNA repair,^{1,2} although not all of these mutations are inherited from a parent. For example, sporadic mutations can occur in somatic/tumor cells only, and de novo mutations can occur for the first time in a germ cell (ie, egg or sperm) or in the fertilized egg itself during early embryogenesis. However, family studies have long documented an increased risk for several forms of cancer among first-degree relatives (ie, parents, siblings, children) and second-degree relatives (ie, grandparents, aunts or uncles, grandchildren, nieces or nephews) of affected individuals. These individuals may have an increased susceptibility to cancer as the result of one or more gene mutations present in parental germline cells; cancers developing in these individuals may be classified as hereditary or familial cancers.

Hereditary cancers are often characterized by mutations associated with increased risk for certain cancers (ie, a high-penetrance phenotype) and transmission to offspring through the mother and/or father.^{3,4} They often have an early age of onset and exhibit an autosomal dominant inheritance pattern (ie, occur when the individual has a pathogenic or likely pathogenic variant in only one copy of a gene). Familial cancers share some but not all features of hereditary cancers. For example, although familial breast cancers occur in a given family more frequently than in the general population, they generally do not exhibit the inheritance patterns or onset age consistent with hereditary cancers. Familial cancers may be associated with chance clustering of sporadic cancer cases within families, genetic variation in lower penetrance genes, a shared environment, or combinations of these factors.⁵⁻⁸

An individual suspected of being at risk for hereditary cancer should be offered genetic counseling.^{9,10} This is consistent with recommendations

from the US Preventive Services Task Force.¹¹ Assessment of an individual's risk for familial or hereditary cancer is based on a thorough evaluation of the personal and family history. With respect to hereditary cancers, advances in molecular genetics have identified a number of genes associated with inherited susceptibility to breast and/or ovarian cancers (eg, *BRCA1/2*, *TP53*, *CDH1*) and have provided a means of characterizing the specific gene mutation or mutations present in certain individuals and families exhibiting an increased risk for cancer. The field of cancer genetics has implications for all aspects of cancer management of individuals with hereditary or familial cancers, including prevention, screening, and treatment.¹²

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Breast and Ovarian were developed with an acute awareness of the preliminary nature of much of our knowledge regarding the clinical application of the rapidly emerging field of molecular genetics, and with an appreciation for the need for flexibility when applying these guidelines to individual families. Furthermore, it should be emphasized that these guidelines were not developed as a substitute for professional genetic counseling. Rather, they are intended to: 1) serve as a resource for health care providers to identify individuals who may benefit from cancer risk assessment and genetic counseling; 2) provide genetic counselors with an updated tool for the assessment of individual breast cancer and ovarian cancer risk and to guide decisions related to genetic testing; and 3) facilitate a multidisciplinary approach in the management of individuals at increased risk for hereditary breast and/or ovarian cancer. Although cancers other than breast and ovarian cancers are associated with these hereditary syndromes, the main focus of these NCCN Guidelines® is on the management of breast and ovarian cancer risk in these individuals. During the last few years, a number of additional genetic aberrations that may contribute to increased risks for development of breast and/or ovarian



cancers have been identified. The current NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian focus primarily on assessment of pathogenic or likely pathogenic variants in *BRCA1/2*, *TP53*, and phosphatase and tensin homolog (*PTEN*), and recommended approaches to genetic testing/counseling and management strategies in individuals with these pathogenic or likely pathogenic variants. Where possible, pathogenic or likely pathogenic variants in more recently identified genes have been addressed to the extent possible given the limited information available.

A glossary of genetic terms is included in Table 1 for reference.

Literature Search Criteria and Guidelines Update Methodology

Prior to the update of this version of the NCCN Guidelines for Genetics/Familial High-Risk Assessment: Breast and Ovarian, an electronic search of the PubMed database was performed to obtain key literature published between March 14, 2017 and February 28, 2018, using the following search terms: (hereditary breast cancer) or (familial breast cancer) or (hereditary ovarian cancer) or (familial ovarian cancer) or (Li-Fraumeni syndrome) or (Cowden syndrome) or (pten hamartoma tumor syndrome) or (brca breast cancer) or (brca ovarian cancer) or (cancer genetic testing) or (cancer genetic counseling). The PubMed database was chosen because it remains the most widely used resource for medical literature and indexes only peer-reviewed biomedical literature.¹³

The search results were narrowed by selecting studies in humans published in English. Results were confined to the following article types: Clinical Trial, Phase II; Clinical Trial, Phase III; Clinical Trial, Phase IV; Guideline; Practice Guidelines; Randomized Controlled Trials; Meta-Analysis; Systematic Reviews; and Validation Studies.

The data from key PubMed articles and articles from additional sources deemed as relevant to these guidelines and discussed by the panel have been included in this version of the Discussion section (eg, e-publications ahead of print, meeting abstracts). Recommendations for which high-level evidence is lacking are based on the panel's review of lower-level evidence and expert opinion.

The complete details of the Development and Update of the NCCN Guidelines are available on the NCCN website (www.NCCN.org).

Genetic Risk Assessment and Counseling

For a patient concerned about or suspected of having a hereditary propensity for breast and/or ovarian cancer, an initial risk evaluation should be performed in order to determine if a formal risk assessment should be undertaken (see *Criteria for Further Genetic Risk Evaluation* in the algorithm). The first step in this preliminary assessment is a broad and flexible evaluation of the personal and family history of the individual with respect to breast and/or ovarian cancer, as well as other cancers.^{14,15} The magnitude of the risk increases with the number of affected relatives in the family and the closeness of the relationship, and is affected by the age at which the affected relative was diagnosed.^{16,17} The younger the age at diagnosis, the more likely it is that a genetic component is present. When assessing a family history for a hereditary pattern, the equal likelihood of paternal or maternal transmission of a gene that predisposes to breast cancer must also be kept in mind.

If an individual or a close family member of that individual meets any one of the criteria presented in the NCCN Guidelines (see *Criteria for Further Genetic Risk Evaluation* in the algorithm), that individual may be at increased risk for breast and/or ovarian cancer, and a referral for genetic assessment may be considered. The maternal and paternal sides of the family should be considered independently for familial patterns of cancer.



Despite meeting testing criteria, relatively few of these individuals undergo genetic testing.¹⁸

For individuals potentially meeting established criteria for one or more of the hereditary cancer syndromes, genetic testing should be considered along with appropriate pre-test counseling. A genetic counselor, medical geneticist, oncologist, surgeon, oncology nurse, or other health professional with expertise and experience in cancer genetics should be involved in this process.⁹ Those not meeting criteria for testing who are still considered at increased risk for familial breast cancer are also likely to benefit from appropriate risk-reduction strategies (eg, a change in the frequency of, or modalities used for, breast cancer screening).⁵ The panel recommends that these individuals follow recommendations in the NCCN Guidelines for Breast Cancer Screening and Diagnosis (available at www.NCCN.org).

Formal Risk Assessment

Cancer genetic risk assessment and genetic counseling is a multi-step process of identifying and counseling individuals at risk for familial or hereditary cancer.

Cancer genetic risk assessment involves use of pedigree analysis with available risk assessment models to determine whether a family history is suggestive of sporadic, familial, or hereditary cancer. Risk assessment includes both an evaluation of an individual's absolute risk for breast and/or ovarian cancer as well as an estimation of the likelihood that the individual has a heritable pathogenic or likely pathogenic variant in his/her family. Genetic risk assessment is a dynamic process and can change if additional relatives are diagnosed with cancer.

Statistical models based on personal and family history characteristics have been developed to estimate a person's interval and lifetime risks of developing breast cancer. For example, the Claus tables may be useful in

providing breast cancer risk estimates for white women without a known cancer-associated gene mutation who have one or two first- or second-degree female relatives with breast cancer.¹⁹ The Gail model was also developed to assess risk for breast cancer.²⁰ The modified model is a computer-based, multivariate, logistic regression model that uses age, race, age at menarche, age at first live birth or nulliparity, number of first-degree relatives with breast cancer, number of previous breast biopsies, and histology of the breast biopsies to produce actuarial estimates of future breast cancer risk.²¹⁻²³ This model considers only family history of breast cancer in first-degree relatives²⁴ and is heavily weighted by benign breast disease. Therefore, the Gail model may underestimate breast cancer risk for women with a significant family history and should not be used for women suspected of having a hereditary syndrome associated with increased risk for breast cancer.²⁴

Decision models developed to estimate the likelihood that a *BRCA1/2* mutation is present include BRCAPRO^{25,26} and the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA).²⁵ A lifetime risk for breast cancer of 20% to 25% or greater as assessed by models based largely on family history has been used in some guidelines to identify a woman as being at high risk for breast cancer. For example, this risk threshold was used in updates to the American Cancer Society (ACS) guidelines on breast screening, which incorporate MRI.^{27,28}

Evaluation of Patient's Needs and Concerns

The first step in evaluating an individual's risk for hereditary breast cancer is to assess her/his concerns and reasons for seeking counseling and to guarantee that her/his personal needs and priorities will be addressed in the counseling process. Several studies have documented a highly exaggerated perception of risk among women with a family history of breast cancer who seek cancer risk counseling.²⁹ This is a situation that



can interfere with the adoption of appropriate health behaviors. In addition, the patient's knowledge about the benefits, risks, and limitations of genetic testing should be assessed as well as the patient's goals. A positive, supportive interaction with the counseling team is an important determinant of ultimate satisfaction with the counseling process and of adherence to recommended health behaviors.

Detailed Family History

A detailed family history is the cornerstone of effective genetic counseling. An examination of family history involves development of an expanded pedigree collected beginning with the health of the individual diagnosed with cancer and proceeding outward to include first-, second-, and third-degree relatives on both the maternal and paternal sides. Standardized pedigree nomenclature should be used.^{30,31} Unaffected family members, both living and deceased, are also included, as their histories also provide information about the magnitude of genetic risk.

Information collected includes cancer diagnoses by primary site, age at diagnosis, bilaterality (when appropriate), and current age or age at death. Whenever possible, cancer diagnoses in the family are verified by obtaining medical records, pathology reports, or death certificates. This is particularly important in the case of a report of an "abdominal" cancer in a female relative—a situation in which cancers of the cervix, uterus, ovary, and/or colon are often confused. It is also important to know the ancestry/ethnicity of the individual, since members of certain groups (eg, Ashkenazi Jewish) have increased risks of carrying pathogenic or likely pathogenic variants for specific diseases. Any family members who received genetic testing should also be noted, as well as testing results.

Other medical conditions that may be associated with or predispose an individual to breast and/or ovarian cancer should also be noted. Family history data are then graphically represented on a pedigree that follows standard nomenclature to illustrate family relationships and disease

information. Factors that limit the informativeness of the pedigree are small family size, a small number of individuals of the susceptible gender for sex-limited cancers, reduced penetrance, early deaths in family members (which precludes the possibility that they will develop adult diseases), prophylactic surgeries that remove an organ from subsequent risk for cancer (eg, hysterectomy for uterine fibroids in which the ovaries are also removed), adoptions, and inaccurate or incomplete information on family members (eg, in the case of adoption).^{5,32}

A prospective registry study of 306 women diagnosed with breast cancer at <50 years of age, who had no first- or second-degree relatives with breast or ovarian cancer, showed that those individuals with a limited family history (defined as fewer than 2 first- or second-degree female relatives or fewer than 2 female relatives surviving beyond 45 years of age in either lineage) may have an underestimated probability of a *BRCA1/2* mutation based on models dependent on family history.³³

Medical and Surgical History

The collection of a detailed medical and surgical history from the proband allows the counselor to estimate the contribution of other risk factors that may interact with or modify family history to determine the risk for cancer. Any personal cancer history should include age of diagnosis, histology, and laterality. A history of previous breast biopsies and pathology results, especially those in which the pathology revealed atypical hyperplasia or lobular carcinoma in situ (LCIS), is associated with an increased risk for breast cancer.^{34,35} Pathologic verification of these diagnoses is encouraged. History of salpingo-oophorectomy and potential exposure to carcinogens (eg, radiation therapy) should also be included in the patient's assessment. When taking the medical history, the clinician should also be alert to the physical manifestations of Cowden syndrome, especially skin conditions (see section below on *Focused Physical Examination*).



Reproductive variables are important determinants of risk for both breast and ovarian cancer, suggesting a significant contribution of hormones to the etiology of these cancers. This possible link is supported by the increased breast cancer risk seen among women who have had prolonged exposure to exogenous estrogens and progestins and the reduction in risk for ovarian cancer observed among women who report using oral contraceptives.³⁶⁻³⁹

Focused Physical Examination

A physical examination performed by a qualified clinician (when available) should be part of the risk assessment. Particular attention should be paid to organs/areas of the body known to be affected in individuals with specific hereditary breast and/or ovarian syndromes. For example, certain patterns of mucocutaneous manifestations are associated with Cowden syndrome, as discussed below; a focused physical examination for Cowden syndrome should include a comprehensive dermatologic examination (including oral mucosa), evaluation of head circumference (to determine presence of macrocephaly), and palpation of the thyroid (see section below on *Cowden Syndrome/PTEN Hamartoma Tumor Syndrome*).

Genetic Counseling

Genetic counseling is a critical component of the cancer risk assessment process. Many patients undergoing genetic testing do not receive proper counseling.⁴⁰ In the national ABOUT study, patients undergoing genetic testing (N = 3628) completed a survey regarding their experience. About 37% of respondents reported receiving counseling prior to testing.⁴¹ Further, during genetic counseling, many counselors fail to provide a discussion of reproductive risk for autosomal recessive conditions such as Fanconi anemia.⁴² See Table 3 for a list of pathogenic/likely pathogenic variants associated with autosomal recessive conditions.

Counseling for hereditary breast and/or ovarian cancer uses a broad approach to place genetic risk in the context of other related risk factors, thereby customizing counseling to the experiences of the individual. The purpose of cancer genetic counseling is to educate individuals about the genetic, biological, and environmental factors related to the individual's cancer diagnosis and/or risk for disease to help them derive personal meaning from cancer genetic information, and to empower them to make educated, informed decisions about genetic testing, cancer screening, and cancer prevention. Individuals need to understand the relevant genetic, medical, and psychosocial information and be able to integrate this information before they can make an informed decision. The presentation of testing information is most effective when tailored to the age and education of the person undergoing counseling, and that individual's personal exposure to the disease, level of risk, and social environment.⁷ Information could be delivered in person or over the phone.⁴³

Pre-test counseling is an essential element of the genetic counseling process in the event that genetic testing for a pathogenic or likely pathogenic variant associated with a hereditary cancer syndrome is under consideration.⁷ The foundation of pre-test genetic counseling is based on the principle of informed consent.⁹ Pre-test counseling should include a discussion of why the test is being offered and how test results may impact medical management, cancer risks associated with the pathogenic or likely pathogenic variant in question, the significance of possible test results (see *Genetic Testing*, below), the likelihood of a positive result, technical aspects and accuracy of the test, economic considerations, risks of genetic discrimination, psychosocial aspects, confidentiality issues, the potential significance of the test results for family members, and other topics.⁷ The patient should be educated regarding inheritance patterns, penetrance, variable expressivity, and the potential for genetic heterogeneity. A discussion of confidentiality issues should include an explanation of the federal Genetic Information Nondiscrimination Act



(GINA) enacted in 2008, which prohibits most health insurers and employers from discrimination on the basis of genetic test results.⁴⁴

Post-test counseling must also be performed and includes disclosure of results, a discussion of the significance of the results, an assessment of the impact of the results on the emotional state of the individual, a discussion of the impact of the results on the medical management of the individual, and how and where the patient will be followed.⁹ In addition, identification of a pathogenic or likely pathogenic variant associated with a hereditary predisposition to breast and/or ovarian cancer in an individual necessitates a discussion of possible inherited cancer risk to relatives and the importance of informing family members about test results.⁷ Results should be interpreted in the context of personal and family history of cancer. It may also be appropriate to offer genetic testing to both parents of an individual who tests positive for one of these pathogenic or likely pathogenic variants to confirm which side of the family carries the variant and is at increased risk. Counseling should also include making the individual aware of any available resources, such as disease-specific support groups, advocacy groups, and research studies.⁴⁵ Individuals who have tested positive for a pathogenic or likely pathogenic variant may have greater distress than anticipated, so provisions for supportive interventions should be provided.

Genetic Testing

The selection of appropriate candidates for genetic testing is based on the personal and familial characteristics that determine the individual's prior probability of being a carrier of a pathogenic or likely pathogenic variant, and on the psychosocial degree of readiness of the person to receive genetic test results. The potential benefits, limitations, and risks of genetic testing are also important considerations in the decision-making process. Many women feel that they are already doing everything they can to minimize their risk of developing breast cancer, and others fear the

emotional toll of finding out that they are a carrier of a pathogenic or likely pathogenic variant, especially if they have children who would be at risk of inheriting the variant. For those who choose not to proceed with testing, the counseling team tailors recommendations for primary and secondary prevention based on the individual's personal and family history.

In the statement on Genetic and Genomic Testing for Cancer Susceptibility from ASCO updated in 2003, genetic testing is recommended when: 1) there is a personal or family history suggesting genetic cancer susceptibility; 2) the test can be adequately interpreted; and 3) the results will aid in the diagnosis or influence the medical or surgical management of the patient or family members at hereditary risk for cancer.⁴⁶ These recommendations were reiterated in the latest 2010 ASCO update on Genetic and Genomic Testing for Cancer Susceptibility with respect to testing individuals for gene mutations known to cause hereditary breast and/or ovarian cancer(s).⁴⁷

As part of pre-test counseling, the counselor reviews the distinctions between true-positive (ie, pathogenic, likely pathogenic), true-negative, indeterminate (or uninformative), and inconclusive (or variants of unknown significance [VUS]) test results (see Table 2), as well as the technical limitations of the testing process. A clear distinction is made between the probability of being a carrier of a pathogenic or likely pathogenic variant and the probability of developing cancer. The probabilistic nature of genetic test results and the potential implications for other family members must also be discussed.

Individuals who have received allogeneic hematopoietic stem cell transplantation (HSCT) should not have molecular genetic testing performed on blood samples, as these blood cells would represent donor-derived DNA. In such cases, DNA of the individual being tested should be extracted from a fibroblast culture, if available. If this is not possible, buccal cells may be considered as an alternative source for DNA;



however, a study has reported that over time, buccal epithelial cells are replaced by donor-derived cells in allogeneic HSCT recipients.^{48,49}

Therefore, genetic testing using buccal swab samples may be limited given this known risk of donor DNA contamination.

The genetic testing strategy is greatly facilitated when a pathogenic or likely pathogenic variant has already been identified in another family member. In that case, the genetic testing laboratory can limit the search for pathogenic or likely pathogenic variants in additional family members to the same location in the gene. In most cases, an individual testing negative for a known familial pathogenic or likely pathogenic variant predisposing to breast cancer can be followed with routine breast screening. Individuals who meet testing criteria but do not undergo gene testing should be followed as if a pathogenic or likely pathogenic variant (ie, *BRCA1/2*, *PTEN*, or *TP53* pathogenic or likely pathogenic variant) is present, if they have a close family member who is a known carrier of the pathogenic or likely pathogenic variant.

For the majority of families in whom presence of a pathogenic or likely pathogenic variant is unknown, it is best to consider testing an affected family member first, especially a family member with early-onset disease, bilateral disease, or multiple primaries, because that individual has the highest likelihood for a positive test result. Unless the affected individual is a member of an ethnic group for which particular founder pathogenic or likely pathogenic variants are known, comprehensive genetic testing (ie, full sequencing of the genes and detection of large gene rearrangements) should be performed by commercial or academic laboratories that are clinically approved or validated.

For individuals with family histories consistent with a pattern of hereditary breast and/or ovarian cancer on both the maternal and paternal sides, the possibility of a second pathogenic or likely pathogenic variant in the family

should be considered, and full sequencing may be indicated, even if a variant has already been identified in a relative.

In the situation of an unaffected individual with a significant family history, the testing of the unaffected individual (or of unaffected family members) should only be considered when no affected family member is available for testing. In such cases, the unaffected individual or unaffected close relative with the highest likelihood of testing positive for the pathogenic or likely pathogenic variant should be tested. A negative test result in such cases, however, is considered indeterminate (see Table 2) and does not provide the same level of information as when there is a known pathogenic or likely pathogenic variant in the family. Thus, one should be mindful that when testing unaffected individuals (in the absence of having tested affected family members), significant limitations may exist in interpreting the test results, and testing multiple family members may be indicated.

In the case of *BRCA*-related breast/ovarian cancer, if no family member with breast or ovarian cancer is living, consideration can be given to testing first- or second-degree family members affected with cancers thought to be related to the pathogenic or likely pathogenic variant in question (eg, prostate or pancreatic cancer). Importantly, the significant limitations of interpreting testing results for an unaffected individual should be discussed prior to testing.

Reports regarding germline findings that may impact medical management should come from laboratories that are certified by the College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA), with some U.S. states (eg, New York) having additional reporting requirements. Certain large genomic rearrangements are not detectable by a primary sequencing assay, thereby necessitating supplementary testing in some cases.⁵⁰⁻⁵³ For example, there are tests that detect rare, large cancer-associated rearrangements of DNA in the



BRCA1/2 genes that are otherwise not detected by direct sequencing of the *BRCA1/2* genes. Therefore, the NCCN Guidelines Panel emphasizes the need for comprehensive testing, which encompasses full *BRCA1/2* sequencing and detection of large gene rearrangements.

A counseling dilemma is posed by the finding of a VUS (see Table 2), a genetic alteration that may actually represent a benign polymorphism unrelated to an increased breast cancer risk or may indicate an increased breast cancer risk. The individual must be counseled in such a situation, because additional information about that specific pathogenic or likely pathogenic variant will be needed before its significance can be understood. These patients should be considered for referral to research studies that aim to define the functional impact of the gene variant, such as variant reclassification programs through clinical labs or registries. Some examples of these programs and registries include ClinVar (the archival database at the National Center for Biotechnology Information [NCBI]); the NIH-funded Clinical Genome Resource (ClinGen; <https://www.clinicalgenome.org/>); the Clinical Cancer Genetics Community Research Network of the United States, Mexico, and South America (CCGCRN; <https://www.cityofhope.org/research/beckman-research-institute/research-departments-and-divisions/population-sciences/clinical-cancer-genomics/ccg-research-program/ccg-community-research-network>); Prospective Registry of Multiplex Testing (PROMPT; <https://connect.patientcrossroads.org/>); the international Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA; <https://enigmaconsortium.org/>); and the International Society for Gastrointestinal Hereditary Tumors (InSIGHT; <http://insight-group.org/>). It is important to note that there may be inconsistencies among how some programs and registries interpret the clinical actionability of some VUS, which may lead to confusion regarding medical management.⁵⁴⁻⁵⁶

Clinicians and scientists should work together to develop a VUS

classification system as more information is discovered in research studies.⁵⁷

Recently, there has been an increase in genetic test results through direct-to-consumer (DTC) services or through tumor profiling. The testing typically used by companies providing ancestry information directly to consumers is microarray-based single nucleotide polymorphism (SNP) testing that has not been validated for clinical use. These companies do not provide comprehensive genetic risk assessment that includes gross deletion or duplication analysis. Third-party services are available to assist patients with interpreting their raw data, but limitations of these services include inadequate informed consent process, clinical validity and utility, and medical oversight.⁵⁸ An analysis of concordance between DTC testing results and results from confirmatory testing for 49 patients showed a false-positive rate of 40%, as well as variant classification errors in 8 patients.⁵⁹ Given the limitations of the information obtained from DTC services, confirmatory germline testing by a certified laboratory is recommended, and changes to a patient's medical management based solely on DTC testing results are not recommended.⁵⁹

The absence of a pathogenic or likely pathogenic variant for a given gene (eg, *BRCA1/2*, *TP53*) from tumor profiling does not rule out the possibility of a germline pathogenic or likely pathogenic variant in that gene. If a patient meets testing criteria for germline testing for a given gene, then testing should be considered despite negative or indeterminate tumor profiling results. Incidental germline findings discovered through other sources (eg, participation in a research study) should be reviewed by a genetics professional.⁶⁰ Confirmatory testing in these cases may be recommended, especially if the reporting laboratory is not appropriately certified.

Following testing, the proband should be advised regarding possible inherited cancer risk to relatives and his/her options for risk assessment



and management. The counselor should recommend genetic counseling and testing for at-risk relatives. Since some pathogenic or likely pathogenic variants are associated with rare autosomal recessive conditions (eg, Fanconi anemia is associated with *ATM*, *BRCA2*, *BRIP1*, and *PALB2* variants), testing of a partner of a carrier of a pathogenic or likely pathogenic variant may be considered to inform reproductive decision-making.⁶¹ See Table 3 for a list of pathogenic/likely pathogenic variants associated with autosomal recessive conditions.

Multi-Gene Testing

Next-generation sequencing allows for the sequencing of multiple genes simultaneously. This is referred to as multi-gene testing. Multi-gene testing for hereditary forms of cancer has rapidly altered the clinical approach to testing at-risk patients and their families. Multi-gene testing simultaneously analyzes a set of genes that are associated with a specific family cancer phenotype or multiple phenotypes. Multiple studies have shown that this approach may detect pathogenic or likely pathogenic variants not found in single-gene testing.⁶²⁻⁶⁴ A study of 198 women referred for *BRCA1/2* testing who underwent multi-gene testing showed 16 deleterious mutations out of 141 women who tested negative for *BRCA1/2* (11.4%; 95% CI, 7.0–17.7).⁶³ The discovery of these mutations led to recommendations for further screening. Therefore, findings from multi-gene testing have the potential to alter clinical management.⁶⁵

Multi-gene testing could include only high-penetrance genes associated with a specific cancer, or both high- and moderate-penetrance genes. Comprehensive cancer risk panels, which include a large number of genes associated with a variety of cancer types, are also available.⁶⁶ The decision to use multi-gene testing for patient care should be no different than the rationale for testing a single gene known to be associated with the development of a specific type of cancer. Testing is focused on identifying a pathogenic or likely pathogenic variant known to be clinically

actionable; that is, whether the management of an individual patient is altered based on the presence or absence of the variant. Multi-gene testing may be most useful when more than one gene can explain an inherited cancer syndrome. For example, though ovarian cancer is mainly associated with *BRCA1/2* pathogenic or likely pathogenic variants, it may also be associated with variants in the following genes: *BARD1*, *BRIP1*, *MRE11A*, *MSH2*, *MSH6*, *NBN*, *PALB2*, *RAD51C*, *RAD51D*, and *TP53*.⁶⁷⁻⁷⁰ Genes associated with hereditary breast cancer include the following that could potentially be included in a multi-gene test: *BRCA1/2*, *ATM*, *BARD1*, *CHEK2*, *PALB2*, *TP53*, *PTEN*, *STK11*, and *CDH1*.^{10,63,69-75} In these cases where more than one pathogenic or likely pathogenic variant could potentially influence a condition, multi-gene testing may be more efficient and/or cost-effective.^{66,76,77} Multi-gene testing may also be considered for those who tested negative (indeterminate) for one particular syndrome, but whose personal and family history is suggestive of an inherited susceptibility.^{66,78}

There are several issues to consider regarding multi-gene testing. First, commercially available tests may differ significantly on a number of factors, such as number of genes analyzed, turnaround time, insurance coverage, and variant reclassification protocol, among others. Tests requiring a longer turnaround time may not be suitable for patients who need rapid results. The specific laboratory and multi-gene test should be chosen carefully.⁶⁶ Second, in some cases, next-generation sequencing may miss some pathogenic or likely pathogenic variants that would have been detected with traditional single-gene analysis.⁶⁶ Third, pathogenic or likely pathogenic variants identified for more than one gene add complexity that may lead to difficulty in making risk management recommendations.⁷⁸ A management plan should only be developed for identified pathogenic or likely pathogenic variants that are clinically actionable.



A major dilemma regarding multi-gene testing is that there are limited data and a lack of clear guidelines regarding degree of cancer risk associated with some of the genes assessed in multi-gene testing, and how to communicate and manage risk for carriers of these genes.^{73,79-82} This issue is compounded by the low incidence rates of hereditary disease, leading to a difficulty in conducting adequately powered studies.⁷⁹ Some multi-gene tests may include moderate-penetrance genes, for which there are little available data regarding degree of cancer risk and guidelines for risk management.^{66,73,83-85} Further, it is possible that the risks associated with these genes may not entirely be due to that gene only, but may be influenced by gene/gene or gene/environment interactions. Also, certain variants in a gene may be associated with a different degree of risk than other variants in that gene. For example, the presence of certain *ATM* genetic variants is associated with an increased risk for early-onset breast cancer and frequent bilateral occurrence, but the association between other *ATM* variants and breast cancer susceptibility is less clear.⁸⁶⁻⁸⁹

As a result of these dilemmas, risk management following detection of a pathogenic or likely pathogenic variant for a moderate-risk gene, and how best to communicate risk to relatives, is currently unknown.^{85,90} Further, the information gained from testing for moderate-penetrance genes may not change risk management recommendations significantly compared to that based on family history only. Multi-gene tests also increase the likelihood of detecting a VUS.^{63,64,66,73,74,85,91} Multi-gene analyses of DNA samples from individuals with breast cancer showed that a VUS was found in 33% to 40% of individuals.⁷⁴ An analysis of 1191 individuals who underwent testing and were enrolled in PROMPT showed that 37% of variants found were classified as a VUS.⁵⁴ The considerable possibility of detecting a VUS adds to the complexity of counseling following multi-gene testing. However, as multi-gene testing is increasingly used, the frequency of a VUS being detected is expected to decrease.

Multi-gene testing is a new and rapidly growing field, but there is currently a lack of evidence regarding proper procedures and risk management strategies that should follow testing, especially when pathogenic or likely pathogenic variants are found for moderate-penetrance genes and when a VUS is found.⁹² For this reason, the NCCN Panel recommends that, when multi-gene testing is offered, it is done in the context of professional genetic expertise, with pre- and post-test counseling being offered. Panel recommendations are in agreement with recommendations by ASCO, which issued an updated statement regarding genetic testing in 2015.⁹³ Given the limited data available in this field, carriers of a pathogenic or likely pathogenic variant should be encouraged to participate in clinical trials or genetic registries.

Hereditary Breast or Breast/Ovarian Cancer Syndromes

Breast cancer is the most frequently diagnosed cancer globally and is the leading cause of cancer death in women.⁹⁴ The ACS estimates that 255,180 Americans will be diagnosed with invasive breast cancer and 41,070 will die of the disease in the United States in 2017.⁹⁵ Up to 10% of breast cancers are due to specific mutations in single genes that are passed down in a family.^{6,8,69,75} Specific patterns of hereditary breast/ovarian cancers are linked to pathogenic or likely pathogenic variants in the *BRCA1/2* genes.^{96,97} In addition, two very rare hereditary cancer syndromes exhibiting an increased risk for breast cancer are Li-Fraumeni syndrome (LFS) and Cowden syndrome, which are related to germline pathogenic or likely pathogenic variants in the *TP53* and *PTEN* genes, respectively.^{98,99} Similar to the *BRCA1/2* genes, the *TP53* and *PTEN* genes encode for proteins involved in processes related to tumor suppression, such as DNA repair and cell cycle regulation.

These hereditary syndromes share several features beyond elevation of breast cancer risk. These syndromes arise from germline pathogenic or likely pathogenic variants that are not within sex-linked genes; hence, the



variants can be inherited from either parent. The syndromes are associated with breast cancer onset at an early age and development of other types of cancer, and exhibit an autosomal dominant inheritance pattern (see Table 1). A database analysis of 35,409 women with breast cancer who underwent multi-gene testing showed that rates of pathogenic variants were highest in women who were diagnosed before 40 years of age and lowest in women diagnosed after 59 years of age.⁷⁵ Offspring of an individual with one of these hereditary syndromes have a 50% chance of inheriting the pathogenic or likely pathogenic variant. In addition, individuals with these hereditary syndromes share increased risks for multiple cases of early-onset disease as well as bilateral disease. The pathogenic or likely pathogenic variants associated with these hereditary syndromes are considered to be highly penetrant, although a subsequent alteration or silencing in the second copy of the gene without the hereditary variant is believed to be necessary for the initiation of cancer development (ie, 2-hit hypothesis).^{100,101} In addition, the manifestations (ie, expression) of these hereditary syndromes are often variable in individuals within a single family (eg, age of onset, tumor site, number of primary tumors). The risk of developing cancer in individuals with one of these hereditary syndromes depends on numerous variables including the gender and age of the individual.

BRCA-Related Breast/Ovarian Cancer Syndrome

Both the *BRCA1* and *BRCA2* genes encode for proteins involved in tumor suppression. The *BRCA1* gene is located on chromosome 17 and is believed to be involved in both DNA repair and the regulation of cell-cycle checkpoints in response to DNA damage. However, the molecular mechanism through which *BRCA1* functions to preserve genomic stability remains unclear.¹⁰² The *BRCA2* gene, located on chromosome 13, is involved in repair of replication-mediated double-strand DNA breaks.^{103,104} The overall prevalence of disease-related mutations in *BRCA1/2* genes has been estimated as 1 in 300 and 1 in 800, respectively.^{105,106} Currently,

hundreds of unique pathogenic or likely pathogenic variants have been identified in both *BRCA1* and *BRCA2* genes. However, a number of founder effects (see Table 1) have been observed in certain populations, wherein the same pathogenic or likely pathogenic variant has been found in multiple, ostensibly unrelated families and can be traced back to a common ancestor. Among the Ashkenazi Jewish population, for example, the frequency of 187delAG and 5385insC variants in *BRCA1* and the 6174delT variant in *BRCA2* approximates 1 in 40.^{6,107} Certain founder pathogenic or likely pathogenic variants have also been identified in other populations.^{105,108-112}

In a sample of 488 women with non-metastatic breast cancer, 6.1% had a *BRCA1/2* mutation, with mutation prevalence decreasing with age (ie, 12% in women diagnosed at 45 years of age or younger and 3% in women diagnosed at 46 years of age or older).¹¹³ It has been estimated that more than 90% of hereditary families with both breast and ovarian cancers are caused by mutation(s) in the *BRCA1/2* genes.¹¹⁴ Hence, the degree of clinical suspicion for a *BRCA* pathogenic or likely pathogenic variant in a single individual with both breast and ovarian cancer or someone with a family history of both breast and ovarian cancer should be very high.

BRCA1/2 pathogenic or likely pathogenic variants can be highly penetrant (for definition, see Table 1), although the probability of cancer development in carriers of *BRCA1/2* pathogenic or likely pathogenic variants is variable, even within families with the same variant.¹¹⁵⁻¹¹⁷ Estimates of penetrance range from a 41% to 90% lifetime risk for breast cancer, with an increased risk for contralateral breast cancer.¹¹⁸⁻¹²⁵ In addition, female carriers of these genes have an estimated 8% to 62% lifetime risk for ovarian cancer, depending on the population studied.^{119-124,126,127} In a 2007 meta-analysis of published data that evaluated *BRCA1/2* penetrance, estimates for mean cumulative risks for breast and ovarian cancer by 70 years of age for *BRCA1* mutation carriers were 57%



and 40%, respectively.¹²⁰ The corresponding estimates for *BRCA2* mutation carriers were 49% and 18%, respectively. In a prospective analysis of risk estimates from individuals with *BRCA1/2* mutations in the United Kingdom (N = 1887), estimates for mean cumulative risks for breast cancer and ovarian cancer by 70 years of age for *BRCA1* mutation carriers were 60% and 59%, respectively.¹²³ The corresponding estimates for *BRCA2* mutation carriers were 55% and 16.5%, respectively. A prospective cohort study including 9856 unaffected *BRCA1/2* carriers showed that a cumulative risk of breast cancer by 80 years of age was 72% for *BRCA1* mutation carriers and 69% for *BRCA2* mutation carriers.¹²⁸ Among the patients diagnosed with unilateral breast cancer (n = 651), the mean cumulative risks for contralateral breast cancer by 70 years of age were estimated to be 83% for *BRCA1* carriers and 62% for *BRCA2* carriers.¹²³ Other estimates of cumulative risk for contralateral breast cancer 20 years after breast cancer diagnosis are 40% for *BRCA1* mutation carriers and 26% for *BRCA2* mutation carriers.¹²⁸ An international study including 19,581 *BRCA1* mutation carriers and 11,900 *BRCA2* mutation carriers showed that 46% of the *BRCA1* mutation carriers and 52% of the *BRCA2* mutation carriers eventually developed breast cancer, and 12% of the *BRCA1* mutation carriers and 6% of the *BRCA2* mutation carriers eventually developed ovarian cancer.¹²⁹ At present, it is unclear whether penetrance is related only to the specific pathogenic or likely pathogenic variant identified in a family or whether additional factors, either genetic or environmental, affect disease expression. It is generally accepted, however, that carriers of *BRCA1/2* pathogenic or likely pathogenic variants have an excessive risk for both breast and ovarian cancer that warrants consideration of more intensive screening and preventive strategies.

Some of the NCCN treatment guidelines for *BRCA*-related cancers now recommend treatment with PARP (poly ADP-ribose polymerase) inhibitors for patients with germline *BRCA1/2* mutations, as PARP inhibitors have

been demonstrated to be active in these patients. These agents include olaparib¹³⁰ and talazoparib¹³¹ for HER2-negative metastatic breast cancer, and olaparib¹³²⁻¹³⁴ and rucaparib^{135,136} for chemotherapy-refractory ovarian cancer. Though some early studies investigating PARP inhibitors in patients who have germline *BRCA1/2* mutations with metastatic castration-resistant prostate cancer or pancreatic cancer are promising,¹³⁷⁻¹³⁹ data from larger randomized trials are needed. DNA repair defects (eg, *BRCA1/2* mutations) have been reported to be predictive for sensitivity to platinum agents in breast and ovarian cancers.¹⁴⁰

Some histopathologic features have been reported to occur more frequently in breast cancers characterized by a *BRCA1/2* pathogenic or likely pathogenic variant. For example, several studies have shown that *BRCA1* breast cancer is more likely to be characterized as ER-/PR-negative and HER2-negative (ie, “triple negative”).¹⁴¹⁻¹⁴⁶ Studies have reported *BRCA1* mutations in 7% to 28% of patients with triple-negative breast cancer.^{75,113,146-153} A meta-analysis examining 12 studies with 2533 patients with breast cancer showed that women with triple-negative breast cancer are more likely to be carriers of a *BRCA1* mutation, relative to women with breast cancer that is not classified as triple-negative (relative risk [RR] = 5.65; 95% CI, 4.15–7.69).¹⁵⁴ Several reports have also suggested the role of *BRCA2* mutations in triple-negative breast cancer. The incidence of *BRCA2* mutations range from 1% to 17% in studies of triple-negative breast cancer cases unselected for age or family history.^{113,147,152,153,155} In a sample of 396 women with HER2-positive breast cancer diagnosed at 40 years of age or younger, 4% had a *BRCA1* or *BRCA2* mutation.¹⁵⁶

An increased incidence of *BRCA1/2* mutations was reported in triple-negative breast cancer cases from at-risk populations. Among Ashkenazi Jewish women with breast cancer unselected for family history (N = 451), triple-negative disease was observed in 14% of patients and *BRCA*



founder mutations were found in 11% of patients.¹⁵⁷ Among the subgroup with triple-negative breast cancer (n = 65), the incidence of *BRCA* mutations was 39% (*BRCA1* mutation in 30%; *BRCA2* mutation in 9%).¹⁵⁷ Other studies including Ashkenazi Jewish women diagnosed with any breast cancer showed that a *BRCA1/2* mutation was detected in 11% to 18%.^{113,158}

Among patients with triple-negative disease, *BRCA* mutation carriers were diagnosed at a younger age compared with non-carriers.^{149,159} In a study of a large cohort of patients with triple-negative breast cancer (N = 403), the median age of diagnosis among carriers of *BRCA1* mutations (n = 65) was 39 years.¹⁴⁸ Patients in this population-based study were unselected for family history or age. Among the group of patients with early-onset (age at diagnosis <40 years) triple-negative breast cancer (n = 106), the incidence of *BRCA1* mutations was 36%; the incidence was 27% among those diagnosed before 50 years of age (n = 208). For patients with triple-negative breast cancer with a family history of breast and/or ovarian cancer (n = 105), *BRCA1* mutations were found in 48% of patients.¹⁴⁸

Male carriers of a *BRCA1/2* mutation also have a greater risk for cancer susceptibility.¹⁶⁰ In one study of 26 high-risk families with at least one case of male breast cancer, 77% demonstrated a *BRCA2* mutation.¹¹⁴ In a sample of 21,401 families who met German Consortium for Hereditary Breast and Ovarian Cancer testing criteria for *BRCA1/2* mutations, a mutation was detected in 35.8% of families with at least one case of male breast cancer with at least one other case of either female breast or ovarian cancer.¹⁶¹ Among male patients with breast cancer who were not selected on the basis of family history, 4% to 14% tested positive for a germline *BRCA2* mutation.¹⁶²⁻¹⁶⁵ In a series of male breast cancer cases (N = 115; primarily from cancer registry data), *BRCA2* mutations were detected in 16% of cases; the incidence of *BRCA2* mutations was 40% among patients selected for family history of breast cancer and 13%

among those unselected for family history.¹⁶⁴ For males with a *BRCA2* mutation, the cumulative lifetime risk for breast cancer has been estimated at 7% to 8%.^{166,167} The cumulative lifetime risk for *BRCA1* mutation carriers is 1.2%.¹⁶⁷ In contrast, for men without a *BRCA1/2* mutation, the lifetime risk for breast cancer has been estimated at approximately 0.1% (1 in 1000).^{164,168}

Relatively few studies have examined rates of *BRCA1/2* pathogenic or likely pathogenic variants in black women. An observational study including 396 black women who were diagnosed with invasive breast cancer before 50 years of age showed that 12.4% were carriers of a *BRCA1/2* mutation.¹⁶⁹ Carriers of a *BRCA1/2* mutation were also significantly more likely to have triple-negative disease ($P < .001$), a family history of breast and/or ovarian cancer ($P < .001$), and a diagnosis before 45 years of age ($P < .05$). Based on these findings, study authors suggested that black women diagnosed with invasive breast cancer at a young age (ie, younger than 50 years of age) should be considered for *BRCA* testing.

The evidence that a *BRCA1/2* mutation is associated with poor survival outcomes for breast cancer has been inconsistent.^{170,171} A meta-analysis including 13 studies showed that *BRCA1* mutation carriers with breast cancer had worse overall survival (OS) compared to those without a *BRCA* mutation (hazard ratio [HR], 1.50; 95% CI, 1.11–2.04), while harboring a *BRCA2* mutation was not significantly associated with worse survival.¹⁷² A more recent meta-analysis including 60 studies and 105,220 patients with breast cancer also found that *BRCA1* carriers had worse OS compared to non-carriers (HR, 1.30; 95% CI, 1.11–1.52; $P = .001$).¹⁷³ *BRCA2* carriers had worse breast cancer-specific survival compared to non-carriers (HR, 1.29; 95% CI, 1.03–1.62; $P = .03$), though OS was not significantly different. This meta-analysis also showed that, among patients with triple-negative breast cancer, *BRCA1/2* mutations are



associated with better OS (HR, 0.49; 95% CI, 0.26–0.92; $P = .03$). However, this subgroup analysis only included two studies. A third meta-analysis including 66 studies also showed that a *BRCA2* mutation was associated with worse breast cancer-specific survival (HR, 1.57; 95% CI, 1.29–1.86), but study results were too heterogeneous for the analysis to be conclusive.¹⁷⁴ An analysis of 119 Swedish women who were diagnosed with early-onset breast cancer showed that not receiving chemotherapy treatment was associated with poor survival in *BRCA1/2* mutation carriers (HR, 3.0; 95% CI, 1.2–7.7; $P = .014$).¹⁷⁵ Carrying a *BRCA1/2* mutation is not significantly associated with nodal metastasis.¹⁷⁶

BRCA1/2 pathogenic or likely pathogenic variants are associated with early-onset breast cancer. In a sample of 21,401 families who met German Consortium for Hereditary Breast and Ovarian Cancer testing criteria for *BRCA1/2* mutations, a mutation was detected in 13.7% of families with a single case of breast cancer diagnosed at younger than 36 years of age.¹⁶¹ An analysis of 6478 patients who were diagnosed with breast cancer before 50 years of age showed that *BRCA1* mutation carriers had worse OS compared to patients who did not have a *BRCA1/2* mutation (HR, 1.28; 95% CI, 1.05–1.57; $P = .01$), but this association was no longer statistically significant when taking into account disease and treatment characteristics (HR, 1.20; 95% CI, 0.97–1.47; $P = .09$).¹⁷⁷

BRCA2 mutations were not significantly associated with decreased OS in these analyses, except for the first 5 years of follow-up (HR, 1.56; 95% CI, 1.06–2.28; $P = .02$). There may be a genetic anticipation effect in those with *BRCA1/2* mutations in that age of disease onset may become lower over time.¹⁷⁸ However, an analysis of 176 families with a known *BRCA1/2* mutation and more than 2 family members with breast or ovarian cancer in consecutive generations showed that this decrease in age of onset across generations may be due to a cohort effect, specifically lifestyle or environmental factors such as increased use of oral contraceptives and increased obesity rates.¹⁷⁹ Though inflammatory breast cancer has not

been found to be significantly associated with *BRCA1/2* pathogenic or likely pathogenic variants, an analysis of 479 women with breast cancer and a *BRCA1/2* pathogenic or likely pathogenic variant showed that women with inflammatory breast cancer were diagnosed at a younger age than women who had breast cancer that was not inflammatory ($P = .024$).¹⁸⁰

Increased risks for cancers of the ovary, fallopian tube, and peritoneum are observed in carriers of *BRCA1/2* mutations.^{181–183} Germline mutations in *BRCA1/2* are responsible for at least 10% of epithelial ovarian cancers.^{184,185} An analysis of 2222 patients with epithelial ovarian cancer showed that 11% carried a *BRCA1/2* mutation when disease was high-grade serous.¹⁸⁶ In the setting of an invasive ovarian cancer diagnosis, as many as 13% to 20% of women have a germline *BRCA1/2* mutation.^{124,187–189} In an analysis of families who met German Consortium for Hereditary Breast and Ovarian Cancer testing criteria for *BRCA1/2* mutations ($N = 21,401$), mutations were detected in 41.9% of families in which there were at least 2 ovarian cancer cases.¹⁶¹ However, it has been reported that about half of families showing a genetic predisposition to ovarian cancer do not have identifiable *BRCA1/2* mutations.¹⁹⁰ Hence, other gene mutations predisposing a patient to ovarian cancer are likely to exist.¹⁹¹ A prospective cohort study including 9856 unaffected *BRCA1/2* carriers showed that a cumulative risk of ovarian cancer by 80 years of age was 44% for *BRCA1* mutation carriers and 17% for *BRCA2* mutation carriers.¹²⁸

Several studies have reported more favorable survival outcomes among *BRCA1/2* mutation carrier patients with ovarian cancer compared with non-carrier patients.^{192–198} In a case-control study of Ashkenazi Jewish patients with epithelial invasive ovarian cancer ($N = 779$), patients with a *BRCA1/2* mutation had significantly longer median survival compared with non-carrier patients (54 months vs. 38 months; $P = .002$).¹⁹⁵ Results from



a pooled analysis from 26 observational studies that included invasive epithelial ovarian cancer cases from *BRCA1/2* mutation carriers ($n = 1213$) and non-carriers ($n = 2666$) showed favorable survival outcomes for patients with a *BRCA1/2* mutation.¹⁹³ The 5-year survival rate for non-carriers, *BRCA1* carriers, and *BRCA2* carriers was 36%, 44%, and 52%, respectively. The survival advantage compared with non-carriers was significant for both the *BRCA1* carriers (HR, 0.78; 95% CI, 0.68–0.89; $P < .001$) and *BRCA2* mutation carriers (HR, 0.61; 95% CI, 0.50–0.76; $P < .001$).¹⁹³ In a population-based case-control study of women with invasive epithelial (nonmucinous) ovarian cancer ($N = 1001$) from the Australian Ovarian Cancer Study Group, *BRCA1/2* mutation carriers had improved survival outcomes compared with non-carriers in terms of median progression-free survival (20 months vs. 16 months; not statistically significant) and median survival (62 months vs. 55.5 months; $P = .031$).¹⁹² Moreover, *BRCA1/2* mutation carriers appeared to be more responsive to cytotoxic chemotherapy (regardless of class of agent) compared with non-carrier patients.

Survival outcomes appear to be most favorable for *BRCA2* mutation carriers; in a subgroup of patients with *BRCA2* mutations ($n = 53$), the median survival was 70 months.¹⁹² In an observational study of patients with high-grade serous ovarian cancer ($N = 316$), patients with *BRCA2* mutations had significantly favorable survival outcomes (HR, 0.33; 95% CI, 0.16–0.69; $P = .003$; 5-year rate: 61% vs. 25%) and progression-free survival (HR, 0.40; 95% CI, 0.22–0.74; $P = .004$; 3-year rate: 44% vs. 16%) compared with non-carrier patients (having wild-type *BRCA*).¹⁹⁷ An observational study including 1345 women with ovarian cancer who participated in clinical trials from the Gynecologic Oncology Group showed that *BRCA2* mutation carriers had significantly longer progression-free survival (HR, 0.60; 95% CI, 0.45–0.79; $P < .001$) and OS (HR, 0.39; 95% CI, 0.25–0.60; $P < .001$) relative to those without mutations.¹⁸⁵ Additionally, *BRCA2* mutations were associated with significantly higher

response rates (compared with non-carriers or with *BRCA1* mutation carriers) to primary chemotherapy. In contrast, *BRCA1* mutations were not associated with prognosis or improved chemotherapy response.¹⁹⁷

The histology of ovarian cancers in carriers of a *BRCA1/2* mutation is more likely to be characterized as serous adenocarcinoma and high grade compared with ovarian cancers in non-mutation carriers, although endometrioid and clear cell ovarian cancers also have been reported in the former population.^{183,184,188,199-201} Mutations are also associated with non-mucinous ovarian carcinoma as opposed to mucinous.^{187,189} Mucinous epithelial ovarian carcinomas may be associated with other gene mutations, such as *KRAS* and *TP53* mutations.²⁰² *TP53* pathogenic or likely pathogenic variants are implicated in LFS (see below). Non-epithelial ovarian carcinomas (eg, germ cell and sex cord-stromal tumors) are not significantly associated with a *BRCA1/2* mutation,²⁰³ but they may be associated with other cancer genetic syndromes. For example, sex cord tumors may be associated with Peutz-Jeghers syndrome (see below), while Sertoli-Leydig tumors are associated with both Peutz-Jeghers syndrome and DICER1-related disorders.²⁰⁴⁻²⁰⁹ Current data show that ovarian low malignant potential tumors (ie, borderline epithelial ovarian tumors) are also not associated with a *BRCA1/2* mutation.¹⁸⁷ Therefore, the panel does not consider the presence of an ovarian low malignant potential tumor to be a criterion for genetic testing. Interestingly, results from a prospective study suggest that women from families at increased risk for hereditary breast cancer without detectable *BRCA* mutations are not at increased risk for ovarian cancer. However, these results may have been confounded by the ethnic characteristics and size of the study population.²¹⁰

In studies of women with a *BRCA1/2* mutation who underwent risk-reducing salpingo-oophorectomy (RRSO), occult gynecologic carcinomas were identified in 4.5% to 9% of cases based on rigorous pathologic



examinations of the ovaries and fallopian tubes.²¹¹⁻²¹³ Tubal intraepithelial carcinoma (TIC) is thought to represent an early precursor lesion for serous ovarian cancers, and TIC (with or without other lesions) was detected in 5% to 8% of cases from patients with a *BRCA1/2* mutation who underwent RRSO.^{211,214,215} The fimbriae or distal tube was reported to be the predominant site of origin for these early malignancies found in patients with *BRCA1/2* mutations.^{211,215,216} Although TIC appeared to present more frequently among *BRCA1/2* mutation carriers compared with non-carriers undergoing RRSO,^{215,216} TIC has also been documented among patients with serous carcinomas unselected for family history or *BRCA* mutation status.²¹⁷ Because TIC was identified in individuals who underwent surgery for risk reduction (for *BRCA1/2* mutation carriers) or other gynecologic indications, the incidence and significance of these early lesions within the general population is unclear. Hence, at the present time, there is no justifiable role for *BRCA* testing for cases based solely on the finding of TIC during pathology evaluation for gynecologic indications.

Germline *BRCA1/2* mutations have been associated with increased risk for prostate cancer,²¹⁸⁻²²⁰ with this association being strongest for advanced or metastatic prostate cancer.²²¹⁻²²³ A study of a large cohort of patients from Spain with prostate cancer (N = 2019) showed that patients with *BRCA1/2* mutations had significantly higher rates of aggressive prostate cancer (Gleason score ≥8), nodal involvement, and distant metastasis compared with non-carriers.²²⁴ In a sample of 692 men with metastatic prostate cancer, unselected for family history or age at diagnosis, 5.3% had a *BRCA2* mutation, and 0.9% had a *BRCA1* mutation.²²³ In addition, analyses from a treatment center database showed that *BRCA1/2* and *ATM* (see below under *Other Pathogenic/Likely Pathogenic Variants Associated with Breast/Ovarian Cancer*) mutation rates were highest in patients with metastatic disease (8.2%). This study also showed that carriers with prostate cancer had significantly decreased survival, compared with patients who were non-carriers (5 years vs. 16

years, respectively; $P < .001$).²²² This association remained statistically significant when controlling for race, age, PSA, and Gleason score. Ashkenazi Jewish ancestry is also associated with *BRCA1/2* mutations in men with prostate cancer, with rates for *BRCA1* being 0% to 2% and rates for *BRCA2* being 1% to 3%.^{218,225-228}

Prior to the increasingly common use of panel testing, studies showed that *BRCA1/2* mutation rates in pancreatic cancer cases ranged from 1% to 11% for *BRCA1* and 0% to 17% for *BRCA2*.²²⁹⁻²³⁷ However, some of these studies included only patients with familial pancreatic cancer^{232,233,236} or those of Ashkenazi Jewish ancestry,²³⁴ both of who may have a greater likelihood of testing positive for a *BRCA1/2* mutation. More recent studies that used panel testing confirm that some pancreatic cancers harbor actionable *BRCA1/2* pathogenic or likely pathogenic variants (0%–3% for *BRCA1* and 1%–6% for *BRCA2*).²³⁸⁻²⁴² Given that mortality rates for this cancer are high,^{243,244} it may be beneficial to family members to test patients near the time of diagnosis, since the option to test the patient may not be available for very long.

Some studies have suggested an increased risk specifically of serous uterine cancer in *BRCA* mutation carriers.²⁴⁵⁻²⁴⁷ Analyses from a multicenter prospective cohort study including 1083 women with a *BRCA1* mutation who underwent RRSO without hysterectomy showed an increased risk for serous and/or serous-like endometrial cancer.²⁴⁸ However, it has been suggested that the increased risk for endometrial cancer observed in some carriers of *BRCA1/2* pathogenic or likely pathogenic variants may be due to the use of tamoxifen therapy by these women rather than the presence of a gene mutation.^{249,250} A meta-analysis including 5 studies of patients with uterine serous cancer and Ashkenazi Jewish ancestry showed that *BRCA1/2* pathogenic/likely pathogenic variant prevalence was greater in women with uterine serous cancer than



in controls (also of Ashkenazi Jewish ancestry) (OR, 5.4; 95% CI, 2.2–13.1).²⁴⁵

One study showed that women with a *BRCA2* mutation have an elevated risk for leukemia (standardized incidence ratio [SIR], 4.76; 95% CI, 1.21–12.96; *P* = .03), particularly women who have received chemotherapy (SIR, 8.11; 95% CI, 2.06–22.07; *P* = .007).²⁵¹ An analysis of 490 families with *BRCA1/2* mutations showed an increased risk for ocular melanoma in *BRCA2* carriers (RR, 99.4; 95% CI, 11.1–359.8).²⁵²

NCCN Recommendations

The NCCN Panel recommends that individuals from a family with a known *BRCA1/2* pathogenic or likely pathogenic variant be considered for testing, irrespective of degree of relatedness (see *BRCA1/2 Testing Criteria* in the algorithm). In individuals from a family without a known *BRCA1/2* pathogenic or likely pathogenic variant, testing should be considered for those individuals who meet the testing criteria discussed below. Meeting one or more criteria warrants further personalized risk assessment, genetic counseling, and, often, genetic testing and management. The probability of detection of a pathogenic or likely pathogenic variant will vary based on family structure. In evaluating risks based on family history factors, the maternal and paternal sides should be considered independently. For the testing criteria mentioned below, “close relatives” pertain to first-, second-, or third-degree blood relatives on the same side (either maternal or paternal side) of the family. Individuals with a limited or unknown family history (eg, having fewer than 2 first- or second-degree female relatives surviving beyond 45 years of age on either the maternal or paternal side) may have an underestimated probability of detection of a familial pathogenic or likely pathogenic variant. The likelihood of detection of a pathogenic or likely pathogenic variant may be very low in families with a large number of unaffected female relatives. Clinical judgment should be used to determine the appropriateness of genetic testing.

The panel recommends that patients with a personal history of breast cancer *in addition to* one or more of the following criteria be considered for *BRCA1/2* testing:

- Diagnosed at 45 years of age or younger;
- Diagnosis of at least 2 additional breast cancer primaries (ie, bilateral tumors or 2 or more clearly separate ipsilateral tumors, occurring synchronously or asynchronously) at any age, in the proband and/or in a close relative;
- Diagnosed between 46 and 50 years of age with an unknown or limited family history, or a diagnosis of an additional breast cancer primary at any age, or with 1 or more close relatives with breast cancer at any age, or 1 or more close relatives with high-grade prostate cancer (Gleason score ≥ 7);
- Diagnosed with triple-negative breast cancer at 60 years of age or younger;
- Diagnosed at any age with 1 or more close relatives with ovarian carcinoma (including fallopian tube and primary peritoneal cancers), metastatic prostate cancer (biopsy-proven and/or with radiographic evidence and including distant metastasis and regional bed or nodes), pancreatic cancer, or breast cancer diagnosed at 50 years of age or younger; and/or
- Having a close male relative with breast cancer at any age.

Germline origin can be inferred with a high degree of confidence in the case of founder variants. In patients with a personal history of breast cancer and Ashkenazi Jewish heritage, no additional family history may be needed to meet testing criteria. In addition, the NCCN Panel recommends



testing for patients with a personal history of ovarian carcinoma, pancreatic cancer, metastatic prostate cancer (radiographic evidence of or biopsy-proven disease), or male breast cancer, all diagnosed at any age.

Testing is recommended for those with a personal history of high-grade prostate cancer (Gleason score ≥ 7) diagnosed at any age with any of the following: a family history of at least one relative with ovarian carcinoma, pancreatic cancer, or metastatic prostate cancer at any age (biopsy-proven and/or with radiographic evidence and including distant metastasis and regional bed or nodes), or breast cancer diagnosed at younger than 50 years of age; two relatives with breast or prostate cancer diagnosed at any age; or Ashkenazi Jewish ancestry.

In individuals with a family history only (ie, no personal history of a *BRCA*-related cancer), significant limitations of interpreting test results should be discussed prior to any testing. Moreover, testing of individuals without a cancer diagnosis should only be considered when an appropriate affected family member is unavailable for testing. When evaluating an individual without a cancer diagnosis for his or her likelihood of carrying a *BRCA1/2* pathogenic or likely pathogenic variant, clinical judgment should be made based on factors such as the individual's current age and the age of unaffected female relatives who link the individual with an affected close relative.

For individuals not meeting testing criteria for a *BRCA1/2* pathogenic or likely pathogenic variant, testing should be considered for other hereditary syndromes. If criteria for other hereditary syndromes are not met, then the panel recommends screening as per the NCCN Screening Guidelines (available at www.NCCN.org).

The goal of these Guidelines is to inform primary and secondary prevention of hereditary breast and/or ovarian cancer. Therefore, these Guidelines do not provide specific recommendations regarding targeted

therapy options for patients with hereditary breast and/or ovarian cancer. Individuals diagnosed with a *BRCA*-related cancer may benefit from genetic testing to determine eligibility for targeted therapy (see NCCN Guidelines for Breast Cancer, Ovarian Cancer, and Prostate Cancer, available at www.NCCN.org). If a *BRCA1/2* pathogenic or likely pathogenic variant is detected through tumor profiling on any tumor type in absence of germline subtraction, then *BRCA1/2* genetic testing should be considered.

Risk Assessment, Counseling, and Management

Detailed in the NCCN Guidelines is a set of specific risk assessment criteria that form part of the decision-making process in evaluating whether an individual suspected of being a carrier of a *BRCA1/2* pathogenic or likely pathogenic variant should be considered for genetic testing (see *BRCA1/2 Testing Criteria* in the algorithm). Following risk assessment and counseling, genetic testing should be considered for individuals for whom hereditary breast/ovarian cancer syndrome testing criteria are met. Testing is generally not recommended in children younger than 18 years of age, since conditions associated with *BRCA1/2* pathogenic or likely pathogenic variants generally have an adult onset, and, thus, medical management would not be impacted.²⁵³ Testing for a *BRCA1/2* pathogenic or likely pathogenic variant is recommended in women with early-onset breast cancer (see *BRCA1/2 Testing Criteria* in the algorithm). Testing rates for these women have been increasing in recent years, with one study of women diagnosed with breast cancer earlier than 40 years of age showing an increase in testing rates from 2006 to 2013 (77%–95%, $P < .001$).²⁵⁴

Individuals from a family with a known *BRCA1/2* pathogenic or likely pathogenic variant should be tested accordingly. For individuals from a family without a known *BRCA1/2* pathogenic or likely pathogenic variant (and who meet testing criteria), genetic testing should be comprehensive, including full sequencing of *BRCA1/2* and testing for large genomic



rearrangements. Individuals from a family with a known *BRCA1/2* pathogenic or likely pathogenic variant who test positive for the familial variant, or for whom *BRCA1/2* pathogenic or likely pathogenic variant testing is not performed, should follow the screening recommendations outlined in *BRCA Mutation-Positive Management* in the algorithm (and discussed below).

Somatic *BRCA1/2* pathogenic or likely pathogenic variants are not common. In a sample of 273 unselected breast cancer patients from Sweden, a somatic *BRCA1/2* mutation was detected in 3%.²⁵⁵ If a pathogenic or likely pathogenic variant is found through tumor profiling, then *BRCA1/2* genetic testing should be considered.²⁵⁶

For individuals of Ashkenazi Jewish descent with no known familial *BRCA1/2* pathogenic or likely pathogenic variants, one approach is to first test for the 3 known founder variants; if the tests are negative for founder pathogenic or likely pathogenic variant, and if the individual's ancestry also included non-Ashkenazi ethnicity (or if other *BRCA1/2* testing criteria are met), comprehensive genetic testing should be considered. However, with new panels available, many clinicians are moving away from this stepped approach and are increasingly using comprehensive testing (see *Multi-Gene Testing*). Additional testing may also be considered if there is a significant family history of cancer on the side of the family without the known pathogenic or likely pathogenic variant.

Whenever possible, an affected family member with the highest likelihood of carrying the *BRCA1/2* pathogenic or likely pathogenic variant should be tested first. If more than one family member is affected, members with the following factors should be considered for testing first: youngest age at diagnosis; having bilateral disease or multiple primaries; having other associated cancers (eg, ovarian); and most closely related to the proband. If no living family member with breast or ovarian cancer exists, consider testing first- or second-degree family members affected with cancer

thought to be related to *BRCA1/2* pathogenic or likely pathogenic variants (eg, prostate cancer, pancreatic cancer, melanoma). The same principles apply when considering genetic testing for LFS and Cowden syndrome (see below).

As previously discussed, testing of unaffected individuals should only be considered when an appropriate affected family member is not available for testing. Individuals who test positive for a pathogenic or likely pathogenic variant should follow the screening recommendations outlined in *BRCA Mutation-Positive Management* in the algorithm (and discussed below). Alternatively, testing another family member with the next highest likelihood of having a pathogenic or likely pathogenic variant may also be considered. For individuals who have not been tested or for those in whom VUS are found (uninformative testing results), participation in a research program or individualized recommendations based on personal history and family history should be offered.

Counseling issues specific for both female and male carriers of a *BRCA1/2* pathogenic or likely pathogenic variant include the increased incidence of pancreatic cancer and melanoma. In addition, the risks to family members of individuals with a known *BRCA1/2* pathogenic or likely pathogenic variant should also be discussed as well as the importance of genetic counseling for these individuals. Counseling issues pertaining specifically to male breast cancer have also been described, and include an increased risk for prostate cancer and pancreatic cancer in male carriers of a *BRCA1/2* pathogenic or likely pathogenic variant.^{257,258}

Recommendations for the medical management of hereditary breast/ovarian cancer syndrome are based on an appreciation of the early onset of disease, the increased risk for ovarian cancer, and the risk for male breast cancer in *BRCA1/2* carriers. An individual with a known *BRCA1/2* pathogenic or likely pathogenic variant in a close family member who does not undergo gene testing should be followed according to the



same screening/management guidelines as a carrier of a *BRCA1/2* pathogenic or likely pathogenic variant. An individual from a family with a known *BRCA1/2* pathogenic or likely pathogenic variant who tests negative for the familial variant should be followed according to the recommendations in the NCCN Guidelines for Breast Cancer Screening and Diagnosis (available at www.NCCN.org).

Screening Recommendations

The emphasis on initiating screening considerably earlier than standard recommendations is a reflection of the early age of onset seen in hereditary breast/ovarian cancer.²⁵⁹ For a woman who is a carrier of a *BRCA1/2* pathogenic or likely pathogenic variant, training in breast awareness with regular monthly practice should begin at 18 years of age, and semiannual clinical breast examinations should begin at 25 years of age. Between the ages of 25 and 29 years, the woman should have annual breast MRI screening with contrast (to be performed on days 7–15 of menstrual cycle for premenopausal women) or annual mammograms only if MRI is not available. The age to begin screening can be individualized if the family history includes a breast diagnosis prior to 30 years of age.^{27,259-262} Breast MRI screening is preferred over mammogram in the 25- to 29-year age group. High-quality breast MRI screening should consist of the following: dedicated breast coil, ability to perform biopsy under MRI guidance, experienced radiologists in breast MRI, and regional availability. Between 30 and 75 years of age, annual mammogram and breast MRI with contrast should both be done. After 75 years of age, management should be considered on an individual basis. In women treated for breast cancer who have not had bilateral mastectomy, mammography and breast MRI screening with contrast should continue as recommended based on age.

Mammography has served as the standard screening modality for detection of breast cancer during the last few decades. There are currently

no data indicating that mammography on its own reduces mortality in women with genetically increased risk for breast cancer.²⁶³ Also, false-negative mammography results are common and have been correlated with factors such as presence of a *BRCA1/2* mutation and high breast tissue density,²⁶⁴⁻²⁶⁷ both of which may occur more frequently among younger women. Rapidly growing or aggressive breast tumors—also more common among younger women—have also been associated with decreased sensitivity of mammographic screening methods.^{264,268} Prospective studies on comparative surveillance modalities in women at high risk for familial breast cancer (ie, confirmed *BRCA1/2* mutation or suspected mutation based on family history) have consistently reported higher sensitivity of MRI screening (77%–94%) compared with mammography (33%–59%) in detecting breast cancers. False-positive rates were higher with MRI in some reports, resulting in a slightly lower or similar specificity with MRI screening (81%–98%) compared with mammography (92%–100%).^{259-261,269-271} The sensitivity with ultrasound screening (33%–65%) appeared similar to that of mammography in this high-risk population.^{259,269-271} In a prospective screening trial (conducted from 1997–2009) that evaluated the performance of annual MRI and mammography in women (aged 25–65 years; N = 496) with confirmed *BRCA1/2* mutation, sensitivity with MRI was significantly higher compared with mammography during the entire study period (86% vs. 19%; $P < .0001$).²⁷² Factors such as age, mutation type, or invasiveness of the tumor did not significantly influence the relative sensitivity of the 2 screening modalities. Importantly, the large majority (97%) of cancers detected by MRI screening were early-stage tumors.²⁷² At a median follow-up of 8 years from diagnosis, none of the surviving patients (n = 24) had developed distant recurrence. In an analysis of 606 women with either a family history of breast cancer or who harbor a genetic mutation associated with increased risk for breast cancer, sensitivity of breast MRI screening was reported to be 79%, while specificity was reported to be 86%.²⁷³



All of these studies discussed above evaluated a screening strategy that was conducted on an annual basis, and many of the studies included individuals without confirmed *BRCA1/2* mutation status. A study of 1219 *BRCA1* carriers and 732 *BRCA2* carriers showed that the increased sensitivity of mammography over MRI was greater for *BRCA2* carriers (12.6%) than for *BRCA1* carriers (3.9%).²⁷⁴ In a retrospective study, a different screening interval was evaluated, using alternating mammography and MRI screening every 6 months in women with a confirmed *BRCA1/2* mutation (N = 73).²⁷⁵ After a median follow-up of 2 years, 13 breast cancers were detected among 11 women; 12 of the tumors were detected by MRI screening but not by mammography obtained 6 months earlier. The sensitivity and specificity with MRI screening was 92% and 87%, respectively.²⁷⁵

The optimal surveillance approach in women at high risk for familial breast cancer remains uncertain, especially for women between the ages of 25 and 30 years. Although earlier studies have reported an unlikely association between radiation exposure from mammography and increased risk for breast cancer in carriers of a *BRCA1/2* mutation,^{276,277} a report from a large cohort study suggested an increased risk in women exposed to radiation at a young age.²⁷⁸ A retrospective cohort study (from the GENE-RAD-RISK study) showed that exposure to diagnostic radiation (including mammography) prior to 30 years of age was associated with increased risk for breast cancer in women with a *BRCA1/2* mutation (N = 1993).²⁷⁸ Thus, one of the potential benefits of incorporating MRI modalities into surveillance strategies may include minimizing the radiation risks associated with mammography, in addition to the higher sensitivity of MRI screening in detecting tumors. The use of MRI, however, may potentially be associated with higher false-positive results and higher costs relative to mammography. The combined use of digital mammography (two-dimensional, 2D) in conjunction with digital breast tomosynthesis (DBT) appears to improve cancer detection and reduce false-positive call-

back rates.²⁷⁹⁻²⁸⁸ Tomosynthesis allows acquisition of three-dimensional (3D) data using a moving x-ray and digital detector. These data are reconstructed using computer algorithms to generate thin sections of images. The combined use of 2D and DBT results in double the radiation exposure compared with mammography alone. However, this increase in radiation dose falls below dose limits of radiation set by the U.S. Food and Drug Administration (FDA) for standard mammography. The radiation dose can be minimized by newer tomosynthesis techniques that create a synthetic 2D image, which may obviate the need for a conventional digital image.^{280,289,290} When mammography is performed, the panel recommends that tomosynthesis be considered. In carriers of a *BRCA1/2* pathogenic or likely pathogenic variant who are younger than 30 years of age, breast MRI screening is preferred over mammography due to the potential radiation exposure risk and less sensitivity for detection of tumors associated with mammography.

The appropriate imaging modalities and surveillance intervals are still under investigation. In a report based on a computer simulation model that evaluated different annual screening strategies in *BRCA1/2* mutation carriers, a screening approach that included annual MRI starting at 25 years of age combined with alternating digital mammography/MRI starting at 30 years of age was shown to be the most effective strategy when radiation risks, life expectancy, and false-positive rates were considered.²⁹¹ Future prospective trials are needed to evaluate the different surveillance strategies in individuals at high risk for familial breast cancer. Annual MRI as an adjunct to screening mammogram and clinical breast examination for women aged 25 years or older with a genetic predisposition to breast cancer is supported by guidelines from the ACS.²⁷

Post-test counseling in women with a confirmed *BRCA1/2* pathogenic or likely pathogenic variant (or highly suspected of having the variant based on presence of known pathogenic or likely pathogenic variant in the family)



includes discussion of risk-reducing mastectomy and/or RRSO.

Counseling for these risk-reducing surgeries should include discussion of extent of cancer risk reduction/protection, risks associated with surgeries, breast reconstructive options, management of menopausal symptoms, and discussion of reproductive desires. It is important to address the psychosocial and quality-of-life aspects of undergoing risk-reducing surgical procedures.²⁹²

Studies assessing whether ovarian cancer screening procedures are sufficiently sensitive or specific have yielded mixed results. The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), which assessed multimodality screening with transvaginal ultrasound (TVUS) and CA-125 versus either TVUS alone or no screening, showed that multimodality screening is more effective at detecting early-stage cancer; however, after a median of 11 years of follow-up, a significant mortality reduction was not observed.^{293,294} In phase II of the UK Familial Ovarian Cancer Screening Study (UK FOCSS), 4348 women with an estimated lifetime ovarian cancer risk no less than 10% underwent ovarian cancer screening via serum CA-125 tests every 4 months (with the risk of ovarian cancer algorithm [ROCA] used to interpret results) and TVUS (annually or within 2 months if abnormal ROCA score).²⁹⁵ Thirteen patients were diagnosed with ovarian cancer as a result of the screening protocol, with 5 of the 13 patients being diagnosed with early-stage cancer. Sensitivity, positive predictive value, and negative predictive value of the screening protocol for detecting ovarian cancer within 1 year were 94.7%, 10.8%, and 100%, respectively. A third study including 3692 women who were at increased familial/genetic risk of ovarian cancer showed that a ROCA-based screening protocol (ie, serum CA-125 testing every 3 months with annual TVUS annually or sooner depending on CA-125 test results) identified 6 incidental ovarian cancers, of which 50% were early stage.²⁹⁶ The results of these studies suggest a potential stage shift when a ROCA-based ovarian cancer screening protocol is followed in high-risk women,

though it remains unknown whether this screening protocol impacts survival. RRSO remains the current standard of care for ovarian cancer risk management in *BRCA1/2* carriers. For women who have not elected RRSO, TVUS and serum CA-125 may be considered at the clinician's discretion starting at 30 to 35 years of age.

Men testing positive for a *BRCA1/2* pathogenic or likely pathogenic variant should have an annual clinical breast examination and undergo training in breast self-examination with regular monthly practice starting at 35 years of age. Regularly scheduled mammography is not recommended by the panel, as there are only limited data to support breast imaging in men, since male breast cancer is rare. Screening for prostate cancer starting at 45 years of age should be recommended for *BRCA2* carriers and considered for *BRCA1* carriers. See the NCCN Guidelines for Prostate Cancer Early Detection (available at www.NCCN.org).

For both men and women testing positive for a *BRCA1/2* pathogenic or likely pathogenic variant, a full body skin and eye exam for melanoma screening and investigational protocols for pancreatic cancer screening should be considered. Individualized screening approaches may be provided according to personal or family history of cancer. The International Cancer of the Pancreas Screening (CAPS) Consortium recommends screening for pancreatic cancer in patients with a *BRCA2* mutation who have a family history of pancreatic cancer.²⁹⁷ Though endoscopic ultrasound (EUS) and endoscopic retrograde cholangiopancreatography (ERCP) were identified as potential screening tools, the Consortium acknowledged that more research is needed on an optimal screening schedule.

Risk Reduction Surgery

Bilateral Total Mastectomy



A meta-analysis including 6 studies (N = 2555) showed that prophylactic bilateral mastectomy reduces the risk for breast cancer (RR, 0.11; 95% CI, 0.04–0.32).²⁹⁸ However, this risk-reducing surgery was not significantly associated with reduced all-cause mortality. Retrospective analyses with median follow-up periods of 13 to 14 years have indicated that bilateral risk-reduction mastectomy (RRM) decreased the risk of developing breast cancer by at least 90% in moderate- and high-risk women and in known *BRCA1/2* mutation carriers.^{299,300} Results from smaller prospective studies with shorter follow-up periods have provided support for concluding that RRM provides a high degree of protection against breast cancer in women with a *BRCA1/2* mutation.^{301,302}

The NCCN Guidelines Panel supports discussion of the option of RRM for women on a case-by-case basis. Counseling regarding the degree of protection offered by such surgery and the degree of cancer risk should be provided. Since risk of breast cancer remains increased with age in carriers of a *BRCA1/2* pathogenic or likely pathogenic variant,¹²⁰ age and life expectancy should be considered during this counseling, as well as family history.

It is important that the potential psychosocial effects of RRM are addressed, although these effects have not been well-studied.³⁰³

Multidisciplinary consultations are recommended prior to surgery and should include the discussions of the risks and benefits of surgery, and surgical breast reconstruction options. Immediate breast reconstruction is an option for many women following RRM, and early consultation with a reconstructive surgeon is recommended for those considering either immediate or delayed breast reconstruction.³⁰⁴ Nipple-sparing mastectomy has been suggested to be a safe and effective risk reduction strategy for patients with a *BRCA1/2* pathogenic or likely pathogenic variant,³⁰⁵ although more data are needed.

Bilateral Salpingo-oophorectomy

Women with a *BRCA1/2* pathogenic or likely pathogenic variant are at increased risk for both breast and ovarian cancers (including fallopian tube cancer and primary peritoneal cancer).^{181,182} Although the risk for ovarian cancer is generally considered to be lower than the risk for breast cancer in a *BRCA1/2* mutation carrier,^{118,119,306} the absence of reliable methods of early detection and the poor prognosis associated with advanced ovarian cancer have lent support for the performance of bilateral RRSO after completion of childbearing in these women.

An observational prospective study of 5783 women with a *BRCA1/2* mutation showed that ovarian cancer is more prevalent in individuals with *BRCA1* (4.2%) than *BRCA2* (0.6%) mutations.³⁰⁷ In *BRCA1* mutation carriers, prevalence of ovarian, fallopian tube, and peritoneal cancers found during risk-reducing surgery was 1.5% for those younger than 40 years of age and 3.8% in those between the ages of 40 and 49 years.³⁰⁷ The highest incidence rate for *BRCA1* mutation carriers was observed between the ages of 50 and 59 years (annual risk, 1.7%); for *BRCA2* mutation carriers, the highest incidence rate was observed between the ages of 60 and 69 years (annual risk, 0.6%). Therefore, the recommended age for RRSO could be younger for women with a *BRCA1* pathogenic or likely pathogenic variant than for women with a *BRCA2* variant.

The effectiveness of RRSO in reducing the risk for ovarian cancer in carriers of a *BRCA1/2* pathogenic or likely pathogenic variant has been demonstrated in a number of studies. For example, results of a meta-analysis involving 10 studies of *BRCA1/2* mutation carriers showed an approximately 80% reduction in the risk for ovarian or fallopian cancer following RRSO.³⁰⁸ In a large prospective study of women who carried deleterious *BRCA1/2* mutations (N = 1079), RRSO significantly reduced the risk for *BRCA1*-associated gynecologic tumors (including ovarian, fallopian tube, or primary peritoneal cancers) by 85% compared with observation during a 3-year follow-up period (HR, 0.15; 95% CI, 0.04–



0.56; $P = .005$).³⁰⁹ An observational study of 5783 women with a *BRCA1/2* mutation showed that risk-reducing oophorectomy reduces risk for ovarian, fallopian, or peritoneal cancer by 80% (HR, 0.20; 95% CI, 0.13–0.30) and all-cause mortality by 77% (HR, 0.23; 95% CI, 0.13–0.39).³⁰⁷ RRSO reduces mortality at all ages in *BRCA1* mutation carriers, but among *BRCA2* mutations carriers RRSO is only associated with reduced mortality in those between the ages of 41 and 60 years.³⁰⁷

A 1% to 4.3% residual risk for a primary peritoneal carcinoma has been reported in some studies.^{212,308,310–313} An analysis of 36 carriers of a *BRCA1/2* mutation who developed peritoneal carcinomatosis following RRSO showed that 86% were carriers of a *BRCA1* mutation specifically.³¹⁴ When comparing to 113 carriers of a *BRCA1/2* mutation who did not develop peritoneal carcinomatosis following RRSO, women who eventually developed peritoneal carcinomatosis were older at time of RRSO ($P = .025$) and had a greater percentage of serous tubal intraepithelial carcinoma (STIC) in their RRSO specimen ($P < .001$), supporting the removal of the fallopian tubes as part of the risk-reducing procedure. Further, an analysis from a multicenter prospective cohort study (N = 1,083) showed an increased risk for serous and/or serous-like endometrial cancer in women with a *BRCA1* mutation who underwent RRSO without hysterectomy.²⁴⁸

RRSO may provide an opportunity for gynecologic cancer detection in high-risk women. An analysis of 966 RRSO procedures showed that invasive or intraepithelial ovarian, tubal, or peritoneal neoplasms were detected in 4.6% of *BRCA1* carriers and 3.5% of *BRCA2* carriers.³¹⁵ Presence of a *BRCA1/2* mutation was associated with detection of clinically occult neoplasms during RRSO ($P = .006$).

RRSO is also reported to reduce the risk for breast cancer in carriers of a *BRCA1/2* mutation.^{298,308,312,313,316} Reductions in breast cancer risk for carriers of a *BRCA1/2* mutation undergoing RRSO may be associated with

decreased hormonal exposure following surgical removal of the ovaries. In the case-control international study by Eisen et al, a 56% (OR, 0.44; 95% CI, 0.29–0.66; $P < .001$) and a 43% (OR, 0.57; 95% CI, 0.28–1.15; $P = 0.11$) breast cancer risk reduction (adjusted for oral contraceptive use and parity) was reported following RRSO in carriers of a *BRCA1* and a *BRCA2* mutation, respectively.³¹⁶ HRs of 0.47 (95% CI, 0.29–0.77)³¹³ and 0.30 (95% CI, 0.11–0.84; $P = .022$)³¹¹ were reported in two other studies comparing breast cancer risk in women with a *BRCA1/2* mutation who had undergone RRSO with carriers of these mutations who opted for surveillance only. These studies are further supported by a meta-analysis that found similar reductions in breast cancer risk of approximately 50% for *BRCA1/2* mutation carriers following RRSO.³⁰⁸

Results of a prospective cohort study suggest that RRSO may be associated with a greater reduction in breast cancer risk for *BRCA2* mutation carriers compared with *BRCA1* mutation carriers.³⁰⁹ Another retrospective analysis including 676 women with stage I or II breast cancer and a *BRCA1/2* mutation showed that oophorectomy was associated with decreased risk of mortality from breast cancer in *BRCA1* mutation carriers (HR, 0.38; 95% CI, 0.19–0.77, $P = .007$), but not in carriers of a *BRCA2* mutation ($P = .23$).³¹⁷ Mortality risk was also significantly impacted in *BRCA1/2* mutation carriers who had ER-negative breast cancer (HR, 0.07; 95% CI, 0.01–0.51, $P = .009$).

A prospective cohort study from the Netherlands (N = 822) did not find a statistically significant difference in breast cancer incidence between *BRCA1/2* mutation carriers who opted for an RRSO and women who did not, regardless of whether the mutation was for *BRCA1* or *BRCA2*.³¹⁸ Study investigators argued that previous study findings showing a 50% decrease in breast cancer risk may have been influenced by bias, specifically inclusion of patients with a history of breast or ovarian cancer in the comparison group and immortal person-time bias. One study that



corrected for immortal person-time bias as a result of this analysis continued to find a protective effect of RRSO on breast cancer incidence in *BRCA1/2* mutation carriers (HR, 0.59; 95% CI, 0.42–0.82, $P < .001$).³¹⁹

Greater reductions in breast cancer risk were observed in women with a *BRCA1* mutation who had an RRSO at 40 years of age or younger (OR, 0.36; 95% CI, 0.20–0.64) relative to *BRCA1* carriers aged 41 to 50 years who had this procedure (OR, 0.50; 95% CI, 0.27–0.92).³¹⁶ A nonsignificant reduction in breast cancer risk was found for women aged 51 years or older, although only a small number of women were included in this group.³¹⁶ However, results from Rebbeck et al also suggest that RRSO after 50 years of age is not associated with a substantial decrease in breast cancer risk.³¹² A more recent study showed that oophorectomy was not significantly associated with decreased risk of breast cancer in *BRCA1/2* mutation carriers ($N = 3,722$).³²⁰ However, stratified analyses in *BRCA2* carriers who were diagnosed with breast cancer before 50 years of age showed that oophorectomy was associated with an 82% reduction in breast cancer (HR, 0.18; 95% CI, 0.05–0.63; $P = .007$). The risk reduction in *BRCA1* carriers was not statistically significant ($P = .51$). Due to the limited data regarding the impact of RRSO on breast cancer risk when taking into account age and the specific mutation (*BRCA1* vs. *BRCA2*), an optimal age for RRSO is difficult to specify.

It has been reported that short-term hormone replacement therapy (HRT) in women undergoing RRSO does not negate the reduction in breast cancer risk associated with the surgery.³²¹ In addition, results of a case-control study of *BRCA1* mutation carriers showed no association between use of HRT and increased breast cancer risk in postmenopausal *BRCA1* mutation carriers.³²² However, caution should be used when considering use of HRT in mutation carriers following RRSO, given the limitations inherent in nonrandomized studies.^{323,324}

Salpingectomy (surgical removal of the fallopian tube with retention of the ovaries) completion rates are increasing, especially in women younger than 50 years of age.³²⁵ Despite some evidence regarding the safety and feasibility of this procedure,^{325,326} more data are needed regarding its efficacy in reducing the risk for ovarian cancer.^{292,327} Further, *BRCA1/2* carriers who undergo salpingectomy without oophorectomy may not get the 50% reduction in breast cancer risk that *BRCA1/2* carriers who undergo oophorectomy receive. Therefore, at this time, the panel does not recommend risk-reducing salpingectomy alone as the standard of care in *BRCA1/2* carriers. Clinical trials of interval salpingectomy with delayed oophorectomy are ongoing (eg, NCT02321228, NCT01907789).

Some studies suggest a link between *BRCA* pathogenic/likely pathogenic variants and development of serous uterine cancer (primarily with *BRCA1*), although the overall risk for uterine cancer was not increased when controlling for tamoxifen use.^{245,246,248} For patients who choose to undergo RRSO, the provider may discuss the risks and benefits of concurrent hysterectomy, but more data are needed to determine the magnitude of the association between *BRCA* pathogenic/likely pathogenic variants and development of serous uterine cancer.

The NCCN Guidelines Panel recommends RRSO for women with a known *BRCA1/2* pathogenic or likely pathogenic variant, typically between 35 and 40 years of age for women with a *BRCA1* pathogenic or likely pathogenic variant. Since ovarian cancer onset tends to be later in women with a *BRCA2* pathogenic or likely pathogenic variant, it is reasonable to delay RRSO for management of ovarian cancer risk until between 40 and 45 years of age in these women, unless age at diagnosis in the family warrants earlier age for consideration of this prophylactic surgery.³⁰⁷ RRSO should only be considered upon completion of childbearing. Peritoneal washings should be performed at surgery, and pathologic assessment should include fine sectioning of the ovaries and fallopian



tubes.^{213,214} The protocol published by CAP (2009) can be consulted for details on specimen evaluation.³²⁸ See the NCCN Guidelines for Ovarian Cancer for treatment of findings (available at www.NCCN.org).

The decision to undergo RRSO is a complex one and should be made ideally in consultation with a gynecologic oncologist, especially when the patient wishes to undergo RRSO before the age at which it is typically recommended (ie, 35 years of age). Topics that should be addressed include impact on reproduction, impact on breast and ovarian cancer risk, risks associated with premature menopause (eg, osteoporosis, cardiovascular disease, cognitive changes, changes to vasomotor symptoms, sexual concerns), and other medical issues. The panel recommends that a gynecologic oncologist help patients considering RRSO understand how it may impact quality of life.

Chemoprevention

The use of selective estrogen receptor modulators (ie, tamoxifen, raloxifene) has been shown to reduce the risk for invasive breast cancer in postmenopausal women considered at high risk for developing breast cancer.³²⁹⁻³³⁴ However, only limited data are available on the specific use of these agents in patients with *BRCA1/2* pathogenic or likely pathogenic variants. As previously discussed, patients with *BRCA1/2* pathogenic or likely pathogenic variants who are diagnosed with breast cancer have elevated risks for developing contralateral breast tumors. In one of the largest prospective series of *BRCA1/2* mutation carriers evaluated, the mean cumulative lifetime risks for contralateral breast cancer were estimated to be 83% for *BRCA1* carriers and 62% for *BRCA2* carriers.¹²³ Patients with *BRCA1/2* mutations who have intact contralateral breast tissue (and who do not undergo oophorectomy or receive chemoprevention) have an estimated 40% risk for contralateral breast cancer at 10 years.³³⁵ Case-control studies from the Hereditary Breast Cancer Clinical Study Group reported that the use of tamoxifen protected

against contralateral breast cancer with an odds ratio (OR) of 0.38 (95% CI, 0.19–0.74) to 0.50 (95% CI, 0.30–0.85) among *BRCA1* mutation carriers and 0.42 (95% CI, 0.17–1.02) to 0.63 (95% CI, 0.20–1.50) among *BRCA2* carriers.^{336,337} This translates to an approximately 45% to 60% reduction in risk for contralateral tumors among *BRCA1/2* mutation carriers with breast cancer. The data were not consistent in regard to the protective effects of tamoxifen in the subset of *BRCA1/2* mutation carriers who also underwent oophorectomy. In addition, no data were available on the estrogen receptor status of the tumors. An evaluation of the subset of healthy individuals with a *BRCA1/2* mutation in the Breast Cancer Prevention Trial revealed that breast cancer risk was reduced by 62% in those with a *BRCA2* mutation receiving tamoxifen relative to placebo (risk ratio, 0.38; 95% CI, 0.06–1.56).³³⁸ However, an analysis of 288 women who developed breast cancer during their participation in this trial showed that tamoxifen use was not associated with a reduction in breast cancer risk in those with a *BRCA1* mutation.³³⁸ These findings may be related to the greater likelihood for development of estrogen receptor-negative tumors in *BRCA1* mutation carriers relative to *BRCA2* mutation carriers. However, this analysis was limited by the very small number of individuals with a *BRCA1/2* mutation (n = 19; 7% of participants diagnosed with breast cancer). Common single-nucleotide polymorphisms have been identified in genes (*ZNF423* and *CTSO*) that are involved in estrogen-dependent regulation of *BRCA1* expression.³³⁹ These gene variants were associated with alterations in breast cancer risk during treatment with selective estrogen receptor modulators, and may eventually pave the way for predicting the likelihood of benefit with these chemopreventive approaches in individual patients.

With respect to the evidence regarding the effect of oral contraceptives on cancer risks in women with a known *BRCA1/2* pathogenic or likely pathogenic variant, case-control studies have demonstrated that oral contraceptives reduced the risk for ovarian cancer by 45% to 50% in



BRCA1 mutation carriers and by 60% in *BRCA2* mutation carriers.^{340,341} Moreover, risks appeared to decrease with longer duration of oral contraceptive use.³⁴¹ In a meta-analysis conducted in a large number of *BRCA1/2* mutation carriers with (n = 1503) and without (n = 6315) ovarian cancer, use of oral contraceptives significantly reduced the risk for ovarian cancer by approximately 50% for both the *BRCA1* mutation carriers (summary relative risk [SRR], 0.51; 95% CI, 0.40–0.65) and *BRCA2* mutation carriers (SRR, 0.52; 95% CI, 0.31–0.87).³⁴² Another meta-analysis including one cohort study (N = 3,181) and three case-control studies (1,096 cases and 2,878 controls) also showed an inverse association between ovarian cancer and having ever used oral contraceptives (OR, 0.58; 95% CI, 0.46–0.73).³⁴³

Studies on the effect of oral contraceptive use on breast cancer risk among *BRCA1/2* mutation carriers have reported conflicting data. In one case-control study, use of oral contraceptives was associated with a modest but statistically significant increase in breast cancer risk among *BRCA1* mutation carriers (OR, 1.20; 95% CI, 1.02–1.40), but not among *BRCA2* mutation carriers.³⁴⁴ Among *BRCA1* mutation carriers, breast cancer risks with oral contraceptives were significantly associated with ≥5 years of oral contraceptive use (OR, 1.33; 95% CI, 1.11–1.60), breast cancer diagnosed before 40 years of age (OR, 1.38; 95% CI, 1.11–1.72), and use of oral contraceptives before 1975 (OR, 1.42; 95% CI, 1.17–1.75).³⁴⁴ In another case-control study, oral contraceptive use for at least 1 year was not significantly associated with breast cancer risk in either *BRCA1/2* mutation carriers.³⁴⁵ However, among *BRCA2* mutation carriers, use of oral contraceptives for at least 5 years was associated with a significantly increased risk for breast cancer (OR, 2.06; 95% CI, 1.08–3.94); results were similar when only the cases with oral contraceptive use on or after 1975 were considered.³⁴⁵ Other case-control studies have reported no significant associations with oral contraceptive use (especially with the use of low-dose formulations after 1975) and risks for breast

cancer in *BRCA1/2* mutation carriers.^{346,347} In fact, in one study, the use of low-dose oral contraceptives for at least 1 year was associated with significantly decreased risks for breast cancer among *BRCA1* mutation carriers (OR, 0.22; 95% CI, 0.10–0.49; *P* < .001), though not for *BRCA2* mutation carriers.³⁴⁷ Differences in the study design employed by these case-control studies make it difficult to compare outcomes between studies, and likely account for the conflicting results. The study design might have differed with regard to factors such as the criteria for defining the “control” population for the study (eg, non-*BRCA1/2* mutation carriers vs. mutation carriers without a cancer diagnosis), consideration of family history of breast or ovarian cancer, baseline demographics of the population studied (eg, nationality, ethnicity, geographic region, age groups), age of onset of breast cancer, and formulations or duration of oral contraceptives used. Two meta-analyses showed that oral contraceptive use is not significantly associated with breast cancer risk in *BRCA1/2* mutation carriers.^{342,343}

Reproductive Options

The outcomes of genetic testing can have a profound impact on family planning decisions for individuals of reproductive age who are found to be carriers of a *BRCA1/2* pathogenic or likely pathogenic variant. Counseling for reproductive options such as prenatal diagnosis, preimplantation genetic diagnosis (PGD), and assisted reproduction may therefore be warranted for couples expressing concern over their future offspring’s carrier status of a *BRCA1/2* pathogenic or likely pathogenic variant. Such counseling should include a comprehensive discussion of the potential risks, benefits, and limitations of reproductive options.

Prenatal diagnosis involves postimplantation genetic analysis of an early embryo, utilizing chorionic villi or amniotic fluid cell samples; genetic testing is typically conducted between week 12 and week 16 of gestation, and testing results may potentially lead to a couple’s decision to terminate



pregnancy.^{348,349} During the past 2 decades, PGD has emerged as an alternative method of genetic testing in early embryos. PGD involves the testing of 1 or 2 cells from embryos in very early stages of development (ie, 6–8 cells) after in vitro fertilization (IVF). This procedure allows for the selection of unaffected embryos to be transferred to the uterus,^{348,349} and may therefore offer the advantage of avoiding potential termination of pregnancy. The PGD process requires the use of IVF regardless of the fertility status of the couple (ie, also applies to couples without infertility issues), and IVF may not always lead to a successful pregnancy. Lastly, the technology or expertise may not be readily available in a couple's geographic location.

Various factors, both medical and personal, must be weighed in the decision to utilize prenatal diagnosis or PGD. Medical considerations may include factors such as the age of onset of the hereditary cancer, penetrance, severity or associated morbidity and mortality of the cancer, and availability of effective cancer risk reduction methods or effective treatments.^{348,349} For example, in cases where both partners carry a *BRCA2* mutation, there may be a high risk for the offspring to develop Fanconi anemia, a rare autosomal recessive condition.⁶¹ A case has been found in which biallelic *BRCA1* mutations caused Fanconi anemia-like disorder.³⁵⁰ Although the use of prenatal diagnosis or PGD is relatively well established for severe hereditary disorders with very high penetrance and/or early onset, its use in conditions associated with lower penetrance and/or later onset (eg, hereditary breast or ovarian cancer syndrome) remains somewhat controversial from both an ethical and regulatory standpoint.

Personal considerations for the decision to utilize prenatal diagnosis or PGD may include individual ethical beliefs, value systems, cultural and religious beliefs, and social and economic factors. Based on results from surveys administered to women at high risk for hereditary breast or

ovarian cancer, 50% to 75% of respondents felt that PGD was an acceptable option for high-risk individuals,^{351,352} yet only about 14% to 33% would consider undergoing PGD themselves.^{351,353} A survey in high-risk men (N = 228; carriers of a *BRCA* mutation; or having a partner or first-degree relative with a *BRCA* mutation) showed that 80% of these men were unaware of PGD. After being informed of the definition of PGD, 34% indicated that they would consider the option of using PGD.³⁵⁴ Importantly, these surveys suggested that the majority of high-risk women and men have little or no knowledge of PGD,^{352,354,355} highlighting the need for better awareness and education regarding potential reproductive options.

Successful births have been reported with the use of PGD and IVF in *BRCA1/2* mutation carriers,^{356,357} but data in the published literature are still very limited. In addition, data pertaining to long-term safety or outcomes of PDG and assisted reproduction in carriers of a *BRCA1/2* pathogenic or likely pathogenic variant are not yet available.

Li-Fraumeni Syndrome

LFS is a rare hereditary cancer syndrome associated with germline *TP53* pathogenic or likely pathogenic variants.⁹⁹ It has been estimated to be involved in only about 1% of hereditary breast cancer cases,³⁵⁸ although results from other studies suggest that germline *TP53* gene mutations may be more common than previously believed, with estimates of 1 in 5000 to 1 in 20,000.^{359,360} There are only about 300 families reported in an LFS registry maintained by an NCCN Member Institution and the NCI.³⁶¹ The tumor suppressor gene, *TP53*, is located on chromosome 17,^{362,363} and the protein product of the *TP53* gene (ie, p53) is located in the cell nucleus and binds directly to DNA. It has been called the “guardian of the genome” and plays important roles in controlling the cell cycle and apoptosis.³⁶²⁻³⁶⁴ Germline mutations in the *TP53* gene have been observed in over 50% (and in over 70% in some studies) of families meeting the classic definition of LFS (see *Li-Fraumeni Syndrome Testing Criteria* in the



algorithm).^{99,359,365} Additional studies are needed to investigate the possibility of other gene mutations in families meeting these criteria not carrying germline *TP53* mutations.³⁶⁶

LFS is a highly penetrant cancer syndrome associated with a high lifetime risk for cancer. An analysis from the NCI Li-Fraumeni Syndrome Study (N = 286) showed a cumulative lifetime cancer incidence of nearly 100%.³⁶⁷ LFS is characterized by a wide spectrum of neoplasms occurring at a young age. It is associated with soft tissue sarcomas, osteosarcomas (although Ewing's sarcoma is less likely to be associated with LFS), premenopausal breast cancer, colon cancer, gastric cancer, adrenocortical carcinoma, and brain tumors.^{99,359,361,364,368-373} Sarcoma, breast cancer, adrenocortical tumors, and certain brain tumors have been referred to as the “core” cancers of LFS since they account for the majority of cancers observed in individuals with germline *TP53* pathogenic or likely pathogenic variants, and, in one study, at least one of these cancers was found in one or more members of all families with a germline *TP53* gene mutation.³⁵⁹ Hypodiploid acute lymphoblastic leukemia is also associated with LFS,^{374,375} and case reports have suggested an association between melanoma and LFS.^{376,377}

The NCI Li-Fraumeni Syndrome Study (N = 286) showed that the cumulative incidence rates by 70 years of age in women are 54%, 15%, 6%, and 5% for breast cancer, soft tissue sarcoma, brain cancer, and osteosarcoma, respectively.³⁶⁷ The cumulative incidence rates by age 70 years in men are 22%, 19%, and 11% for soft tissue sarcoma, brain cancer, and osteosarcoma, respectively. Interestingly, two retrospective studies have reported a very high frequency of HER2-positive breast tumors (67%–83% of evaluated breast tumors) among patients with germline *TP53* mutations, which suggests that amplification of HER2 may arise in conjunction with *TP53* mutations.^{378,379} This association between HER2-positive breast cancer and germline *TP53* mutations warrants

further investigation, as such patients may potentially benefit from chemoprevention therapies that incorporate HER2-targeted agents.

Individuals with LFS often present with certain cancers (eg, soft tissue sarcomas, brain tumors, adrenocortical carcinomas) in early childhood,³⁷⁰ and have an increased risk of developing multiple primary cancers during their lifetimes.³⁸⁰ Results of a segregation analysis of data collected on the family histories of 159 patients with childhood soft tissue sarcoma showed carriers of germline *TP53* mutations to have estimated cancer risks of approximately 60% and 95% by 45 and 70 years, respectively.³⁸¹ Although similar cancer risks are observed in men and women with LFS when gender-specific cancers are not considered, female breast cancer is commonly associated with the syndrome.³⁵⁹ It is important to mention that estimations of cancer risks associated with LFS are limited to at least some degree by selection bias since dramatically affected kindreds are more likely to be identified and become the subject of further study.

A number of different sets of criteria have been used to help identify individuals with LFS. For the purposes of the NCCN Guidelines, 2 sets of these criteria are used to facilitate the identification of individuals who are candidates for testing for *TP53* pathogenic or likely pathogenic variants.

Classic LFS criteria, based on a study by Li and Fraumeni involving 24 LFS kindreds, include the following: a member of a kindred with a known *TP53* pathogenic or likely pathogenic variant; a combination of an individual diagnosed at 45 years of age or younger with a sarcoma and a first-degree relative diagnosed with cancer at 45 years of age or younger; and an additional first- or second-degree relative in the same lineage with cancer diagnosed at younger than 45 years of age or a sarcoma diagnosed at any age (see *Li-Fraumeni Syndrome Testing Criteria* in the algorithm). Classic LFS criteria have been estimated to have a high positive predictive value (estimated at 56%) as well as a high specificity, although the sensitivity is relatively low (estimated at 40%).³⁵⁹ Thus, it is



not uncommon for individuals with patterns of cancer outside of these criteria to be carriers of germline *TP53* mutations.^{373,382} Classic LFS criteria make up one set of criteria included in the guidelines to guide selection of individuals for *TP53* pathogenic or likely pathogenic variant testing (see *Li-Fraumeni Syndrome Testing Criteria* in the algorithm).

Other groups have broadened the classic LFS criteria to facilitate identification of individuals with LFS.^{368,383-385} One set of these less strict criteria proposed by Birch and colleagues shares many of the features of classic LFS criteria, although a larger range of cancers is included.^{359,368} Individuals with de novo germline *TP53* mutations (no mutation in either biological parent) have also been identified.^{359,360,369} These cases would not be identified as *TP53* testing candidates based on classic LFS criteria due to requirement of a family history. This issue is circumvented, in part, by the criteria for *TP53* testing proposed by Chompret and colleagues, which recommends testing for patients with multiple primary tumors of at least 2 “core” tumor types (ie, sarcoma, breast cancer, adrenocortical carcinoma, brain tumors) diagnosed at <36 years of age or patients with adrenocortical carcinoma diagnosed at any age, regardless of family history (see *Li-Fraumeni Syndrome Testing Criteria* in the algorithm).³⁸⁴ The Chompret criteria have an estimated positive predictive value of 20% to 35%,^{359,384} and, when incorporated as part of *TP53* testing criteria in conjunction with classic LFS criteria, have been shown to improve the sensitivity to 95% (ie, the Chompret criteria added to classic LFS criteria detected 95% of patients with *TP53* mutations).³⁵⁹ The Chompret criteria are the second set of criteria included in the NCCN Guidelines. Although not part of the original published criteria set forth by Chompret et al, the panel recommends adopting the 2015 Revised Chompret Criteria and testing individuals with choroid plexus carcinoma or rhabdomyosarcoma of embryonal anaplastic subtype diagnosed at any age and regardless of family history (for inclusion in criterion 3), based on reports of considerable incidence of *TP53* mutations found in patients with these rare forms of

cancer.^{359,369,386-388} The panel supports the broader age cut-offs proposed by Tinat et al, based on a study in a large number of families, which detected germline *TP53* mutations in affected individuals with later tumor onsets.^{386,388}

Women with early-onset breast cancer (age of diagnosis ≤30 years), with or without family history of core tumor types, are another group for whom *TP53* gene mutation testing may be considered.³⁸⁷ Several studies have investigated the likelihood of a germline *TP53* mutation in this population.^{359,386,389-392} In a study of *TP53* mutations evaluated at a single reference laboratory, Gonzalez et al found that all women younger than 30 years of age with breast cancer who had a first- or second-degree relative with at least one of the core cancer types (n = 5) had germline *TP53* mutations.³⁵⁹ In an analysis of patients with early-onset breast cancer (age of diagnosis <30 years) tested for *TP53* mutation at a single institution (N = 28), 6 patients (33%) were found to have *TP53* mutations.³⁹³ Among the patients who were tested, a *TP53* mutation was found in approximately 8% who did not meet traditional LFS criteria for testing. In another study in patients with *BRCA1/2* mutation-negative early-onset breast cancer (age of diagnosis ≤35 years) tested for *TP53* mutation at a single institution (N = 83), approximately 5% were found to have *TP53* mutations.³⁹¹ Deleterious *TP53* mutations were identified in 3 of 4 patients (75%) with a family history of at least 2 LFS-associated tumors (breast cancer, bone or soft tissue sarcoma, brain tumors, or adrenocortical carcinoma) and in 1 of 17 patients (6%) with a family history of breast cancer only.³⁹¹ Among women <30 years of age with breast cancer and without a family history, the incidence of *TP53* mutations has been reported at 3% to 8%.^{359,390,392,393} Other studies have found an even lower incidence of germline *TP53* gene mutations in this population. For example, Bougeard et al reported that only 0.7% of unselected women with breast cancer before 33 years of age were carriers of a germline *TP53* mutation.³⁸⁶ Furthermore, Ginsburg and colleagues found no germline *TP53* mutations



in 95 unselected women with early-onset breast cancer who previously tested negative for *BRCA1/2* mutations.³⁸⁹

Finally, a member of a family with a known *TP53* pathogenic or likely pathogenic variant is considered to be at sufficient risk to warrant variant testing, even in the absence of any other risk factors. Individuals not meeting testing criteria should be followed according to recommendations tailored to his/her personal cancer history and family history, and testing for other hereditary syndromes may be considered. *TP53* pathogenic/likely pathogenic variants are common in tumors.^{394,395} Therefore, if a *TP53* somatic mutation is found in the absence of paired germline analysis, then germline testing may not be warranted unless there is clinical suspicion of a germline pathogenic or likely pathogenic variant.

Risk Assessment, Counseling, and Management

The approach to families with other hereditary breast cancer syndromes, such as LFS, reflects that of hereditary breast/ovarian cancer in many ways. However, there are some syndrome-specific differences with regard to assessment and management. In the case of LFS, there are multiple associated cancers, both pediatric and adult, that should be reflected in the expanded pedigree (see *Li-Fraumeni Syndrome Testing Criteria* in the algorithm). Cancers associated with LFS include but are not limited to premenopausal breast cancer, bone and soft tissue sarcomas, CNS tumor, adrenocortical carcinoma, hypodiploid acute lymphoblastic leukemia, unusually early onset of other adenocarcinomas, or other childhood cancers.^{359,375,380,387} Verification of these sometimes very rare cancers is particularly important.

An individual with a known *TP53* pathogenic or likely pathogenic variant in a close family member who does not undergo testing should be followed according to the same recommendations as a carrier of a *TP53* pathogenic or likely pathogenic variant (see *Li-Fraumeni Syndrome Management in Adults* in the algorithm). In situations where an individual

(or family member) from a family with no known familial *TP53* pathogenic or likely pathogenic variant undergoes genetic testing, and no variant is found, testing for other hereditary breast syndromes should be considered if testing criteria are met (see *BRCA1/2 Testing Criteria* and *Cowden Syndrome (CS)/PTEN Hamartoma Tumor Syndrome (PHTS) Testing Criteria* in the algorithm). Alternatively, testing another family member with the next highest likelihood of having a pathogenic or likely pathogenic variant may be considered. As previously discussed in the *BRCA1/2* testing section above, testing of unaffected individuals should only be considered when an appropriate affected family member is not available for testing. Importantly, the significant limitations of interpreting testing results for an unaffected individual should be discussed prior to testing.

Employment of a screening protocol that includes MRI may improve early cancer detection in individuals with LFS.³⁹⁶ In 2017, the panel made revisions to the LFS management recommendations following revisions to the “Toronto protocol,” screening recommendations developed by a multi-institutional group of experts.³⁹⁷ NCCN recommendations for management of LFS apply specifically to adults with LFS, and discussions with patients should address the limitations of screening for the many cancers associated with this syndrome. Pediatricians should be made aware of the risk for childhood cancers in affected families and review with these families the screening recommendations for children with LFS.³⁹⁷ It is also important to address the psychosocial and quality-of-life aspects of this syndrome. Given the complexity of LFS management, individuals with LFS should be followed at centers with expertise in management of this syndrome.

For those at risk for breast cancer, training and education in breast self-examination should start at 18 years of age, with the patient performing regular self-examination on a monthly basis. For members of families with LFS, breast cancer surveillance by clinical breast examination is



recommended every 6 to 12 months, beginning at 20 years of age (or at the age of the earliest known breast cancer in the family, if younger than 20 years of age) because of the very early age of breast cancer onset seen in these families. Recommendations for breast screening in LFS are similar to those for *BRCA*-related breast and ovarian cancer syndrome management, although screening is begun at an earlier age. They include annual breast MRI screening with contrast (preferred) or mammogram if MRI is not available for women aged 20 to 29 years; annual mammogram and breast MRI screening with contrast in women aged 30 to 75 years; and management on an individual basis for women older than 75 years. For women with a family history of breast cancer diagnosed earlier than 20 years of age, breast MRI screening with contrast may begin at the earliest age of diagnosis. In women treated for breast cancer who have not had bilateral mastectomy, mammography and breast MRI screening with contrast should continue as recommended based on age. When mammography is performed, the panel recommends that tomosynthesis be considered. As with carriers of a *BRCA1/2* pathogenic or likely pathogenic variant, breast MRI screening in women who are younger than 30 years of age is preferred over mammography due to the potential radiation exposure risk and less sensitivity for detection of tumors.

Although there are no data regarding risk reduction surgery in women with LFS, options for risk-reducing mastectomy should be discussed on a case-by-case basis. Counseling for risk-reducing surgeries may include discussion of extent of cancer risk reduction/protection, risks associated with surgeries, degree of age-specific cancer risk, reconstructive options, and competing risks from other cancers. Family history and life expectancy should also be considered during this counseling.

Many of the other cancers associated with germline *TP53* pathogenic or likely pathogenic variants do not lend themselves to early detection. Thus, additional recommendations are general and include comprehensive

physical examinations (including neurologic examination) every 6 to 12 months, especially when there is a high index of suspicion for second malignancies in cancer survivors and rare cancers (see *Li-Fraumeni Syndrome Management* in the algorithm). Clinicians should address screening limitations for other cancers associated with LFS. Colonoscopy and upper endoscopy should be done every 2 to 5 years, starting at 25 years of age, or 5 years before the earliest known colon cancer diagnosis in family history. Education regarding signs and symptoms of cancer is important. Patients should be advised about the risk to relatives, and genetic counseling for relatives is recommended. Annual dermatologic examination should be done beginning at 18 years of age.

Whole-body MRI for screening of cancers associated with LFS is being evaluated in multiple international trials. Use of whole-body MRI is appealing due to its wide anatomic coverage and the potential to cut down on the number of imaging studies that a patient undergoes.³⁹⁸ A meta-analysis including 578 individuals with *TP53* mutations across 13 prospective cohorts showed that baseline whole-body MRI identified cancer in 7% of the sample, with 83% of the cancers being localized and able to treat with curative intent.³⁹⁹ In a prospective observational study, a clinical surveillance protocol for *TP53* mutation carriers from families affected by LFS was incorporated.⁴⁰⁰ The surveillance protocol included biochemical methods and imaging techniques, such as annual brain MRI, annual rapid whole-body MRI, ultrasound of the abdomen and pelvis, and colonoscopy.⁴⁰¹ For surveillance of breast cancers, the protocol was similar to the NCCN Guidelines for LFS Management.⁴⁰⁰ Eleven-year follow-up of this study, which included 89 *TP53* mutation carriers, showed that this surveillance protocol may be beneficial, with 84% (16 out of 19) of patients who were diagnosed with cancer and had chosen to undergo surveillance being alive at final follow-up, compared to 49% (21 out of 43) of patients who were diagnosed with cancer and had chosen to not undergo surveillance ($P = .012$).⁴⁰¹ Five-year OS was greater for patients



undergoing surveillance (88.8%) compared to patients not undergoing surveillance (59.6%), $P = .013$. The clinical surveillance protocol employed was shown to be feasible, though further evaluation is warranted.⁴⁰⁰ Based on these study results the panel recommends annual whole-body MRI as a category 2B recommendation. This is consistent with recommendations described in the Toronto protocol.³⁹⁷ The panel acknowledges that this surveillance method may not be uniformly available. Patients who do not have access to whole-body MRI should be encouraged to enroll in clinical trials, or alternative comprehensive imaging methods may be used. The panel also acknowledges that whole-body MRI screening of all individuals with LFS may result in false positives and overdiagnosis.^{399,402} Further, the utility of whole-body MRI has not been evaluated in individuals with a *TP53* pathogenic/likely pathogenic variant who don't have a classic family history of LFS, a group that is increasingly being identified through multigene testing. The brain may be examined as part of whole-body MRI or as a separate exam.

Only very limited data exist on the use of prenatal diagnostics/genetic testing for *TP53* mutations in families with LFS.^{403,404} Counseling for reproductive options such as prenatal diagnosis, PGD, and assisted reproduction may be warranted for couples expressing concern over their future offspring's carrier status of a pathogenic or likely pathogenic variant. Such counseling should include a comprehensive discussion of the potential risks, benefits, and limitations of reproductive options. For general discussions on the topic of reproductive options and counseling considerations, see the section above on *Reproductive Options* under *Risk Assessment, Counseling, and Management for BRCA-Related Breast/Ovarian Cancer Syndrome*.

Cowden Syndrome/*PTEN* Hamartoma Tumor Syndrome

The spectrum of disorders resulting from germline pathogenic or likely pathogenic variants in *PTEN*⁴⁰⁵ are referred to as the *PTEN* hamartoma

tumor syndrome (PHTS). The spectrum of PHTS includes Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome (BRRS), adult Lhermitte-Duclos disease (LDD), Proteus-like syndrome,^{98,406,407} and autism spectrum disorders with macrocephaly.^{98,407,408}

The estimated penetrance of *PTEN* mutation is high, at approximately 80%.⁴⁰⁹ The incidence of Cowden syndrome has been reported to be 1 in 200,000, although it is likely to be underestimated due to difficulties associated with making a clinical diagnosis of the disease.^{410,411} Cowden syndrome is an autosomal dominant disorder, and most cases are associated with germline *PTEN* pathogenic or likely pathogenic variants, though one study found that germline *KILLIN* methylation may also be associated with this syndrome.⁴¹²

Hamartomas (benign tumors resulting from an overgrowth of normal tissue) are a common manifestation of the PHTS syndromes. Cowden syndrome is associated with multiple hamartomatous and/or cancerous lesions in various organs and tissues, including the skin, mucous membranes, breast, thyroid, endometrium, and brain.^{98,413} However, it has been suggested that patients with other PHTS diagnoses associated with *PTEN* pathogenic or likely pathogenic variants should be assumed to have Cowden syndrome-associated cancer risks.

The lifetime risk for breast cancer for women diagnosed with Cowden syndrome has been estimated at 25% to 50%, with an average age of 38 to 50 years at diagnosis.^{98,413-415} Some studies (as discussed above) have reported a higher cumulative lifetime risk for breast cancer (77%–85%) in individuals with Cowden syndrome or *PTEN* mutations.⁴¹⁶⁻⁴¹⁸ There have been only 2 cases of breast cancer reported in men with Cowden syndrome.⁴¹⁵ Although many women with Cowden syndrome experience benign breast disease,⁹⁸ there is no evidence that the rate is higher than in the general population.⁴¹⁵



Thyroid disease, including benign multinodular goiter, adenomatous nodules, and follicular adenomas, has been reported to occur in approximately 30% to 68% of adults with *PTEN* mutations,^{407,419} and the lifetime risk for thyroid cancer (follicular or papillary) has been estimated at 3% to 10%.^{98,420} However, data tend to be aggregated, so it is difficult to calculate rates for multinodular goiter versus solitary nodules.⁴¹⁵ A retrospective chart review of 47 children with *PTEN* mutations showed that 26% had abnormal thyroid imaging.⁴²¹

Macrocephaly (defined as head circumference greater than the 97th percentile)⁴²² is a common finding in patients with Cowden syndrome. It has been estimated that approximately 80% to 100% of individuals with this syndrome will exhibit this clinical finding.⁴¹⁵ Adult LDD and autism spectrum disorder characterized by macrocephaly are strongly associated with Cowden syndrome.^{406,409,417,423} A rare, slow-growing, benign hamartomatous lesion of the brain, LDD, is a dysplastic gangliocytoma of the cerebellum.^{98,417} In a multicenter prospective study examining 3042 probands who met clinical criteria for Cowden syndrome, 6% met criteria for LDD.⁴¹⁹ In a study of individuals meeting the diagnostic criteria for Cowden syndrome, the cumulative lifetime risk for LDD was reported to be 32%.⁴¹⁷ The preponderance of evidence supports a strong association between adult-onset LDD and the presence of a *PTEN* gene mutation,^{409,424} although exceptions have been reported.⁴²⁵ In addition, there is a relatively large body of evidence to support that 10% to 20% of individuals with autism spectrum disorder and macrocephaly carry germline *PTEN* mutations.^{408,426-429}

As in many other hereditary cancer syndromes, affected individuals are more likely to develop bilateral and multifocal cancer in paired organs.⁴⁰⁹ Although not well defined, women with Cowden syndrome may have a 5% to 10% risk for endometrial cancer.^{98,430} ⁴¹⁵ While many women with Cowden syndrome may also have uterine fibroids, this risk is not likely to

be much greater than in women without Cowden syndrome or *PTEN* mutation.⁴¹⁵

In addition, brain tumors and vascular malformations affecting any organ are occasionally seen in individuals with Cowden syndrome, although the risks for developing these conditions are not well defined.^{98,415} It is important to note, however, that most of the data on the frequencies of the clinical features of Cowden syndrome are from compilations of case reports of relatively young individuals who may have subsequently developed additional signs of the disease (ie, new cancerous lesions), and these data are also likely to be confounded by selection bias.⁹⁸

Furthermore, a considerable number of these studies were published prior to the establishment in 1996 of the International Cowden Consortium operational diagnostic criteria for the syndrome, which were based on published data and the expert opinion of individuals representing a group of centers mainly in North America and Europe.^{98,431}

Benign skin lesions are experienced by most to all Cowden syndrome patients.^{407,413,421} Skin lesions associated with Cowden syndrome include trichilemmomas (ie, benign tumors derived from the outer root sheath epithelium of a hair follicle), oral papillomas, mucocutaneous neuromas (hamartoma of the peripheral nerve sheath), palmo-plantar keratoses, penile pigmentation in males, lipomas and vascular anomalies, and fibromas.^{415,421,432} Trichilemmomas associated with Cowden syndrome tend to appear on the face, particularly the eyes, mouth, nose, and forehead.⁴¹⁵ Most individuals with Cowden syndrome exhibit characteristic mucocutaneous lesions by their twenties, and such lesions have been reported to occur in 99% of individuals with Cowden syndrome, showing nearly complete penetrance, although this may be a reflection of selection bias in the cases reported.^{184,406} The presence of three or more mucocutaneous neuromas is considered a major diagnostic criterion of PHTS,⁴¹⁵ while the presence of 2 or more trichilemmomas has been



reported to be pathognomonic for Cowden syndrome.^{433,434} However, since most of the evidence regarding trichilemmomas is from the older literature, it is possible that the association with Cowden syndrome is somewhat overestimated.⁹⁸ There are reports of individuals with a solitary trichilemmoma who do not have Cowden syndrome.^{433,434} Nevertheless, due to the strong association between these lesions and Cowden syndrome and the difficulty in clinically distinguishing between a trichilemmoma and another mucocutaneous lesion, it is important that a diagnosis of trichilemmoma is histologically confirmed.

It was previously estimated that about half of individuals with Cowden syndrome have gastrointestinal polyps.⁴³⁵ However, this was almost certainly an underestimate.^{435,436} In an analysis of 67 *PTEN* mutation carriers undergoing colonoscopy, colorectal polyps were found in 92.5% of patients.⁴³⁵ About half of the patients undergoing colonoscopy had hyperplastic polyps, and about 25% had polyps that were hamartomatous, ganglioneuromatous, or adenomatous.⁴³⁵ Adenomatous or hyperplastic polyps were associated with development of colorectal cancer in this sample. Out of 39 *PTEN* mutation carriers undergoing esophagogastroduodenoscopy (EGD), upper gastrointestinal polyps were found in 67% of patients.⁴³⁵ A systematic review of published case series (N = 102) regarding gastrointestinal manifestations in PHTS and component syndromes showed that 92.5% of these patients had polyps, with 64% having 50 or more.⁴³⁷ Histologies were described as: hyperplastic (44%), adenomatous (40%), hamartomatous (38%), ganglioneuroma (33%), and inflammatory (24.5%). Other studies have also reported ganglioneuromatous polyps (ie, rare, benign peripheral nervous system tumors) in this population.^{415,438} A retrospective chart review of 47 children with *PTEN* mutations showed that only 13% had gastrointestinal polyps, but 34% had other gastrointestinal symptoms such as abdominal pain, rectal bleeding, and/or constipation.⁴²¹ Early-onset (<50 years of age) colorectal cancer has been reported in 13% of patients

with *PTEN* mutation-associated Cowden syndrome, suggesting that routine colonoscopy may be warranted in this population.⁴³⁵ The lifetime risk for colorectal cancer has been estimated as 9% to 16%.^{417,418}

Several studies have projected lifetime estimates of cancer risk that are significantly higher than previously estimated. In a study of patients meeting diagnostic criteria for Cowden syndrome (N = 211; identified from published literature and records from a single institution), the cumulative lifetime risk for any cancer was 89%.⁴¹⁷ *PTEN* mutations had been identified in 97 of 105 patients (92%) who underwent testing. The cumulative lifetime cancer risks for all evaluable patients (n = 210) were 81% for female breast cancer, 21% for thyroid cancer, 19% for endometrial cancer, 15% for renal cancer, and 16% for colorectal cancer.⁴¹⁷ In a prospective study that evaluated genotype-phenotype associations between *PTEN* mutations and cancer risks,⁴¹⁸ deleterious germline mutations in *PTEN* were identified in 368 patients. Calculation of age-adjusted SIRs using cancer incidence data from the SEER database showed elevated SIRs among individuals with *PTEN* mutations for breast cancer (25), thyroid cancer (51), endometrial cancer (43), colorectal cancer (10), renal cancer (31), and melanoma (8.5). The estimated cumulative lifetime cancer risks were 85% for breast, 35% for thyroid, 28% for endometrial, 9% for colorectal, 34% for renal, and 6% for melanoma.⁴¹⁸ In another study in individuals with PHTS found to have deleterious germline *PTEN* mutations (N = 154; detailed information available in n = 146), age- and gender-adjusted SIRs were elevated for female breast cancer (39), endometrial cancer (49), female thyroid cancer (43), male thyroid cancer (199.5), female melanoma (28), and male melanoma (39).⁴¹⁶ The cumulative lifetime risks in these individuals were 77% for female breast cancer and 38% for thyroid cancer. The cumulative lifetime risk for any cancer was 85% overall, and women with PHTS were found to have a 2-fold greater cancer risk compared with men with PHTS.⁴¹⁶ It is important to note, however, that all three of these studies suffer from



significant ascertainment biases, in that patients were usually selected for *PTEN* testing based on the presence of these malignancies, which would inflate the projected lifetime cancer estimates. An observational study of 180 patients with *PTEN* mutations used Kaplan-Meier methods to estimate that female carriers (n = 99) have an 87% cumulative risk of developing any cancer and/or LDD by 60 years of age, while male carriers have a cumulative risk of 56%.⁴³⁹

The BRRS variant of PHTS has been characterized by the presence of multiple lipomas, gastrointestinal hamartomatous polyps, macrocephaly, hemangiomas, developmental delay, and, in males, pigmented macules on the glans penis,⁴⁴⁰ although formal diagnostic criteria have not been established for this syndrome. *PTEN* gene mutations testing in individuals characterized with BRRS have been reported in approximately 60% of these patients.⁴⁴¹ Further, in another study, 10% of patients with BRRS for whom a *PTEN* gene mutation test was negative were shown to be carriers of large *PTEN* gene deletions.⁴²³

Risk Assessment, Counseling, and Management

The assessment of individuals suspected of having Cowden syndrome/PHTS incorporates both a history of the benign and malignant conditions associated with the syndrome and a targeted physical examination, including the skin and oral mucosa, breast, and thyroid gland and head circumference (see *Cowden Syndrome/PHTS Testing Criteria* in the algorithm). The NCCN Guidelines Panel has established a list of criteria to help indicate which individuals are candidates for testing for *PTEN* pathogenic or likely pathogenic variants (see *Cowden Syndrome/PHTS Testing Criteria* in the algorithm). These criteria are used to assess the need for further risk assessment and genetic testing, but are not intended to serve as clinical diagnostic criteria.

Testing Criteria

Testing criteria for Cowden syndrome/PHTS are grouped into 3 general categories. A patient is considered for testing for *PTEN* pathogenic or likely pathogenic variants based on whether he/she meets certain criteria or combinations of criteria from these 3 categories. The first criteria category includes individuals meeting diagnostic criteria for Cowden syndrome⁴⁴²: a personal history of BRRS, adult LDD, autism spectrum disorder with macrocephaly, or 2 or more biopsy-proven trichilemmomas. Any individual presenting with one or more of these diagnoses warrants *PTEN* testing. Previously, some of the criteria from this group have sometimes been referred to as “pathognomonic,” although it is unlikely that any of these conditions can stand alone as a definitive diagnostic criterion for Cowden syndrome/PHTS. Another criterion that can be considered to be sufficient to warrant testing for *PTEN* pathogenic or likely pathogenic variants is a family history that includes the presence of a known *PTEN* pathogenic or likely pathogenic variant.

The next category of criteria represents “major” features associated with Cowden syndrome/PHTS.^{407,411,419,442} The major criteria include the presence of breast cancer, macrocephaly (ie, megalcephaly),⁴²² endometrial cancer, follicular thyroid cancer, multiple gastrointestinal hamartomas or ganglioneuromas, macular pigmentation of the glans penis, and certain mucocutaneous lesions that are often observed in patients with Cowden syndrome (ie, one biopsy-proven trichilemmoma, multiple palmoplantar keratoses, multiple or extensive oral mucosal papillomatosis, multiple cutaneous facial papules). With respect to decisions related to the presence of mucocutaneous lesions, the panel did not consider the available literature to be adequate to accurately specify the number or extent of these lesions required for the condition to be defined as a major criterion for Cowden syndrome/PHTS, and clinical judgment is needed when evaluating such lesions. An individual exhibiting 2 or more major criteria where one criterion is macrocephaly meets the



testing threshold. An individual with 3 or more major criteria (without macrocephaly) is also considered to meet the threshold for testing. In addition, individuals exhibiting 1 major criterion with 3 or more minor criteria (discussed below) also meet the testing threshold; if an individual exhibits 2 or more major criteria (eg, breast cancer, follicular thyroid cancer) but does not have macrocephaly, then one of the major criteria may be included as one of the 3 minor criteria to meet the testing threshold.

The final category of criteria represents features with a “minor” association with Cowden syndrome/PHTS.^{407,411,419,442} These include autism spectrum disorder (without macrocephaly), colon cancer, esophageal glycogenic acanthosis (3 or more), lipomas, intellectual disability, papillary or follicular variant of papillary thyroid cancer, thyroid structural lesions other than follicular thyroid cancer (eg, adenoma, nodules, goiter), renal cell carcinoma, a single gastrointestinal hamartoma or ganglioneuroma, testicular lipomatosis, or vascular anomalies (including multiple intracranial developmental venous anomalies). The panel felt that evidence from the literature was insufficient to include fibrocystic breast disease, fibromas, or uterine fibroids as part of the testing criteria. An individual would need to exhibit 4 or more minor criteria or, as discussed above, 3 or more minor criteria and one major criterion to meet testing.

Lastly, an at-risk individual (first-degree relative of an affected individual) with one or more major criterion or 2 or more minor criteria, along with a relative diagnosed with Cowden syndrome/PHTS or BRRS (for whom testing has not been performed), would also meet the threshold for *PTEN* testing. Individuals not meeting testing criteria should be followed according to recommendations tailored to his/her personal cancer history and family history. Testing for other hereditary syndromes may also be considered, if appropriate.

Genetic Testing

Following risk assessment and counseling, genetic testing should be considered in individuals for whom testing criteria are met. The NCCN Guidelines Panel recommends comprehensive testing, which should include full sequencing, gene deletion/duplication analysis, and promoter analysis. A comprehensive clinical test should not include testing for succinate dehydrogenase (*SDH*), as there is no conclusive evidence that this gene is associated with PHTS.⁴⁴³

Clinical Diagnostic Criteria

The *PTEN* mutation frequency in individuals meeting International Cowden Consortium diagnostic criteria for Cowden syndrome has previously been estimated at about 80%.^{415,441} However, evaluation of data based on samples analyzed at a single academic pathology laboratory (N = 802 evaluable) reported a much lower frequency (34%) of *PTEN* mutations among individuals meeting diagnostic criteria⁴¹¹ for Cowden syndrome.⁴⁰⁷ The authors concluded that the current Consortium diagnostic criteria are not as sensitive in identifying individuals with *PTEN* pathogenic or likely pathogenic variants as previously estimated. Since *PTEN* pathogenic or likely pathogenic variants are relatively rare, recommendations regarding Cowden syndrome diagnostic criteria may be based on studies with a small number of patients. Studies with larger samples have their flaws as well, as patients are selected for testing based on the number and magnitude of clinical features, which may lead to overestimation of the features of Cowden syndrome.⁴¹⁵ A review was conducted examining each consortium diagnostic criterion, and revised criteria were proposed that are more stringent and take into account clinical features that are often seen in PHTS.⁴¹⁵ The criteria were designed by focusing on clinical features associated with *PTEN* pathogenic or likely pathogenic variants. The panel recommends using these criteria for clinical diagnosis of PHTS.



Like the testing criteria, diagnostic criteria are categorized as major and minor. Major criteria are as follows: breast cancer, epithelial endometrial cancer, follicular thyroid cancer, 3 or more gastrointestinal hamartomas (including ganglioneuromas, excluding hyperplastic polyps), LDD, macrocephaly (regardless of stature, 58 cm for females, 60 cm for males), and macular pigmentation of the glans penis. A final major criterion is multiple mucocutaneous lesions (3 or more multiple trichilemmomas, 3 or more palmoplantar keratotic pits and/or acral hyperkeratotic papules, 3 or more mucocutaneous neuromas, or oral papillomas). Oral papillomas may be included if there are 3 or more, or if there is evidence from a biopsy or from a dermatologist diagnosis.

Minor criteria include the following: autism spectrum disorder, colon cancer, 3 or more esophageal glycogenic acanthosis, 3 or more lipomas, mental retardation (IQ ≤75), renal cell carcinoma, testicular lipomatosis, thyroid cancer (papillary or follicular variant of papillary), thyroid structural lesions, and vascular anomalies (eg, multiple intracranial developmental venous anomalies).

A clinical diagnosis in an individual would include the following: exhibiting 3 or more major criteria where one is macrocephaly, LDD, or gastrointestinal hamartomas; or 2 major and 3 minor criteria. A clinical diagnosis in a family in which one individual meets these PHTS clinical diagnosis criteria or has a *PTEN* pathogenic or likely pathogenic variant would include the following: any 2 major criteria with or without any minor criteria; 1 major and 2 minor criteria; or 3 minor criteria.

An individual with a known *PTEN* pathogenic or likely pathogenic variant in a close family member who does not undergo gene testing should be followed according to the same guideline as a carrier of a *PTEN* variant (see *Cowden Syndrome/PHTS Management* in the algorithm). In situations where an individual (or family member) from a family with no known familial *PTEN* pathogenic or likely pathogenic variant undergoes

genetic testing and no variant is found, testing for other hereditary breast syndromes should be considered if testing criteria are met (see *BRCA1/2 Testing Criteria* and *Li-Fraumeni Syndrome Testing Criteria* in the algorithm). Alternatively, testing another family member with the next highest likelihood of having a pathogenic or likely pathogenic variant may be considered. Multi-gene testing may also be considered.

If a *PTEN* pathogenic or likely pathogenic variant is not found, or a VUS was found and Cowden syndrome/PHTS diagnostic criteria are met, then individual management should proceed based on the recommended guidelines (see *Cowden Syndrome/PHTS Management* in the algorithm). If diagnostic criteria are not met, then research and individualized recommendations based on personal and family history should be offered, and testing for other hereditary syndromes may be considered.

Screening Recommendations

Cancer is the major health risk associated with Cowden syndrome/PHTS. Therefore, the NCCN Panel had outlined guidelines for prevention and early detection screening of commonly associated cancers with Cowden syndrome/PHTS. Current medical management recommendations for individuals with Cowden syndrome/PHTS include annual physical examinations, starting at 18 years of age (or 5 years before the youngest age of diagnosis of a component cancer in the family).

The recommendations for *women* with Cowden syndrome/PHTS focus on primary and secondary prevention options for breast cancer since this is the most commonly associated cancer in individuals with Cowden syndrome/PHTS based on the available literature. Women should begin regular monthly breast self-examinations at 18 years of age and have a semiannual clinical breast examination beginning at 25 years of age or 5 to 10 years earlier than the earliest known breast cancer in the family (whichever comes first). Women should also have an annual mammogram and breast MRI screening with contrast starting at 30 to 35 years of age,



or 5 to 10 years earlier than the earliest known breast cancer in the family (whichever comes first). After 75 years of age, management should be considered on an individual basis. In women treated for breast cancer who have not had bilateral mastectomy, mammography and breast MRI screening with contrast should continue as recommended based on age. When mammography is performed, the panel recommends that tomosynthesis be considered.

Although there are no data regarding risk reduction surgery in women with Cowden syndrome, the option of RRM and hysterectomy should be discussed on a case-by-case basis. Oophorectomy is not indicated for Cowden syndrome alone, but may be indicated for other reasons. Counseling for risk-reducing surgeries may include discussion of extent of cancer risk reduction/protection, risks associated with surgeries, reconstructive options, and reproductive desires. It is also important to address the psychosocial and quality-of-life aspects of undergoing risk-reducing surgical procedures.

Given that Cowden syndrome is rare, there are no data on screening for endometrial cancer in these patients. The panel recommends patient education regarding the symptoms of endometrial cancer including the necessity of a prompt response to symptoms such as abnormal bleeding. Prompt reporting promotes early detection of endometrial cancer. The evaluation of these symptoms should include an endometrial biopsy. Endometrial cancer screening does not have proven benefit in women with Cowden syndrome. However, endometrial biopsy is highly sensitive and specific as a diagnostic procedure. Therefore, screening through endometrial biopsy every 1 to 2 years may be considered.

Routine transvaginal ultrasound to screen for endometrial cancer in postmenopausal women has not been shown to be sufficiently sensitive or specific to warrant a positive recommendation but may be considered at the clinician's discretion. However, transvaginal ultrasound is not

recommended as a screening tool in premenopausal women due to the wide range of endometrial strip thickness throughout the normal menstrual cycle.

Both men and women with Cowden syndrome/PHTS have approximately at least a 3% to 10% lifetime risk of developing thyroid cancer,⁹⁸ compared to about 1% in the general population.⁴⁴⁴ An annual thyroid ultrasound should be performed, beginning at the time of PHTS diagnosis (including in childhood). In addition, colonoscopy is recommended starting at 35 years of age, or earlier if symptomatic. If a close relative was diagnosed with colon cancer before 40 years of age, then colonoscopy screening should begin 5 to 10 years before the age of the earliest known diagnosis. Colonoscopy should be performed every 5 years or more frequently in cases where the patient is symptomatic or polyps are found. To screen for renal cell carcinoma, renal ultrasound should be considered every 1 to 2 years beginning at 40 years of age. Dermatologic management may be considered for some patients. If there are symptoms in children, then assessment of psychomotor abilities should be considered, as well as a brain MRI. Education regarding the signs and symptoms of cancer is important; patients should also be advised about the risk to relatives, and genetic counseling is recommended for at-risk relatives.

No published data exist on the use of prenatal diagnostics/genetic testing for *PTEN* pathogenic or likely pathogenic variants in families with Cowden syndrome. However, for couples expressing the desire that their offspring not carry a familial *PTEN* pathogenic or likely pathogenic variant, options for prenatal diagnosis, PGD, and assisted reproduction can be discussed. Such counseling should include a comprehensive discussion of the potential risks, benefits, and limitations of reproductive options. For general discussions on the topic of reproductive options and counseling considerations, see the Discussion section above on *Reproductive*



Options under Risk Assessment, Counseling, and Management for BRCA-Related Breast/Ovarian Cancer Syndrome.

Other Pathogenic/Likely Pathogenic Variants Associated with Breast/Ovarian Cancer

In the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian, the panel primarily focuses on assessment of known high-penetrance pathogenic or likely pathogenic variants (ie, *BRCA1/2*, *TP53*, *PTEN*) and recommendations for genetic testing, counseling, and management strategies in individuals with these variants. A retrospective analysis of 337 patients who met NCCN criteria for *BRCA1/2* mutation testing and underwent multigene testing showed that 25 patients (7.4%) had non-*BRCA* mutations.⁸¹ The most common of these mutations were *PALB2* (23%), *CHEK2* (15%), and *ATM* (15%). Below is a description of additional pathogenic or likely pathogenic variants that the panel argues warrants additional screening beyond what is recommended in the general population (ie, those without the specific variant). These include pathogenic or likely pathogenic variants for *ATM*, *BRIP1*, *CDH1*, *CHEK2*, *NBN*, *PALB2*, *RAD51C*, *RAD51D*, and *STK11*. Risk management for pathogenic or likely pathogenic variants associated with Lynch syndrome and neurofibromatosis type 1 (NF1) are also described.

The investigators of an analysis of breast cancer risk in carriers of moderately penetrant genetic mutations posited that, based on an absolute risk approach, screening with mammography in these carriers should begin when the estimated 5-year risk of developing breast cancer exceeds 1%, consistent with recommendations for the average-risk population.⁸¹ Likewise, breast MRI screening in these carriers should begin when the estimated 5-year risk of developing breast cancer exceeds 2.2%. However, for practical reasons, beginning MRI and mammographic screening at the same time is a reasonable approach. The age at which breast screening is recommended may be impacted by the presence of

risk factors such as family history of breast cancer, especially early-onset breast cancer.⁸¹ In those with a family history of early-onset breast cancer, breast screening may begin 5 to 10 years earlier than the youngest breast cancer diagnosis in the family. In women treated for breast cancer who have not had bilateral mastectomy, breast screening should continue as recommended based on age. When mammography is performed, the panel recommends that tomosynthesis be considered. Currently there is insufficient evidence to recommend risk-reducing mastectomy in carriers of moderately penetrant genetic mutations,⁸¹ though this option may be considered and discussed in the presence of a family history of breast cancer.

There is insufficient evidence to recommend a specific age at which RRSO should be considered in carriers of moderately penetrant pathogenic or likely pathogenic variants (ie, *BRIP1*, *RAD51C*, *RAD51D*). The decision to carry out RRSO should not be made lightly, given the impact of premature menopause. Therefore, Tung and colleagues,⁸¹ who carried out an analysis of ovarian cancer risk in carriers of moderately penetrant genetic mutations, argued that RRSO should not be considered until a woman's expected lifetime risk of developing ovarian cancer exceeds 2.6%, which is the expected lifetime risk of a woman with a *BRCA*-negative family history of ovarian cancer. See the discussion below in the sections for *BRIP1* and *RAD51C/RAD51D* for more information on the specific age at which RRSO may be discussed.

The pathogenic or likely pathogenic variants described below may be included concurrently in panel testing (see *Multi-Gene Testing* above). Lower penetrance genes that may be included as part of multi-gene testing but for which there is currently insufficient evidence of an association with breast and/or ovarian cancer include: *BARD1*, *FANCC*, *MRE11A*, *MUTYH* heterozygotes, *RECQL4*, *RAD50*, *RINT1*, *SLX4*, *SMARCA4*, and *XRCC2*. Risk management recommendations for these



genes should take into account family history and other clinical factors. A more comprehensive review of these lower-penetrance genes is described in another publication.⁴⁴⁵

ATM

Pathogenic or likely pathogenic variants in the *ATM* (ataxia-telangiectasia mutated) gene may increase risk for breast cancer. A meta-analysis including 19 studies showed that the cumulative lifetime risk for breast cancer in individuals with an *ATM* pathogenic or likely pathogenic variant is 6% by age 50 years and 33% by age 80 years.⁴⁴⁶ A meta-analysis of three cohort studies of relatives with ataxia-telangiectasia showed an estimated RR of 2.8 (90% CI, 2.2–3.7; $P < .001$).⁴⁴⁷ Other analyses of patients with breast cancer showed that about 1% had an *ATM* mutation.^{69,70,113,448} An analysis of 82 Dutch patients with early-onset breast cancer showed that 8.5% ($n = 7$) of the patients had a detected *ATM* mutation.⁴⁴⁹

The association between specific types of *ATM* genetic variants and breast cancer susceptibility is less clear,^{86–89} with some evidence showing that certain missense mutations may act in a dominant-negative fashion to increase cancer risk, relative to truncating mutations.^{86,87} A meta-analysis including five studies showed that *ATM* mutation carriers have a 38% lifetime risk of developing breast cancer, with carriers of the c.7271T>G missense mutation having a 69% risk of developing breast cancer by 70 years of age.⁴⁵⁰ An analysis from a case-control study (42,671 breast cancer cases and 42,164 controls) showed a significant association between the c.7271T>G variant and breast cancer risk (OR, 11.60; 95% CI, 1.50–89.90; $P = .001$).⁴⁵¹ An analysis of 27 families in which pathogenic *ATM* variants were identified showed an association between the c.7271T>G variant and increased risk for breast cancer (HR, 8.0; 95% CI, 2.3–27.4; $P < .001$).⁴⁵²

Results of the case-control WECARE study suggested that radiation exposure may be associated with increased risk for contralateral breast cancer in women who are carriers of very rare *ATM* missense variants predicted to be deleterious.⁴⁵³ However, a meta-analysis including five studies showed that radiation therapy (with conventional dosing) is not contraindicated in patients with a heterozygous *ATM* mutation.⁴⁵⁰ Therefore, there is currently insufficient evidence to recommend against radiation therapy in women who are carriers diagnosed with cancer.

The panel recommends annual mammogram for women with a mutated *ATM* gene beginning at 40 years of age, with consideration of annual breast MRI. There are no data on the benefit of risk-reducing mastectomy for women with *ATM* mutations,⁸¹ but this procedure may be considered based on family history. Large studies of patients with ovarian cancer have shown that there may be a moderately increased risk for ovarian cancer in carriers of an *ATM* mutation,^{68,70} but there is currently insufficient evidence to recommend RRSO in these carriers. Given the association between *ATM* and development of the autosomal recessive condition ataxia telangiectasia, counseling for carriers of *ATM* pathogenic or likely pathogenic variants should include a discussion of reproductive options. *ATM* mutations have been found in patients with pancreatic^{239,454} and prostate cancers,^{222,455} but there is currently insufficient evidence to recommend screening for these cancers in carriers of an *ATM* pathogenic or likely pathogenic variant.

BARD1

An association between breast cancer and mutations in the *BRCA1*-associated RING domain 1 (*BARD1*) gene has been found in two large case-control studies. The first study included 65,057 women with breast cancer who were referred for genetic testing.⁶⁹ The prevalence rate for *BARD1* mutations in this sample was 0.18%, which was significantly greater than the prevalence rate for the controls (OR, 2.16; 95% CI, 1.31–



3.63; $P < .05$). The second case-control analysis (planned as part of a larger study), which included 15,826 patients with breast cancer, showed a prevalence rate of 0.25% (OR, 1.92; 95% CI, 1.36–2.72; $P < .001$).⁷⁰

Despite this suggestion of an increased risk for breast cancer in individuals with a *BARD1* mutation, the panel has determined that more evidence is needed to provide recommendations for breast screening for these individuals.

BRIP1

Panel testing of germline DNA in women with ovarian cancer has shown that the prevalence rate of the *BRCA1* interaction protein C-terminal helicase 1 gene (*BRIP1*), a Fanconi anemia gene, is about 1%.^{68,70,185} An analysis of 3236 women with epithelial ovarian cancer, 3431 controls, and 2000 unaffected high-risk women from an ovarian cancer screening trial (UKFOCSS) showed that *BRIP1* is associated with an increased risk for ovarian cancer ($P < .001$), with the RR for invasive epithelial ovarian cancer being 11.22 (95% CI, 3.22–34.10; $P < .001$) and 14.09 for high-grade serous disease (95% CI, 4.04–45.02; $P < .001$).⁴⁵⁶ An analysis of an Icelandic population (656 ovarian cancer cases, 3913 controls) also showed an association between *BRIP1* and increased risk for ovarian cancer (OR, 8.13; 95% CI, 4.74–13.95; $P < .001$).⁴⁵⁷ The cumulative lifetime risk of developing ovarian cancer by 80 years of age in *BRIP1* mutation carriers is estimated to be 5.8% (95% CI, 3.6–9.1).⁴⁵⁶

Tung and colleagues⁸¹ argued that RRSO should not be considered in these mutation carriers until their cumulative risk exceeds that of a woman with a first-degree relative with a non-*BRCA*-related ovarian cancer (approximately 2.64). For carriers of a *BRIP1* pathogenic or likely pathogenic variant, this would be around 50 to 55 years of age. However, some women may have additive risk factors (eg, multiple family members with ovarian cancer, lack of parity),⁴⁵⁸ and delaying the discussion of RRSO until 50 years of age may miss some cases of early-onset ovarian

cancer. Therefore, the panel recommends that RRSO in carriers of a *BRIP1* pathogenic or likely pathogenic variant be considered beginning at 45 to 50 years of age. A discussion about risk-reducing surgery may be initiated earlier if there is a family history of early-onset ovarian cancer. Ultimately, large prospective trials are needed to make a firm age recommendation regarding when a discussion about RRSO should begin in these variant carriers.

There is currently insufficient evidence of an association between increased breast cancer risk and *BRIP1*, and no single truncating variant has been found to be associated with increased risk for breast cancer.⁴⁵⁹ *BRIP1* is associated with Fanconi anemia, inherited in an autosomal recessive manner. Therefore, counseling for carriers of *BRIP1* pathogenic or likely pathogenic variants should include a discussion of reproductive options.

CDH1

Germline mutations in *CDH1* are associated with hereditary diffuse gastric cancer and lobular breast cancer, and studies have reported a cumulative lifetime risk for breast cancer of 39% to 52%.^{460,461} Given the considerable risk for lobular breast cancer in women with a *CDH1* pathogenic or likely pathogenic variant, the panel recommends screening with annual mammogram (or consideration of breast MRI), beginning at 30 years of age. Screening may be considered earlier in patients with a family history of early-onset breast cancer. Risk-reducing mastectomy may be discussed with these carriers, depending on family history. See the NCCN Guidelines for Gastric Cancer (available at www.NCCN.org) for screening recommendations for gastric cancer for individuals with a *CDH1* pathogenic or likely pathogenic variant.

CHEK2

Another breast cancer susceptibility gene that has been identified is *CHEK2* (cell cycle checkpoint kinase 2). Panel testing of germline DNA in



large samples of patients with breast cancer has shown that the prevalence rate of a *CHEK2* pathogenic or likely pathogenic variant is about 1%.^{69,70,448} Deleterious *CHEK2* mutations have been reported to occur with a higher frequency in Northern and Eastern European countries compared with North America.^{445,462-464} The cumulative lifetime risk for breast cancer in women with *CHEK2* mutations and familial breast cancer has been estimated to range from approximately 28% to 37%, and is higher in women with stronger family histories of breast cancer than those without.^{465,466} The estimated RR for breast cancer, based on data from two large case-control studies, was 3.0 (90% CI, 2.6–3.5).⁴⁴⁷

Studies investigating the association between breast cancer risk and specific *CHEK2* variants have primarily been based on the truncating variant 1100delC. An analysis from the Copenhagen General Population Study (N = 86,975) showed that *CHEK2* 1100delC heterozygotes had an increased risk for breast cancer when analyses were stratified by age and sex (HR, 2.08; 95% CI, 1.51–2.85).⁴⁶⁷ A case-control study (10,860 cases and 9,065 controls) carried out by the CHEK2 Breast Cancer Case-Control Consortium of Europe and Australia showed that the 1100delC variant is associated with increased risk for breast cancer, even in women unselected for family history (OR, 2.34; 95% CI, 1.72–3.20; $P < .001$).⁴⁶⁸ Another case-control study (44,777 cases and 42,997 controls) showed that heterozygous 1100delC carriers have a significantly increased risk of developing ER-positive breast cancer (OR, 2.55; 95% CI, 2.10–3.10; $P < .001$), but not ER-negative breast cancer (OR, 1.32; 95% CI, 0.93–1.88; $P = 0.12$).⁴⁶⁹ Results from a meta-analysis including 18 case-control studies (26,336 cases and 44,219 controls) showed that the missense variant I157T is associated with a modestly increased risk for breast cancer (OR, 1.58; 95% CI, 1.42–1.75; $P < .001$).⁴⁷⁰

The panel recommends annual mammogram for women with a mutated *CHEK2* gene beginning at 40 years of age, with consideration of annual

breast MRI. Forty years was chosen by the panel as the age at which to begin breast screening, taking into account the average 5-year risk for breast cancer in carriers of *CHEK2* pathogenic or likely pathogenic variants (see section above on carriers of *ATM* pathogenic or likely pathogenic variants), based on risk data that only take into account frameshift mutations such as 1100delC.⁸¹ There are no data on the benefit of risk-reducing mastectomy for women with *CHEK2* mutations,⁸¹ but this procedure may be considered based on family history.

MLH1, MSH2, MSH6, PMS2, EPCAM

Women with Lynch syndrome are at increased risk for endometrial and ovarian cancers (up to 60% and 24%, respectively).⁴⁷¹⁻⁴⁷⁴ Total abdominal hysterectomy and/or bilateral salpingo-oophorectomy are options that may be considered for risk reduction in women who have completed child-bearing and carry an *MLH1*, *MSH2*, *EPCAM*, *PMS2*, or *MSH6* mutation.⁴⁷⁵⁻⁴⁷⁹ There is no clear evidence to support routine screening for gynecologic cancers in these carriers of these pathogenic or likely pathogenic variants. Annual endometrial sampling may be considered, but the benefit is uncertain.^{475,480-483} Routine TVUS and serum CA-125 testing are not endorsed because they have not been shown to be sufficiently sensitive or specific^{475,480-484}; however, there may be circumstances where these tests may be helpful.

Some studies have suggested that some of the mismatch repair genes linked to Lynch syndrome (*MLH1* and *MSH2*) may be associated with increased risk for breast cancer.^{485,486} However, there is currently not enough evidence for the panel to recommend breast screening for women with Lynch syndrome beyond that which is recommended for the average-risk population.

More information regarding Lynch syndrome can be found in the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal (available at www.NCCN.org).

**NBN**

The *NBN* gene is responsible for producing the protein nibrin. Women with heterozygous *NBN* mutations are at increased risk of developing breast cancer (OR, 3.1; 95% CI, 1.4–6.6; $P = .004$).⁴⁸⁷ A meta-analysis including 7 studies showed a significant association between the variant 657del5 and breast cancer risk (OR, 2.42; 95% CI, 1.54–3.80).⁴⁸⁸ An analysis of women with breast cancer in Poland (N = 562) showed that this founder mutation is associated with early-onset breast cancer (OR, 8.36; 95% CI, 2.57–27.27; $P < .001$).⁴⁸⁹ The panel recommends annual mammogram for women with a mutated *NBN* gene beginning at 40 years of age, with consideration of annual breast MRI. Forty years was chosen by the panel as the age at which to begin breast screening, taking into account the average 5-year risk for breast cancer in carriers of these pathogenic or likely pathogenic variants (see above).⁸¹ This recommendation is based primarily on data derived from the Slavic truncating mutation 657del5.^{487–490} There are no data on the benefit of risk-reducing mastectomy for women with *NBN* pathogenic or likely pathogenic variants. Therefore, risk-reducing mastectomy is not recommended in carriers of these pathogenic or likely pathogenic variants, but this procedure may be considered based on family history. The *NBN* gene is associated with development of the autosomal recessive condition Nijmegen breakage syndrome. Therefore, counseling for carriers of *NBN* pathogenic or likely pathogenic variants should include a discussion of reproductive options.

NF1

NF1 is an autosomal dominant hereditary cancer syndrome that is caused by an *NF1* pathogenic or likely pathogenic variant. NF1 is associated with increased risk for malignant peripheral nerve sheath tumors, other CNS tumors, and gastrointestinal stromal tumors.^{491–494} A population-based study in Finland of 1404 patients with NF1 showed an estimated lifetime cancer risk of 59.6%.⁴⁹¹ This study showed a significant association between NF1 and increased risk for breast cancer (SIR, 3.04; 95% CI,

2.06–4.31; $P < .001$). Among patients with breast cancer, NF1 was associated with poorer survival, with 5-year survival rates for patients with NF1 being 67.9%, compared to 87.8% in patients without NF1. Excess incidence was highest in women younger than 40 years of age (SIR, 11.10; 95% CI, 5.56–19.50; $P < .001$). A population-based study in England of 848 patients with NF1 also showed an increased risk for breast cancer (SIR, 3.5; 95% CI, 1.9–5.9), especially among women younger than 50 years (SIR, 4.9; 95% CI, 2.4–8.8).⁴⁹⁵ Cumulative lifetime risk of developing breast cancer by 50 years of age was 8.4% in this sample.

Given the increased risk for early-onset breast cancer in carriers of these pathogenic or likely pathogenic variants, annual breast screening with mammography should begin at 30 years of age.⁴⁹⁶ Screening with breast MRI could also be considered. These screening recommendations apply only to individuals with a clinical diagnosis of NF1. The presence of neurofibromas in the breast may lead to false-positive MRI results, but more data are needed to determine the sensitivity and specificity of breast MRI in individuals with NF1. A prospective study of patients with NF1 from the United Kingdom (N = 448) showed that breast cancer risk in these mutation carriers is not significantly increased at 50 years of age and beyond.⁴⁹⁴ Case-control analyses of women with NF1 from England showed that RR estimates for women aged 30 to 39 years was 6.5 (95% CI, 2.6–13.5) and 4.4 for women aged 40 to 49 years (95% CI, 2.5–7.0).⁴⁹⁷ RR estimates then drop for women aged 50 to 59 years (RR, 2.6; 95% CI, 1.5–4.2) and continue to drop as age increases (RR, 1.9; 95% CI, 1.0–3.3 for women aged 60–69 years and RR, 0.8; 95% CI, 0.2–2.2 for women aged 70–79 years). These studies show that, beginning at age 50, breast cancer risk in women with NF1 may not significantly differ from that of women in the general population. Therefore, breast MRI screening in patients with NF1 may be discontinued at 50 years of age. There are no data regarding the benefit of risk-reducing mastectomy for women with *NF1* pathogenic or likely pathogenic variants. Therefore, risk-reducing



mastectomy is not recommended in these patients, but this procedure may be considered based on family history. Complications related to NF1 (eg, neurologic complications) may appear early in life, and these have the potential to be severe.⁴⁹⁸ Therefore, referral to a neurofibromatosis specialist for management is recommended.

PALB2

PALB2 (partner and localizer of *BRCA2*) is a Fanconi anemia gene. *PALB2* pathogenic or likely pathogenic variants are associated with increased risk for breast cancer, with studies of patients with breast cancer showing that 0.6% to 3% harbor a pathogenic *PALB2*

mutation.^{69,70,152,448,499-501} A meta-analysis of three studies estimated an RR of 5.3 (90% CI, 3.0–9.4).⁴⁴⁷ Breast cancer risk increases with age in women with a *PALB2* mutation, with a 14% lifetime risk by 50 years of age, and a 35% lifetime risk by 70 years of age.⁵⁰² The risk also increases with increasing number of relatives affected with breast cancer. Breast cancer risk by 70 years of age for those with no first-degree relatives with breast cancer was 33%, compared to 58% in those with two first-degree relatives.⁵⁰² In a study of patients with breast cancer from Poland who underwent genetic testing, contralateral breast cancer was reported in 10% of *PALB2* carriers.⁵⁰¹ This study also showed that 10-year survival among *PALB2* carriers with breast cancer was 48%, compared to 72% in *BRCA1* mutation carriers and 75% in non-carriers ($P < .001$). Further, 10-year survival among those with tumors ≥ 2 cm was substantially worse (32.4%) than those with tumors < 2 cm (82.4%) (HR, 7.04; 95% CI, 2.47–20.07; $P < .001$).

The panel recommends annual mammogram for carriers of a *PALB2* pathogenic or likely pathogenic variant beginning at 30 years of age, as this is the age when the average 5-year risk for breast cancer in these mutation carriers exceeds 1%.^{81,502} Breast MRI screening may also be considered. There are no data on the benefit of risk-reducing mastectomy

for women with *PALB2* pathogenic or likely pathogenic variants,⁸¹ but this procedure may be considered based on family history. Though some studies suggest that there may be an association between *PALB2* and increased ovarian cancer risk,^{185,503} there is currently insufficient evidence to consider RRSO in carriers of these pathogenic or likely pathogenic variants. *PALB2* is associated with Fanconi anemia, inherited in an autosomal recessive manner.⁵⁰⁴ Therefore, counseling for carriers of *PALB2* pathogenic or likely pathogenic variants should include a discussion of reproductive options.

RAD51C and RAD51D

Genes in the *RAD51* protein family are involved in homologous recombination and DNA repair. *RAD51C* and *RAD51D* have been shown to be associated with increased risk for ovarian cancer. Panel testing of germline DNA in women with ovarian cancer have shown that the prevalence rate of the *RAD51C* or *RAD51D* pathogenic or likely pathogenic variant is about 1%.^{68,70,185} In a comparison of 1132 probands with a family history of ovarian cancer and 1156 controls, *RAD51C* was associated with an increased risk for ovarian cancer (RR, 5.88; 95% CI, 2.91–11.88; $P < .001$).⁵⁰⁵ Analyses from the same trial (911 probands and 1060 controls) also showed an association between *RAD51D* and increased risk for ovarian cancer (RR, 6.30; 95% CI, 2.86–13.85; $P < .011$).⁵⁰⁶ In a case-control analysis of 3429 women with epithelial ovarian cancer and 2772 controls, both *RAD51C* (OR, 5.2; 95% CI, 1.1–24; $P = .035$) and *RAD51D* (OR, 12.0; 95% CI, 1.5–90; $P = .019$) were associated with an increased risk for ovarian cancer.⁵⁰⁷

The cumulative risk of developing ovarian cancer in carriers of a *RAD51C* mutation does not approach 2.6% (ie, the expected lifetime risk for a woman with a *BRCA*-negative family history of ovarian cancer) until 60 to 64 years of age, with the cumulative risk between the ages of 55 to 59 years being 1.5%.^{81,507} In carriers of a *RAD51D* mutation, the cumulative



risk approaches 2.6% around 50 to 54 years of age. As with carriers of a *BRIP1* pathogenic or likely pathogenic variant, there may be the presence of additive risk factors that may increase the risk for early-onset ovarian cancer. Therefore, the panel recommends that RRSO in carriers of *RAD51C* and *RAD51D* pathogenic or likely pathogenic variants be considered beginning at 45 to 50 years of age. A discussion about risk-reducing surgery may be initiated earlier if there is a family history of early-onset ovarian cancer. As with *BRIP1* pathogenic or likely pathogenic variants, large prospective trials are needed to make a firm age recommendation regarding when a discussion about RRSO should begin in carriers of *RAD51C* and *RAD51D* pathogenic or likely pathogenic variants.

There is currently insufficient evidence that *RAD51C* and *RAD51D* pathogenic or likely pathogenic variants are associated with increased risk for breast cancer. Therefore, carriers of these variants are advised to follow guidelines for women at average risk of developing breast cancer. *RAD51C* is associated with Fanconi anemia, inherited in an autosomal recessive manner. Therefore, counseling for carriers of a *RAD51C* pathogenic or likely pathogenic variant should include a discussion of reproductive options.

STK11

Germline *STK11* pathogenic or likely pathogenic variants are associated with Peutz-Jeghers syndrome (PJS), an autosomal dominant disorder characterized by gastrointestinal polyps, mucocutaneous pigmentation, and elevated risk for gastrointestinal cancers as well as breast or non-epithelial ovarian cancers. Breast cancer risk in women with PJS is 8% at 40 years of age, 13% at 50 years of age, 31% at 60 years of age, and 45% at 70 years of age.⁵⁰⁸ There are no data on the benefit of risk-reducing mastectomy for women with *STK11* pathogenic or likely pathogenic variants. Therefore, risk-reducing mastectomy is not

recommended in these patients, but this procedure may be considered based on family history. Information regarding screening for patients with PJS can be found in the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal (available at www.NCCN.org).



Table 1. Glossary of Relevant Genetic Terms (from the National Cancer Institute [NCI])

Autosomal dominant

Autosomal dominant inheritance refers to genetic conditions that occur when a pathogenic or likely pathogenic variant is present in one copy of a given gene (ie, the person is heterozygous).

Autosomal recessive

Autosomal recessive inheritance refers to genetic conditions that occur only when pathogenic or likely pathogenic variants are present in both copies of a given gene (ie, the person is homozygous for a pathogenic or likely pathogenic variant, or carries two different variants of the same gene, a state referred to as compound heterozygosity).

de novo mutation

An alteration in a gene that is present for the first time in one family member as a result of a pathogenic or likely pathogenic variant in a germ cell (egg or sperm) of one of the parents, or a pathogenic or likely pathogenic variant that arises in the fertilized egg itself during early embryogenesis. Also called new mutation.

Familial

A phenotype or trait that occurs with greater frequency in a given family than in the general population; familial traits may have a genetic and/or nongenetic etiology.

Family history

The genetic relationships within a family combined with the medical history of individual family members. When represented in diagram form using standardized symbols and terminology, it is usually referred to as a pedigree or family tree.

Founder effect

A pathogenic or likely pathogenic variant observed with high frequency in a population founded by a small ancestral group that was once geographically or culturally isolated, in which one or more of the founders was a carrier of the mutant gene.

Germline

The cells from which eggs or sperm (ie, gametes) are derived.

Kindred

An extended family.

Pedigree

A graphic illustration of family history.

Penetrance

A characteristic of a genotype; it refers to the likelihood that a clinical condition will occur when a particular genotype is present.

Proband

The individual through whom a family with a genetic disorder is ascertained. In males this is called a propositus, and in females it is called a probanda.

Sporadic cancer

This term has two meanings. It is sometimes used to differentiate cancers occurring in people who do not have a germline pathogenic or likely pathogenic variant that confers increased susceptibility to cancer from cancers occurring in people who are known to carry a variant. Cancer developing in people who do not carry a high-risk pathogenic or likely pathogenic variant is referred to as **sporadic cancer**. **The distinction is not absolute, because genetic background may influence the likelihood of cancer even in the absence of a specific predisposing variant. Alternatively, sporadic is also sometimes used to describe cancer occurring in individuals without a family history of cancer.**

**Table 2. Genetic Test Results to Determine the Presence of a Cancer-Predisposing Gene**

<i>Result</i>	<i>Description</i>
<i>True-positive</i>	The person is a carrier of an alteration in a known cancer-predisposing gene.
<i>True-negative</i>	The person is not a carrier of a known cancer-predisposing gene that has been positively identified in another family member.
<i>Indeterminate (uninformative)</i>	The person is not a carrier of a known cancer-predisposing gene, and the carrier status of other family members is either also negative or unknown.
<i>Inconclusive (variants of unknown significance)</i>	The person is a carrier of an alteration in a gene that currently has no known significance.



**Table 3. Pathogenic/Likely Pathogenic Variants
Associated with Autosomal Recessive Condition**

<i>Pathogenic/Likely Pathogenic Variants</i>
<i>ATM</i>
<i>BRCA2</i>
<i>BRIP1</i>
<i>NBN</i>
<i>PALB2</i>
<i>RAD51C</i>

Discussion
update in
progress



References

1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. *Cell* 1990;61:759-767. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2188735>.
2. Vogelstein B, Kinzler KW. The multistep nature of cancer. *Trends Genet* 1993;9:138-141. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8516849>.
3. Lynch HT, Watson P, Conway TA, Lynch JF. Clinical/genetic features in hereditary breast cancer. *Breast Cancer Res Treat* 1990;15:63-71. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2322650>.
4. Pharoah PD, Day NE, Duffy S, et al. Family history and the risk of breast cancer: a systematic review and meta-analysis. *Int J Cancer* 1997;71:800-809. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9180149>.
5. Berliner JL, Fay AM. Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors. *J Genet Couns* 2007;16:241-260. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17508274>.
6. Foulkes WD. Inherited susceptibility to common cancers. *N Engl J Med* 2008;359:2143-2153. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19005198>.
7. Trepanier A, Ahrens M, McKinnon W, et al. Genetic cancer risk assessment and counseling: recommendations of the national society of genetic counselors. *J Genet Couns* 2004;13:83-114. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15604628>.
8. Pharoah PD, Antoniou A, Bobrow M, et al. Polygenic susceptibility to breast cancer and implications for prevention. *Nat Genet* 2002;31:33-36. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11984562>.
9. Lancaster JM, Powell CB, Chen LM, Richardson DL. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. *Gynecol Oncol* 2015;136:3-7. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25238946>.
10. Shiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. *Ann Oncol* 2015;26:1291-1299. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25605744>.
11. Moyer VA. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med* 2014;160:271-281. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24366376>.
12. Weitzel JN, Blazer KR, MacDonald DJ, et al. Genetics, genomics, and cancer risk assessment: state of the art and future directions in the era of personalized medicine. *CA Cancer J Clin* 2011;61:327-359. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21858794>.
13. U.S. National Library of Medicine-Key MEDLINE® Indicators. Available at: http://www.nlm.nih.gov/bsd/bsd_key.html. Accessed July 24, 2014.
14. Murff HJ, Byrne D, Syngal S. Cancer risk assessment: quality and impact of the family history interview. *Am J Prev Med* 2004;27:239-245. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15450637>.
15. Murff HJ, Spigel DR, Syngal S. Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. *JAMA* 2004;292:1480-1489. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15383520>.
16. Colditz GA, Willett WC, Hunter DJ, et al. Family history, age, and risk of breast cancer. Prospective data from the Nurses' Health Study. *JAMA* 1993;270:338-343. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8123079>.
17. Slattery ML, Kerber RA. A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database. *JAMA* 1993;270:1563-1568. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8371466>.



18. Childers CP, Childers KK, Maggard-Gibbons M, Macinko J. National estimates of genetic testing in women with a history of breast or ovarian cancer. *J Clin Oncol* 2017;35:3800-3806. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28820644>.

19. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. *Cancer* 1994;73:643-651. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8299086>.

20. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. *J Natl Cancer Inst* 1989;81:1879-1886. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2593165>.

21. Costantino JP, Gail MH, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. *J Natl Cancer Inst* 1999;91:1541-1548. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10491430>.

22. Gail MH, Costantino JP. Validating and improving models for projecting the absolute risk of breast cancer. *J Natl Cancer Inst* 2001;93:334-335. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11238688>.

23. Rockhill B, Spiegelman D, Byrne C, et al. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. *J Natl Cancer Inst* 2001;93:358-366. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11238697>.

24. Euhus DM, Leitch AM, Huth JF, Peters GN. Limitations of the Gail model in the specialized breast cancer risk assessment clinic. *Breast J* 2002;8:23-27. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11856157>.

25. Antoniou AC, Hardy R, Walker L, et al. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data

from UK genetics clinics. *J Med Genet* 2008;45:425-431. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18413374>.

26. Parmigiani G, Chen S, Iversen ES, Jr., et al. Validity of models for predicting BRCA1 and BRCA2 mutations. *Ann Intern Med* 2007;147:441-450. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17909205>.

27. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. *CA Cancer J Clin* 2007;57:75-89. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17392385>.

28. Murphy CD, Lee JM, Drohan B, et al. The American Cancer Society guidelines for breast screening with magnetic resonance imaging: an argument for genetic testing. *Cancer* 2008;113:3116-3120. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18932252>.

29. Bluman LG, Rimer BK, Berry DA, et al. Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. *J Clin Oncol* 1999;17:1040-1046. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10071299>.

30. Bennett RL, French KS, Resta RG, Doyle DL. Standardized human pedigree nomenclature: update and assessment of the recommendations of the National Society of Genetic Counselors. *J Genet Couns* 2008;17:424-433. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18792771>.

31. Bennett RL, Steinhaus KA, Uhrich SB, et al. Recommendations for standardized human pedigree nomenclature. Pedigree Standardization Task Force of the National Society of Genetic Counselors. *Am J Hum Genet* 1995;56:745-752. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7887430>.

32. Calzone KA, Soballe PW. Genetic testing for cancer susceptibility. *Surg Clin North Am* 2008;88:705-721. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18672137>.



33. Weitzel JN, Lagos VI, Cullinane CA, et al. Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA 2007;297:2587-2595. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17579227>.

34. Bodian CA, Perzin KH, Lattes R. Lobular neoplasia. Long term risk of breast cancer and relation to other factors. Cancer 1996;78:1024-1034. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8780540>.

35. Osborne MP, Hoda SA. Current management of lobular carcinoma in situ of the breast. Oncology (Williston Park) 1994;8:45-49; discussion 49, 53-44. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8167087>.

36. Beral V, Doll R, Hermon C, et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008;371:303-314. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18294997>.

37. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-3253. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12824205>.

38. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12117397>.

39. Weiss LK, Burkman RT, Cushing-Haugen KL, et al. Hormone replacement therapy regimens and breast cancer risk(1). Obstet Gynecol 2002;100:1148-1158. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12468157>.

40. Kurian AW, Li Y, Hamilton AS, et al. Gaps in incorporating germline genetic testing into treatment decision-making for early-stage breast

cancer. J Clin Oncol 2017;35:2232-2239. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28402748>.

41. Armstrong J, Toscano M, Kotchko N, et al. Utilization and outcomes of BRCA genetic testing and counseling in a national commercially insured population: the ABOUT study. JAMA Oncol 2015;1-10. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26426480>.

42. Mets S, Tryon R, Veach PM, Zierhut HA. Genetic counselors' experiences regarding communication of reproductive risks with autosomal recessive conditions found on cancer panels. J Genet Couns 2016;25:359-372. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26454646>.

43. Forrest LE, Young MA. Clinically significant germline mutations in cancer-causing genes identified through research studies should be offered to research participants by genetic counselors. J Clin Oncol 2016;34:898-901. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26786918>.

44. Genetic Information Non-Discrimination Act of 2008 (GINA). Vol. Public Law No. 110-233. Available at: <https://www.eeoc.gov/laws/statutes/gina.cfm>.

45. Berliner JL, Fay AM, Cummings SA, et al. NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer. J Genet Couns 2013;22:155-163. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23188549>.

46. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 2003;21:2397-2406. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12692171>.

47. Robson ME, Storm CD, Weitzel J, et al. American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 2010;28:893-901. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20065170>.



48. Hong YC, Liu HM, Chen PS, et al. Hair follicle: a reliable source of recipient origin after allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2007;40:871-874. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17704789>.

49. Tran SD, Pillemer SR, Dutra A, et al. Differentiation of human bone marrow-derived cells into buccal epithelial cells in vivo: a molecular analytical study. *Lancet* 2003;361:1084-1088. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12672312>.

50. Bougeard G, Baert-Desurmont S, Tournier I, et al. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. *J Med Genet* 2006;43:531-533. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16258005>.

51. Chibon F, Primois C, Bressieux JM, et al. Contribution of PTEN large rearrangements in Cowden disease: a multiplex amplifiable probe hybridisation (MAPH) screening approach. *J Med Genet* 2008;45:657-665. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18456716>.

52. Palma MD, Domchek SM, Stopfer J, et al. The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families. *Cancer Res* 2008;68:7006-7014. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18703817>.

53. Weitzel JN, Lagos VI, Herzog JS, et al. Evidence for common ancestral origin of a recurring BRCA1 genomic rearrangement identified in high-risk Hispanic families. *Cancer Epidemiol Biomarkers Prev* 2007;16:1615-1620. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17646271>.

54. Balmana J, Digiovanni L, Gaddam P, et al. Conflicting interpretation of genetic variants and cancer risk by commercial laboratories as assessed by the prospective registry of multiplex testing. *J Clin Oncol* 2016;34:4071-4078. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27621404>.

55. Vail PJ, Morris B, van Kan A, et al. Comparison of locus-specific databases for BRCA1 and BRCA2 variants reveals disparity in variant classification within and among databases. *J Community Genet*

2015;6:351-359. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25782689>.

56. Lincoln SE, Yang S, Cline MS, et al. Consistency of BRCA1 and BRCA2 variant classifications among clinical diagnostic laboratories. *JCO Precis Oncol* 2017;1. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28782058>.

57. Eccles DM, Mitchell G, Monteiro AN, et al. BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance. *Ann Oncol* 2015;26:2057-2065. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26153499>.

58. Badalato L, Kalokairinou L, Borry P. Third party interpretation of raw genetic data: an ethical exploration. *Eur J Hum Genet* 2017;25:1189-1194. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28832567>.

59. Tandy-Connor S, Guiltinan J, Krempely K, et al. False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care. *Genet Med* 2018;20:1515-1521. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29565420>.

60. Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. *Genet Med* 2013;15:565-574. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23788249>.

61. Offit K, Levan O, Mullaney B, et al. Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. *J Natl Cancer Inst* 2003;95:1548-1551. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14559878>.

62. Walsh T, Casadei S, Coats KH, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. *JAMA* 2006;295:1379-1388. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16551709>.



63. Kurian AW, Hare EE, Mills MA, et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. *J Clin Oncol* 2014;32:2001-2009. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24733792>.

64. Kurian AW, Ward KC, Hamilton AS, et al. Uptake, results, and outcomes of germline multiple-gene sequencing after diagnosis of breast cancer. *JAMA Oncol* 2018;4:1066-1072. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29801090>.

65. Desmond A, Kurian AW, Gabree M, et al. Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment. *JAMA Oncol* 2015;1:943-951. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26270727>.

66. Hall MJ, Forman AD, Pilarski R, et al. Gene panel testing for inherited cancer risk. *J Natl Compr Canc Netw* 2014;12:1339-1346. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25190699>.

67. Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. *Proc Natl Acad Sci U S A* 2011;108:18032-18037. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22006311>.

68. Lilyquist J, LaDuca H, Polley E, et al. Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls. *Gynecol Oncol* 2017;147:375-380. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28888541>.

69. Couch FJ, Shimelis H, Hu C, et al. Associations between cancer predisposition testing panel genes and breast cancer. *JAMA Oncol* 2017;3:1190-1196. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28418444>.

70. Kurian AW, Hughes E, Handorf EA, et al. Breast and ovarian cancer penetrance estimates derived from germline multiple-gene sequencing results in women. *JCO Precision Oncology* 2017;1:1-12. Available at: <http://ascopubs.org/doi/abs/10.1200/PO.16.00066>.

71. Decker B, Allen J, Luccarini C, et al. Rare, protein-truncating variants in ATM, CHEK2 and PALB2, but not XRCC2, are associated with increased breast cancer risks. *J Med Genet* 2017;54:732-741. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28779002>.

72. Castera L, Krieger S, Rousselin A, et al. Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes. *Eur J Hum Genet* 2014;22:1305-1313. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24549055>.

73. Rainville IR, Rana HQ. Next-generation sequencing for inherited breast cancer risk: counseling through the complexity. *Curr Oncol Rep* 2014;16:371. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24488544>.

74. Tung N, Battelli C, Allen B, et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. *Cancer* 2015;121:25-33. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25186627>.

75. Buys SS, Sandbach JF, Gammon A, et al. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. *Cancer* 2017;123:1721-1730. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28085182>.

76. Hall MJ, Obeid E, Daly MB. Multigene panels to evaluate hereditary cancer risk: reckless or relevant? *J Clin Oncol* 2016;34:4186-4187. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27551136>.

77. Manchanda R, Patel S, Gordeev VS, et al. Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation testing in unselected general population women. *J Natl Cancer Inst* 2018;110:714-725. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29361001>.

78. Walsh T, Lee MK, Casadei S, et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. *Proc Natl Acad Sci U S A* 2010;107:12629-12633. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20616022>.



79. Bombard Y, Bach PB, Offit K. Translating genomics in cancer care. J Natl Compr Canc Netw 2013;11:1343-1353. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24225968>.

80. Blazer KR, Slavin T, Weitzel JN. Increased reach of genetic cancer risk assessment as a tool for precision management of hereditary breast cancer. JAMA Oncol 2016;2:723-724. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26869327>.

81. Tung N, Domchek SM, Stadler Z, et al. Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol 2016;13:581-588. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/27296296>.

82. van Marcke C, De Leener A, Berliere M, et al. Routine use of gene panel testing in hereditary breast cancer should be performed with caution. Crit Rev Oncol Hematol 2016;108:33-39. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27931838>.

83. Cragun D, Radford C, Dolinsky JS, et al. Panel-based testing for inherited colorectal cancer: a descriptive study of clinical testing performed by a US laboratory. Clin Genet 2014;86:510-520. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24506336>.

84. LaDuca H, Stuenkel AJ, Dolinsky JS, et al. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. Genet Med 2014;16:830-837. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24763289>.

85. Mauer CB, Pirzadeh-Miller SM, Robinson LD, Euhus DM. The integration of next-generation sequencing panels in the clinical cancer genetics practice: an institutional experience. Genet Med 2014;16:407-412. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24113346>.

86. Brunet J, Gutierrez-Enriquez S, Torres A, et al. ATM germline mutations in Spanish early-onset breast cancer patients negative for BRCA1/BRCA2 mutations. Clin Genet 2008;73:465-473. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18384426>.

87. Heikkinen K, Rapakko K, Karppinen SM, et al. Association of common ATM polymorphism with bilateral breast cancer. Int J Cancer 2005;116:69-72. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15756685>.

88. Thompson D, Antoniou AC, Jenkins M, et al. Two ATM variants and breast cancer risk. Hum Mutat 2005;25:594-595. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15880680>.

89. Tommiska J, Jansen L, Kilpivaara O, et al. ATM variants and cancer risk in breast cancer patients from Southern Finland. BMC Cancer 2006;6:209. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16914028>.

90. Obeid EI, Hall MJ, Daly MB. Multigene panel testing and breast cancer risk: is it time to scale down? JAMA Oncol 2017;3:1176-1177. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28418452>.

91. Kapoor NS, Curcio LD, Blakemore CA, et al. Multigene panel testing detects equal rates of pathogenic BRCA1/2 mutations and has a higher diagnostic yield compared to limited BRCA1/2 analysis alone in patients at risk for hereditary breast cancer. Ann Surg Oncol 2015;22:3282-3288. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26219241>.

92. Axilbund JE. Panel testing is not a panacea. J Clin Oncol 2016;34:1433-1435. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26976416>.

93. Robson ME, Bradbury AR, Arun B, et al. American Society of Clinical Oncology Policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 2015;33:3660-3667. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26324357>.

94. Forouzanfar MH, Foreman KJ, Delossantos AM, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 2011;378:1461-1484. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21924486>.

95. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7-30. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28055103>.



96. Blackwood MA, Weber BL. BRCA1 and BRCA2: from molecular genetics to clinical medicine. J Clin Oncol 1998;16:1969-1977. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9586917>.
97. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002;108:171-182. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11832208>.
98. Pilarski R. Cowden syndrome: a critical review of the clinical literature. J Genet Couns 2009;18:13-27. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18972196>.
99. Schneider KA, Garber J. Li-Fraumeni syndrome. GeneReviews; 2013. Available at: <http://www.ncbi.nlm.nih.gov/books/NBK1311/>.
100. Oliveira C, Bordin MC, Grehan N, et al. Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. Hum Mutat 2002;19:510-517. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11968083>.
101. Simon R, Zhang X. On the dynamics of breast tumor development in women carrying germline BRCA1 and BRCA2 mutations. Int J Cancer 2008;122:1916-1917. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18098285>.
102. Yun MH, Hiom K. Understanding the functions of BRCA1 in the DNA-damage response. Biochem Soc Trans 2009;37:597-604. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19442256>.
103. Cipak L, Watanabe N, Bessho T. The role of BRCA2 in replication-coupled DNA interstrand cross-link repair in vitro. Nat Struct Mol Biol 2006;13:729-733. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16845393>.
104. Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994;265:2088-2090. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8091231>.
105. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol 2009;113:957-966. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19305347>.
106. Whittemore AS. Risk of breast cancer in carriers of BRCA gene mutations. N Engl J Med 1997;337:788-789. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9289641>.
107. Metcalfe KA, Poll A, Royer R, et al. Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol 2010;28:387-391. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20008623>.
108. Csokay B, Udvarhelyi N, Sulyok Z, et al. High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history. Cancer Res 1999;59:995-998. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10070953>.
109. Ji J, Hemminki K. Familial risk for histology-specific bone cancers: an updated study in Sweden. Eur J Cancer 2006;42:2343-2349. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16859907>.
110. Mikaelssdottir EK, Valgeirsdottir S, Eyfjord JE, Rafnar T. The Icelandic founder mutation BRCA2 999del5: analysis of expression. Breast Cancer Res 2004;6:R284-290. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15217494>.
111. Petrij-Bosch A, Peelen T, van Vliet M, et al. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet 1997;17:341-345. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9354803>.
112. Tonin PN, Mes-Masson AM, Futreal PA, et al. Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet 1998;63:1341-1351. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9792861>.
113. Tung N, Lin NU, Kidd J, et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast



cancer. J Clin Oncol 2016;34:1460-1468. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/26976419>.

114. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998;62:676-689. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/9497246>.

115. Abeliovich D, Kaduri L, Lerer I, et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 1997;60:505-514. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/9042909>.

116. Levy-Lahad E, Catane R, Eisenberg S, et al. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 1997;60:1059-1067. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/9150153>.

117. Petrucelli N, Daly MB, Bars Culver JO, Feldman GL. BRCA1 and BRCA2 hereditary breast/ovarian cancer. GeneReviews; 2011. Available at: Available at: <http://www.ncbi.nlm.nih.gov/books/NBK1247/>.

118. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer 2000;83:1301-1308. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/11044354>.

119. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-1130. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/12677558>.

120. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25:1329-1333. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/17416853>.

121. Ford D, Easton DF, Bishop DT, et al. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994;343:692-695. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/7907678>.

122. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643-646. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14576434>.

123. Mavaddat N, Peock S, Frost D, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013;105:812-822. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/23628597>.

124. Risch HA, McLaughlin JR, Cole DE, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006;98:1694-1706. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/17148771>.

125. van den Broek AJ, van 't Veer LJ, Hoening MJ, et al. Impact of age at primary breast cancer on contralateral breast cancer risk in BRCA1/2 mutation carriers. J Clin Oncol 2016;34:409-418. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/26700119>.

126. Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 2006;296:185-192. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/16835424>.

127. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700-710. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11179017>.

128. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. Jama 2017;317:2402-2416. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/28632866>.



129. Rebbeck TR, Mitra N, Wan F, et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. *Jama* 2015;313:1347-1361. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25849179>.

130. Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. *N Engl J Med* 2017;377:523-533. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28578601>.

131. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. *N Engl J Med* 2018;379:753-763. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30110579>.

132. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. *Lancet Oncol* 2011;12:852-861. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21862407>.

133. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. *Lancet* 2010;376:245-251. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20609468>.

134. Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. *J Clin Oncol* 2010;28:2512-2519. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20406929>.

135. Kristeleit R, Shapiro GI, Burris HA, et al. A phase I-II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors. *Clin Cancer Res* 2017;23:4095-4106. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28264872>.

136. Swisher EM, Lin KK, Oza AM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international,

multicentre, open-label, phase 2 trial. *Lancet Oncol* 2017;18:75-87. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27908594>.

137. Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. *J Clin Oncol* 2015;33:244-250. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25366685>.

138. Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastatic prostate cancer. *N Engl J Med* 2015;373:1697-1708. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26510020>.

139. Shroff RT, Hendifar A, McWilliams RR, et al. Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation. *JCO Precis Oncol* 2018;2018. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30051098>.

140. Imyanitov EN, Moiseyenko VM. Drug therapy for hereditary cancers. *Hered Cancer Clin Pract* 2011;9:5. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21819606>.

141. Atchley DP, Albarracin CT, Lopez A, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. *J Clin Oncol* 2008;26:4282-4288. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18779615>.

142. Eerola H, Heikkilä P, Tamminen A, et al. Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families. *Breast Cancer Res* 2005;7:R465-469. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15987451>.

143. Lakhani SR, Reis-Filho JS, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. *Clin Cancer Res* 2005;11:5175-5180. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16033833>.

144. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers



estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002;20:2310-2318.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11981002>.

145. Lee E, McKean-Cowdin R, Ma H, et al. Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. J Clin Oncol 2011;29:4373-4380. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22010008>.

146. Young SR, Pilarski RT, Donenberg T, et al. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 2009;9:86. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19298662>.

147. Evans DG, Howell A, Ward D, et al. Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer. J Med Genet 2011;48:520-522. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21653198>.

148. Fostira F, Tsiitlaidou M, Papadimitriou C, et al. Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat 2012;134:353-362. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22434525>.

149. Gonzalez-Angulo AM, Timms KM, Liu S, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 2011;17:1082-1089. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21233401>.

150. Rummel S, Varner E, Shriver CD, Ellsworth RE. Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer. Breast Cancer Res Treat 2013;137:119-125. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23192404>.

151. Saura C, Saanchez-Olle G, Bosch N, et al. High prevalence of BRCA1/2 germline mutations in female breast cancer patients with triple-negative phenotype (TNBC) and family history [abstract]. J Clin Oncol

2010;28(Supple 15):Abstract 1534. Available at: http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/1534.

152. Couch FJ, Hart SN, Sharma P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol 2015;33:304-311. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25452441>.

153. Shimelis H, LaDuca H, Hu C, et al. Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing. J Natl Cancer Inst 2018. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30099541>.

154. Tun NM, Villani G, Ong K, et al. Risk of having BRCA1 mutation in high-risk women with triple-negative breast cancer: a meta-analysis. Clin Genet 2014;85:43-48. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24000781>.

155. Meyer P, Landgraf K, Hogel B, et al. BRCA2 mutations and triple-negative breast cancer. PLoS One 2012;7:e38361. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22666503>.

156. Eccles DM, Li N, Handwerker R, et al. Genetic testing in a cohort of young patients with HER2-amplified breast cancer. Ann Oncol 2016;27:467-473. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26681682>.

157. Comen E, Davids M, Kirchhoff T, et al. Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women. Breast Cancer Res Treat 2011;129:185-190. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21394499>.

158. Walsh T, Mandell JB, Norquist BM, et al. Genetic predisposition to breast cancer due to mutations other than BRCA1 and BRCA2 founder alleles among Ashkenazi Jewish women. JAMA Oncol 2017;3:1647-1653. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28727877>.



159. Lee LJ, Alexander B, Schnitt SJ, et al. Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers. *Cancer* 2011;117:3093-3100. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21264845>.

160. Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. *J Clin Oncol* 2004;22:735-742. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14966099>.

161. Kast K, Rhiem K, Wappenschmidt B, et al. Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer. *J Med Genet* 2016;53:465-471. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26928436>.

162. Basham VM, Lipscombe JM, Ward JM, et al. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. *Breast Cancer Res* 2002;4:R2. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11879560>.

163. Couch FJ, Farid LM, DeShano ML, et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. *Nat Genet* 1996;13:123-125. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8673091>.

164. Ding YC, Steele L, Kuan CJ, et al. Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States. *Breast Cancer Res Treat* 2011;126:771-778. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20927582>.

165. Friedman LS, Gayther SA, Kurosaki T, et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. *Am J Hum Genet* 1997;60:313-319. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9012404>.

166. Evans DG, Susnerwala I, Dawson J, et al. Risk of breast cancer in male BRCA2 carriers. *J Med Genet* 2010;47:710-711. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20587410>.

167. Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. *J Natl Cancer Inst* 2007;99:1811-1814. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18042939>.

168. What are the key statistics about breast cancer in men? 2015. Available at: <http://www.cancer.org/cancer/breastcancerinmen/detailedguide/breast-cancer-in-men-key-statistics>. Accessed May 28, 2015.

169. Pal T, Bonner D, Cragun D, et al. A high frequency of BRCA mutations in young black women with breast cancer residing in Florida. *Cancer* 2015;121:4173-4180. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26287763>.

170. Bordeleau L, Panchal S, Goodwin P. Prognosis of BRCA-associated breast cancer: a summary of evidence. *Breast Cancer Res Treat* 2010;119:13-24. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19789974>.

171. Verhoog LC, Berns EM, Brekelmans CT, et al. Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients. *J Clin Oncol* 2000;18:119s-124s. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/11060339>.

172. Zhong Q, Peng HL, Zhao X, et al. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis. *Clin Cancer Res* 2015;21:211-220. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25348513>.

173. Baretta Z, Mocellin S, Goldin E, et al. Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis. *Medicine (Baltimore)* 2016;95:e4975. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27749552>.

174. van den Broek AJ, Schmidt MK, van 't Veer LJ, et al. Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what's the evidence? A systematic review with meta-analysis. *PLoS One*



2015;10:e0120189. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25816289>.

175. Nilsson MP, Hartman L, Idvall I, et al. Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status. *Breast Cancer Res Treat* 2014;144:133-142. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24477976>.

176. Noori SF, Gangi A, Nelson ME, et al. Comparison of nodal metastasis between BRCA mutation carriers and non-BRCA mutation carriers with breast cancer. *Ann Surg Oncol* 2014;21:3324-3329. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25047471>.

177. Schmidt MK, van den Broek AJ, Tollenaar RA, et al. Breast cancer survival of BRCA1/BRCA2 mutation carriers in a hospital-based cohort of young women. *J Natl Cancer Inst* 2017;109. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28376189>.

178. Litton JK, Ready K, Chen H, et al. Earlier age of onset of BRCA mutation-related cancers in subsequent generations. *Cancer* 2012;118:321-325. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21913181>.

179. Guindalini RS, Song A, Fackenthal JD, et al. Genetic anticipation in BRCA1/BRCA2 families after controlling for ascertainment bias and cohort effect. *Cancer* 2016;122:1913-1920. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26992017>.

180. Gutierrez Barrera AM, Fouad TM, Song J, et al. BRCA mutations in women with inflammatory breast cancer. *Cancer* 2018;124:466-474. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29044548>.

181. Levine DA, Argenta PA, Yee CJ, et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. *J Clin Oncol* 2003;21:4222-4227. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14615451>.

182. Piver MS, Jishi MF, Tsukada Y, Nava G. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history

of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. *Cancer* 1993;71:2751-2755. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8467455>.

183. Arts-de Jong M, de Bock GH, van Asperen CJ, et al. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: a systematic review. *Eur J Cancer* 2016;61:137-145. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27209246>.

184. Jazaeri AA, Lu K, Schmandt R, et al. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. *Mol Carcinog* 2003;36:53-59. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12557260>.

185. Norquist BM, Harrell MI, Brady MF, et al. Inherited mutations in women with ovarian carcinoma. *JAMA Oncol* 2016;2:482-490. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26720728>.

186. Song H, Cicek MS, Dicks E, et al. The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. *Hum Mol Genet* 2014;23:4703-4709. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24728189>.

187. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. *Cancer* 2005;104:2807-2816. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16284991>.

188. Schrader KA, Hurlburt J, Kalloger SE, et al. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy. *Obstet Gynecol* 2012;120:235-240. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22776961>.

189. Zhang S, Royer R, Li S, et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. *Gynecol Oncol* 2011;121:353-357. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21324516>.



190. Gayther SA, Russell P, Harrington P, et al. The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. *Am J Hum Genet* 1999;65:1021-1029. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10486320>.

191. Sekine M, Nagata H, Tsuji S, et al. Localization of a novel susceptibility gene for familial ovarian cancer to chromosome 3p22-p25. *Hum Mol Genet* 2001;10:1421-1429. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11440995>.

192. Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. *J Clin Oncol* 2012;30:2654-2663. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22711857>.

193. Bolton KL, Chenevix-Trench G, Goh C, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. *JAMA* 2012;307:382-390. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22274685>.

194. Cass I, Baldwin RL, Varkey T, et al. Improved survival in women with BRCA-associated ovarian carcinoma. *Cancer* 2003;97:2187-2195. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12712470>.

195. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, et al. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. *J Clin Oncol* 2008;26:20-25. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18165636>.

196. Tan DS, Rothermundt C, Thomas K, et al. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. *J Clin Oncol* 2008;26:5530-5536. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18955455>.

197. Yang D, Khan S, Sun Y, et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator

phenotype in patients with ovarian cancer. *JAMA* 2011;306:1557-1565. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21990299>.

198. Dong F, Davineni PK, Howitt BE, Beck AH. A BRCA1/2 mutational signature and survival in ovarian high-grade serous carcinoma. *Cancer Epidemiol Biomarkers Prev* 2016;25:1511-1516. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27496093>.

199. Bjorge T, Lie AK, Hovig E, et al. BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study. *Br J Cancer* 2004;91:1829-1834. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15477862>.

200. Lakhani SR, Manek S, Penault-Llorca F, et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. *Clin Cancer Res* 2004;10:2473-2481. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15073127>.

201. Press JZ, De Luca A, Boyd N, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. *BMC Cancer* 2008;8:17. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18208621>.

202. Rechsteiner M, Zimmermann AK, Wild PJ, et al. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. *Exp Mol Pathol* 2013;95:235-241. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23965232>.

203. Werness BA, Ramus SJ, DiCioccio RA, et al. Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry. *Int J Gynecol Pathol* 2004;23:29-34. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14668547>.

204. Ayadi-Kaddour A, Bouraoui S, Bellil K, et al. Colonic adenocarcinoma and bilateral malignant ovarian sex cord tumor with annular tubules in Peutz-Jeghers syndrome. *Pathologica* 2004;96:117-120. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15524052>.



205. Clements A, Robison K, Granai C, et al. A case of Peutz-Jeghers syndrome with breast cancer, bilateral sex cord tumor with annular tubules, and adenoma malignum caused by STK11 gene mutation. *Int J Gynecol Cancer* 2009;19:1591-1594. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19955943>.

206. Kondi-Pafiti A, Bakalianou K, Iavazzo C, et al. Endometrial carcinoma and ovarian sex cord tumor with annular tubules in a patient with history of Peutz-Jeghers syndrome and multiple malignancies. *Eur J Gynaecol Oncol* 2011;32:452-454. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21941977>.

207. Lele SM, Sawh RN, Zaharopoulos P, et al. Malignant ovarian sex cord tumor with annular tubules in a patient with Peutz-Jeghers syndrome: a case report. *Mod Pathol* 2000;13:466-470. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10786816>.

208. Young RH. Sex cord-stromal tumors of the ovary and testis: their similarities and differences with consideration of selected problems. *Mod Pathol* 2005;18 Suppl 2:S81-98. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/15502809>.

209. Goulvent T, Ray-Coquard I, Borel S, et al. DICER1 and FOXL2 mutations in ovarian sex cord-stromal tumours: a GINECO Group study. *Histopathology* 2016;68:279-285. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26033501>.

210. Kauff ND, Mitra N, Robson ME, et al. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. *J Natl Cancer Inst* 2005;97:1382-1384. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16174860>.

211. Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. *J Clin Oncol* 2007;25:3985-3990. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17761984>.

212. Finch A, Shaw P, Rosen B, et al. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.

Gynecol Oncol 2006;100:58-64. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16137750>.

213. Powell CB, Chen LM, McLennan J, et al. Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. *Int J Gynecol Cancer* 2011;21:846-851. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21670699>.

214. Powell CB, Kenley E, Chen LM, et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. *J Clin Oncol* 2005;23:127-132. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15625367>.

215. Shaw PA, Rouzbahman M, Pizer ES, et al. Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. *Mod Pathol* 2009;22:1133-1138. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19543244>.

216. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. *Am J Surg Pathol* 2006;30:230-236. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16434898>.

217. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. *Am J Surg Pathol* 2007;31:161-169. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17255760>.

218. Agalliu I, Gern R, Leanza S, Burk RD. Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations. *Clin Cancer Res* 2009;15:1112-1120. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19188187>.

219. Leongamornlert D, Mahmud N, Tymrakiewicz M, et al. Germline BRCA1 mutations increase prostate cancer risk. *Br J Cancer* 2012;106:1697-1701. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22516946>.



220. van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. *J Med Genet* 2005;42:711-719. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16141007>.

221. Abida W, Armenia J, Gopalan A, et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. *JCO Precis Oncol* 2017;2017. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28825054>.

222. Na R, Zheng SL, Han M, et al. Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death. *Eur Urol* 2017;71:740-747. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27989354>.

223. Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. *N Engl J Med* 2016;375:443-453. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/27433846>.

224. Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. *J Clin Oncol* 2013;31:1748-1757. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23569316>.

225. Kirchhoff T, Kauff ND, Mitra N, et al. BRCA mutations and risk of prostate cancer in Ashkenazi Jews. *Clin Cancer Res* 2004;10:2918-2921. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15131025>.

226. Gallagher DJ, Gaudet MM, Pal P, et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. *Clin Cancer Res* 2010;16:2115-2121. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20215531>.

227. Hamel N, Kotar K, Foulkes WD. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer. *BMC Med Genet* 2003;4:7. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/12911837>.

228. Nastiuk KL, Mansukhani M, Terry MB, et al. Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men. *Prostate* 1999;40:172-177. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/10398279>.

229. Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. *Cancer Res* 1996;56:5360-5364. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/8968085>.

230. Lal G, Liu G, Schmock B, et al. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. *Cancer Res* 2000;60:409-416. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10667595>.

231. Murphy KM, Brune KA, Griffin C, et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. *Cancer Res* 2002;62:3789-3793. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12097290>.

232. Couch FJ, Johnson MR, Rabe KG, et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. *Cancer Epidemiol Biomarkers Prev* 2007;16:342-346. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17301269>.

233. Ghiorzo P, Fornarini G, Sciallero S, et al. CDKN2A is the main susceptibility gene in Italian pancreatic cancer families. *J Med Genet* 2012;49:164-170. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/22368299>.

234. Lucas AL, Shakya R, Lipsyc MD, et al. High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions. *Clin Cancer Res* 2013;19:3396-3403. Available at:

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3959126/>.

235. Holter S, Borgida A, Dodd A, et al. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. *J*



Clin Oncol 2015;33:3124-3129. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/25940717>.

236. Zhen DB, Rabe KG, Gallinger S, et al. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet Med 2015;17:569-577. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/25356972>.

237. Salo-Mullen EE, O'Reilly EM, Kelsen DP, et al. Identification of germline genetic mutations in patients with pancreatic cancer. Cancer 2015;121:4382-4388. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/26440929>.

238. Mandelker D, Zhang L, Kemel Y, et al. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing. JAMA 2017;318:825-835. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/28873162>.

239. Shindo K, Yu J, Suenaga M, et al. Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma. J Clin Oncol 2017;35:3382-3390. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/28767289>.

240. Huang KL, Mashl RJ, Wu Y, et al. Pathogenic germline variants in 10,389 adult cancers. Cell 2018;173:355-370 e314. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/29625052>.

241. Chaffee KG, Oberg AL, McWilliams RR, et al. Prevalence of germline mutations in cancer genes among pancreatic cancer patients with a positive family history. Genet Med 2018;20:119-127. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/28726808>.

242. Hu C, Hart SN, Polley EC, et al. Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. JAMA 2018;319:2401-2409. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/29922827>.

243. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/29313949>.

244. Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 2012;62:118-128. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/22281605>.

245. de Jonge MM, Mooyaart AL, Vreeswijk MP, et al. Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: A meta-analysis and case report. Eur J Cancer 2017;72:215-225. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/28049106>.

246. Lavie O, Ben-Arie A, Segev Y, et al. BRCA germline mutations in women with uterine serous carcinoma--still a debate. Int J Gynecol Cancer 2010;20:1531-1534. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/21119368>.

247. Saule C, Mouret-Fourme E, Briaux A, et al. Risk of serous endometrial carcinoma in women with pathogenic BRCA1/2 variant after risk-reducing salpingo-oophorectomy. J Natl Cancer Inst 2018;110. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28954295>.

248. Shu CA, Pike MC, Jotwani AR, et al. Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations. JAMA Oncol 2016;2:1434-1440. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/27367496>.

249. Beiner ME, Finch A, Rosen B, et al. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol 2007;104:7-10. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/16962648>.

250. Lee YC, Milne RL, Lheureux S, et al. Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers. Eur J Cancer 2017;84:114-120. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28802188>.



251. Iqbal J, Nussenzweig A, Lubinski J, et al. The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study. *Br J Cancer* 2016;114:1160-1164. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26986251>.

252. Moran A, O'Hara C, Khan S, et al. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. *Fam Cancer* 2012;11:235-242. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22187320>.

253. Ethical and policy issues in genetic testing and screening of children. *Pediatrics* 2013;131:620-622. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23428972>.

254. Rosenberg SM, Ruddy KJ, Tamimi RM, et al. BRCA1 and BRCA2 mutation testing in young women with breast cancer. *JAMA Oncol* 2016;2:730-736. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26867710>.

255. Winter C, Nilsson MP, Olsson E, et al. Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic. *Ann Oncol* 2016;27:1532-1538. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27194814>.

256. Meric-Bernstam F, Brusco L, Daniels M, et al. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. *Ann Oncol* 2016;27:795-800. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26787237>.

257. Mohamad HB, Apffelstaedt JP. Counseling for male BRCA mutation carriers: a review. *Breast* 2008;17:441-450. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18657973>.

258. Ibrahim M, Yadav S, Ogunleye F, Zakalik D. Male BRCA mutation carriers: clinical characteristics and cancer spectrum. *BMC Cancer* 2018;18:179. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29433453>.

259. Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. *JAMA* 2004;292:1317-1325. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15367553>.

260. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. *N Engl J Med* 2004;351:427-437. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15282350>.

261. Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). *Lancet* 2005;365:1769-1778. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15910949>.

262. Stoutjesdijk MJ, Boetes C, Jager GJ, et al. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. *J Natl Cancer Inst* 2001;93:1095-1102. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11459871>.

263. Berg WA. How well does supplemental screening magnetic resonance imaging work in high-risk women? *J Clin Oncol* 2014;32:2193-2196. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24934782>.

264. Buist DS, Porter PL, Lehman C, et al. Factors contributing to mammography failure in women aged 40-49 years. *J Natl Cancer Inst* 2004;96:1432-1440. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15467032>.

265. Mandelson MT, Oestreicher N, Porter PL, et al. Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. *J Natl Cancer Inst* 2000;92:1081-1087. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10880551>.

266. Tilanus-Linthorst M, Verhoog L, Obdeijn IM, et al. A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. *Int J*



Cancer 2002;102:91-95. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12353239>.

267. van Gils CH, Otten JD, Verbeek AL, et al. Effect of mammographic breast density on breast cancer screening performance: a study in Nijmegen, The Netherlands. J Epidemiol Community Health 1998;52:267-271. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9616416>.

268. Gilliland FD, Joste N, Stauber PM, et al. Biologic characteristics of interval and screen-detected breast cancers. J Natl Cancer Inst 2000;92:743-749. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/10793111>.

269. Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005;23:8469-8476. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16293877>.

270. Riedl CC, Ponhold L, Flory D, et al. Magnetic resonance imaging of the breast improves detection of invasive cancer, preinvasive cancer, and premalignant lesions during surveillance of women at high risk for breast cancer. Clin Cancer Res 2007;13:6144-6152. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17947480>.

271. Sardanelli F, Podo F, D'Agnolo G, et al. Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results. Radiology 2007;242:698-715. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17244718>.

272. Passaperuma K, Warner E, Causer PA, et al. Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer 2012;107:24-30. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22588560>.

273. Lehman CD, Lee JM, DeMartini WB, et al. Screening MRI in women with a personal history of breast cancer. J Natl Cancer Inst 2016;108. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26744477>.

274. Phi XA, Saadatmand S, De Bock GH, et al. Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis. Br J Cancer 2016;114:631-637. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26908327>.

275. Le-Petross HT, Whitman GJ, Atchley DP, et al. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer. Cancer 2011;117:3900-3907. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21365619>.

276. Goldfrank D, Chuai S, Bernstein JL, et al. Effect of mammography on breast cancer risk in women with mutations in BRCA1 or BRCA2. Cancer Epidemiol Biomarkers Prev 2006;15:2311-2313. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17119064>.

277. Narod SA, Lubinski J, Ghadirian P, et al. Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet Oncol 2006;7:402-406. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16648044>.

278. Pijpe A, Andrieu N, Easton DF, et al. Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ 2012;345:e5660. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22956590>.

279. Ciatto S, Houssami N, Bernardi D, et al. Integration of 3D digital mammography with tomosynthesis for population breast-cancer screening (STORM): a prospective comparison study. Lancet Oncol 2013;14:583-589. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23623721>.

280. Skaane P, Bandos AI, Gullien R, et al. Comparison of digital mammography alone and digital mammography plus tomosynthesis in a population-based screening program. Radiology 2013;267:47-56. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23297332>.

281. Rafferty EA, Park JM, Philpotts LE, et al. Assessing radiologist performance using combined digital mammography and breast



tomosynthesis compared with digital mammography alone: results of a multicenter, multireader trial. *Radiology* 2013;266:104-113. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23169790>.

282. Friedewald SM, Rafferty EA, Conant EF. Breast cancer screening with tomosynthesis and digital mammography-reply. *JAMA* 2014;312:1695-1696. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25335157>.

283. Lourenco AP, Barry-Brooks M, Baird GL, et al. Changes in recall type and patient treatment following implementation of screening digital breast tomosynthesis. *Radiology* 2015;274:337-342. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25247407>.

284. Rose SL, Tidwell AL, Ice MF, et al. A reader study comparing prospective tomosynthesis interpretations with retrospective readings of the corresponding FFDM examinations. *Acad Radiol* 2014;21:1204-1210. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25107868>.

285. Destounis S, Arieno A, Morgan R. Initial experience with combination digital breast tomosynthesis plus full field digital mammography or full field digital mammography alone in the screening environment. *J Clin Imaging Sci* 2014;4:9. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24744966>.

286. Margolies L, Cohen A, Sonnenblick E, et al. Digital breast tomosynthesis changes management in patients seen at a tertiary care breast center. *ISRN Radiol* 2014;2014:658929. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24967297>.

287. Lang K, Andersson I, Rosso A, et al. Performance of one-view breast tomosynthesis as a stand-alone breast cancer screening modality: results from the Malmö Breast Tomosynthesis Screening Trial, a population-based study. *Eur Radiol* 2016;26:184-190. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25929946>.

288. Gilbert FJ, Tucker L, Gillan MG, et al. Accuracy of digital breast tomosynthesis for depicting breast cancer subgroups in a UK retrospective

reading study (TOMMY Trial). *Radiology* 2015;277:697-706. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26176654>.

289. Zuckerman SP, Conant EF, Keller BM, et al. Implementation of synthesized two-dimensional mammography in a population-based digital breast tomosynthesis screening program. *Radiology* 2016;160366. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27467468>.

290. Skaane P, Bandos AI, Eben EB, et al. Two-view digital breast tomosynthesis screening with synthetically reconstructed projection images: comparison with digital breast tomosynthesis with full-field digital mammographic images. *Radiology* 2014;271:655-663. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24484063>.

291. Lowry KP, Lee JM, Kong CY, et al. Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis. *Cancer* 2012;118:2021-2030. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21935911>.

292. Hartmann LC, Lindor NM. The role of risk-reducing surgery in hereditary breast and ovarian cancer. *N Engl J Med* 2016;374:454-468. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26840135>.

293. Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. *Lancet* 2016;387:945-956. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26707054>.

294. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). *Lancet Oncol* 2009;10:327-340. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19282241>.

295. Rosenthal AN, Fraser LSM, Philpott S, et al. Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the United Kingdom Familial Ovarian Cancer Screening Study. *J Clin Oncol*



2017;35:1411-1420. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/28240969>.

296. Skates SJ, Greene MH, Buys SS, et al. Early detection of ovarian cancer using the risk of ovarian cancer algorithm with frequent CA125 testing in women at increased familial risk - combined results from two screening trials. Clin Cancer Res 2017;23:3628-3637. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/28143870>.

297. Canto MI, Harinck F, Hruban RH, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013;62:339-347. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23135763>.

298. Li X, You R, Wang X, et al. Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: a meta-analysis and systematic review. Clin Cancer Res 2016;22:3971-3981. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/26979395>.

299. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340:77-84. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/9887158>.

300. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001;93:1633-1637. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/11698567>.

301. Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001;345:159-164. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/11463009>.

302. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004;22:1055-1062. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/14981104>.

303. van Dijk S, van Roosmalen MS, Otten W, Stalmeier PF. Decision making regarding prophylactic mastectomy: stability of preferences and the impact of anticipated feelings of regret. J Clin Oncol 2008;26:2358-2363. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18467728>.

304. Morrow M, Mehrara B. Prophylactic mastectomy and the timing of breast reconstruction. Br J Surg 2009;96:1-2. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19109821>.

305. Jakub JW, Peled AW, Gray RJ, et al. Oncologic safety of prophylactic nipple-sparing mastectomy in a population with BRCA mutations: a multi-institutional study. JAMA Surg 2018;153:123-129. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/28903167>.

306. Satagopan JM, Boyd J, Kauff ND, et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 2002;8:3776-3781. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12473589>.

307. Finch AP, Lubinski J, Moller P, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 2014;32:1547-1553. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/24567435>.

308. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009;101:80-87. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19141781>.

309. Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008;26:1331-1337. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18268356>.

310. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609-1615. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12023992>.



311. Kemei Y, Kauff ND, Robson ME, et al. Four-year follow-up of outcomes following risk-reducing salpingo-oophorectomy in BRCA mutation carriers [abstract]. J Clin Oncol (Meeting Abstracts) 2005;23(Suppl 16):Abstract 1013. Available at: http://meeting.ascopubs.org/cgi/content/abstract/23/16_suppl/1013.

312. Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999;91:1475-1479. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10469748>.

313. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616-1622. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12023993>.

314. Harmsen MG, Piek MJ, Bulten J, et al. Peritoneal carcinomatosis after risk-reducing surgery in BRCA1/2 mutation carriers. Cancer 2018;124:952-959. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29315498>.

315. Sherman ME, Piedmonte M, Mai PL, et al. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol 2014;32:3275-3283. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25199754>.

316. Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 2005;23:7491-7496. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16234515>.

317. Metcalfe K, Lynch HT, Foulkes WD, et al. Effect of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers. JAMA Oncol 2015;1:306-313. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26181175>.

318. Heemskerk-Gerritsen BA, Seynaeve C, van Asperen CJ, et al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation

carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst 2015;107. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25788320>.

319. Chai X, Domchek S, Kauff N, et al. RE: Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst 2015;107. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26264690>.

320. Kotsopoulos J, Huzarski T, Gronwald J, et al. Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2017;109. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27601060>.

321. Rebbeck TR, Friebel T, Wagner T, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2005;23:7804-7810. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16219936>.

322. Eisen A, Lubinski J, Gronwald J, et al. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst 2008;100:1361-1367. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18812548>.

323. Chlebowski RT, Prentice RL. Menopausal hormone therapy in BRCA1 mutation carriers: uncertainty and caution. J Natl Cancer Inst 2008;100:1341-1343. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18812547>.

324. Garber JE, Hartman AR. Prophylactic oophorectomy and hormone replacement therapy: protection at what price? J Clin Oncol 2004;22:978-980. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14981100>.

325. McAlpine JN, Hanley GE, Woo MM, et al. Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. Am J Obstet Gynecol 2014;210:471.e471-411. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24412119>.



326. Findley AD, Siedhoff MT, Hobbs KA, et al. Short-term effects of salpingectomy during laparoscopic hysterectomy on ovarian reserve: a pilot randomized controlled trial. *Fertil Steril* 2013;100:1704-1708. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23993887>.

327. Daly MB, Drescher CW, Yates MS, et al. Salpingectomy as a means to reduce ovarian cancer risk. *Cancer Prev Res (Phila)* 2015;8:342-348. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25586903>.

328. College of American Pathologists (CAP). Protocol for the Examination of Specimens From Patients With Carcinoma of the Ovary. 2009. Available at: http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2009/Ovary_09protocol.pdf. Accessed March 2011.

329. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. *JAMA* 1999;281:2189-2197. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10376571>.

330. Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. *Lancet* 2013;381:1827-1834. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23639488>.

331. Lippman ME, Cummings SR, Disch DP, et al. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk. *Clin Cancer Res* 2006;12:5242-5247. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16951244>.

332. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. *J Natl Cancer Inst* 2004;96:1751-1761. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15572757>.

333. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. *JAMA* 2006;295:2727-2741. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16754727>.

334. Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. *Cancer Prev Res (Phila)* 2010;3:696-706. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20404000>.

335. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. *J Clin Oncol* 2004;22:2328-2335. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15197194>.

336. Gronwald J, Tung N, Foulkes WD, et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. *Int J Cancer* 2006;118:2281-2284. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16331614>.

337. Narod SA, Brunet JS, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. *Lancet* 2000;356:1876-1881. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11130383>.

338. King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. *JAMA* 2001;286:2251-2256. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11710890>.

339. Ingle JN, Liu M, Wickerham DL, et al. Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. *Cancer Discov* 2013;3:812-825. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23764426>.



340. McLaughlin JR, Risch HA, Lubinski J, et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. *Lancet Oncol* 2007;8:26-34. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17196508>.

341. Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. *Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med* 1998;339:424-428. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9700175>.

342. Iodice S, Barile M, Rotmensz N, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. *Eur J Cancer* 2010;46:2275-2284. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20537530>.

343. Moorman PG, Havrilesky LJ, Gierisch JM, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. *J Clin Oncol* 2013;31:4188-4198. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24145348>.

344. Narod SA, Dube MP, Klijn J, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. *J Natl Cancer Inst* 2002;94:1773-1779. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12464649>.

345. Haile RW, Thomas DC, McGuire V, et al. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. *Cancer Epidemiol Biomarkers Prev* 2006;15:1863-1870. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17021353>.

346. Lee E, Ma H, McKean-Cowdin R, et al. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study. *Cancer Epidemiol Biomarkers Prev* 2008;17:3170-3178. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18990759>.

347. Milne RL, Knight JA, John EM, et al. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and

BRCA2 mutations. *Cancer Epidemiol Biomarkers Prev* 2005;14:350-356. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15734957>.

348. Offit K, Kohut K, Clagett B, et al. Cancer genetic testing and assisted reproduction. *J Clin Oncol* 2006;24:4775-4782. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16840542>.

349. Offit K, Sagi M, Hurley K. Preimplantation genetic diagnosis for cancer syndromes: a new challenge for preventive medicine. *JAMA* 2006;296:2727-2730. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17164459>.

350. Sawyer SL, Tian L, Kahkonen M, et al. Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. *Cancer Discov* 2015;5:135-142. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25472942>.

351. Menon U, Harper J, Sharma A, et al. Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer. *Hum Reprod* 2007;22:1573-1577. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17428877>.

352. Quinn G, Vadaparampil S, Wilson C, et al. Attitudes of high-risk women toward preimplantation genetic diagnosis. *Fertil Steril* 2009;91:2361-2368. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18440521>.

353. Vadaparampil ST, Quinn GP, Knapp C, et al. Factors associated with preimplantation genetic diagnosis acceptance among women concerned about hereditary breast and ovarian cancer. *Genet Med* 2009;11:757-765. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19710615>.

354. Quinn GP, Vadaparampil ST, Miree CA, et al. High risk men's perceptions of pre-implantation genetic diagnosis for hereditary breast and ovarian cancer. *Hum Reprod* 2010;25:2543-2550. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20713415>.

355. Quinn GP, Vadaparampil ST, King LM, et al. Conflict between values and technology: perceptions of preimplantation genetic diagnosis among women at increased risk for hereditary breast and ovarian cancer. *Fam*



Cancer 2009;8:441-449. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19554475>.

356. Jasper MJ, Liebelt J, Hussey ND. Preimplantation genetic diagnosis for BRCA1 exon 13 duplication mutation using linked polymorphic markers resulting in a live birth. Prenat Diagn 2008;28:292-298. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18302307>.

357. Sagi M, Weinberg N, Eilat A, et al. Preimplantation genetic diagnosis for BRCA1/2--a novel clinical experience. Prenat Diagn 2009;29:508-513.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19248143>.

358. Sidransky D, Tokino T, Helzlsouer K, et al. Inherited p53 gene mutations in breast cancer. Cancer Res 1992;52:2984-2986. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/1581912>.

359. Gonzalez KD, Noltner KA, Buzin CH, et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 2009;27:1250-1256. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19204208>.

360. Laloo F, Varley J, Ellis D, et al. Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet 2003;361:1101-1102. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12672316>.

361. Masciari S, Dewanwala A, Stoffel EM, et al. Gastric cancer in individuals with Li-Fraumeni syndrome. Genet Med 2011;13:651-657.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21552135>.

362. Lane DP. Cancer. p53, guardian of the genome. Nature 1992;358:15-16. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1614522>.

363. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/9039259>.

364. Garber JE, Goldstein AM, Kantor AF, et al. Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res 1991;51:6094-6097.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1933872>.

365. Nichols KE, Malkin D, Garber JE, et al. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 2001;10:83-87. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/11219776>.

366. Siddiqui R, Onel K, Facio F, et al. The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li-Fraumeni-like kindreds. Fam Cancer 2005;4:177-181. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15951970>.

367. Mai PL, Best AF, Peters JA, et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer 2016;122:3673-3681. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/27496084>.

368. Birch JM, Hartley AL, Tricker KJ, et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 1994;54:1298-1304. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/8118819>.

369. Krutikova V, Trkova M, Fleitz J, et al. Identification of five new families strengthens the link between childhood choroid plexus carcinoma and germline TP53 mutations. Eur J Cancer 2005;41:1597-1603. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15925506>.

370. Li FP, Fraumeni JF, Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969;71:747-752.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/5360287>.

371. Li FP, Fraumeni JF, Jr., Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988;48:5358-5362. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/3409256>.

372. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.



Science 1990;250:1233-1238. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/1978757>.

373. Varley JM, Evans DG, Birch JM. Li-Fraumeni syndrome--a molecular and clinical review. Br J Cancer 1997;76:1-14. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/9218725>.

374. Holmfeldt L, Wei L, Diaz-Flores E, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013;45:242-252. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23334668>.

375. Kamihara J, Rana HQ, Garber JE. Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome. Hum Mutat 2014;35:654-662. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24706533>.

376. Curiel-Lewandrowski C, Speetzen LS, Cranmer L, et al. Multiple primary cutaneous melanomas in Li-Fraumeni syndrome. Arch Dermatol 2011;147:248-250. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/21339461>.

377. Giavedoni P, Ririe M, Carrera C, et al. Familial melanoma associated with Li-Fraumeni Syndrome and Atypical Mole Syndrome: total-body digital photography, dermoscopy and confocal microscopy. Acta Derm Venereol 2017;97:720-723. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/28218344>.

378. Melhem-Bertrandt A, Bojadzieva J, Ready KJ, et al. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer 2011;118:908-913. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/21761402>.

379. Wilson JR, Bateman AC, Hanson H, et al. A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. J Med Genet 2010;47:771-774. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/20805372>.

380. Hisada M, Garber JE, Fung CY, et al. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998;90:606-611. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9554443>.

381. Lustbader ED, Williams WR, Bondy ML, et al. Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients. Am J Hum Genet 1992;51:344-356. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/1642235>.

382. Birch JM, Blair V, Kelsey AM, et al. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene 1998;17:1061-1068. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/9764816>.

383. Chompret A. The Li-Fraumeni syndrome. Biochimie 2002;84:75-82. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11900879>.

384. Chompret A, Abel A, Stoppa-Lyonnet D, et al. Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet 2001;38:43-47. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/11332399>.

385. Eeles RA. Germline mutations in the TP53 gene. Cancer Surv 1995;25:101-124. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/8718514>.

386. Bougeard G, Sesboue R, Baert-Desurmont S, et al. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet 2008;45:535-538. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/18511570>.

387. Bougeard G, Renaux-Petel M, Flaman JM, et al. Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol 2015;33:2345-2352. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/26014290>.

388. Tinat J, Bougeard G, Baert-Desurmont S, et al. 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 2009;27:e108-109; author reply e110. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/19652052>.

389. Ginsburg OM, Akbari MR, Aziz Z, et al. The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30.



Fam Cancer 2009;8:563-567. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/19714488>.

390. Lalloo F, Varley J, Moran A, et al. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer 2006;42:1143-1150. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/16644204>.

391. Lee DS, Yoon SY, Looi LM, et al. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients. Breast Cancer Res 2012;14:R66. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/22507745>.

392. Mouchawar J, Korch C, Byers T, et al. Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study. Cancer Res 2010;70:4795-4800. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/20501846>.

393. McCuaig JM, Armel SR, Novokmet A, et al. Routine TP53 testing for breast cancer under age 30: ready for prime time? Fam Cancer 2012;11:607-613. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/22851211>.

394. Leroy B, Anderson M, Soussi T. TP53 mutations in human cancer: database reassessment and prospects for the next decade. Hum Mutat 2014;35:672-688. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/24665023>.

395. Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature 2013;502:333-339. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24132290>.

396. Mai PL, Khincha PP, Loud JT, et al. Prevalence of cancer at baseline screening in the National Cancer Institute Li-Fraumeni syndrome cohort. JAMA Oncol 2017;3:1640-1645. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/28772286>.

397. Kratz CP, Achatz MI, Brugieres L, et al. Cancer screening recommendations for individuals with Li-Fraumeni Syndrome. Clin Cancer Res 2017;23:e38-e45. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/28572266>.

398. Greer MC, Voss SD, States LJ. Pediatric cancer predisposition imaging: focus on whole-body MRI. Clin Cancer Res 2017;23:e6-e13. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28572262>.

399. Ballinger ML, Best A, Mai PL, et al. Baseline surveillance in Li-Fraumeni syndrome using whole-body magnetic resonance imaging: a meta-analysis. JAMA Oncol 2017;3:1634-1639. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/28772291>.

400. Villani A, Tabori U, Schiffman J, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol 2011;12:559-567. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21601526>.

401. Villani A, Shore A, Wasserman JD, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol 2016;17:1295-1305. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/27501770>.

402. Asdahl PH, Ojha RP, Hasle H. Cancer screening in Li-Fraumeni Syndrome. JAMA Oncol 2017;3:1645-1646. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/28772307>.

403. Avigad S, Peleg D, Barel D, et al. Prenatal diagnosis in Li-Fraumeni syndrome. J Pediatr Hematol Oncol 2004;26:541-545. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/15342977>.

404. Prochazkova K, Foretova L, Sedlacek Z. A rare tumor and an ethical dilemma in a family with a germline TP53 mutation. Cancer Genet Cytogenet 2008;180:65-69. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/18068537>.



405. Orloff MS, Eng C. Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome. *Oncogene* 2008;27:5387-5397. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18794875>.
406. Eng C. PTEN hamartoma tumor syndrome (PTHS). *GeneReviews*; 2009. Available at: <http://www.ncbi.nlm.nih.gov/books/NBK1488/>.
407. Pilarski R, Stephens JA, Noss R, et al. Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features. *J Med Genet* 2011;48:505-512. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21659347>.
408. Varga EA, Pastore M, Prior T, et al. The prevalence of PTEN mutations in a clinical pediatric cohort with autism spectrum disorders, developmental delay, and macrocephaly. *Genet Med* 2009;11:111-117. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19265751>.
409. Hobert JA, Eng C. PTEN hamartoma tumor syndrome: an overview. *Genet Med* 2009;11:687-694. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19668082>.
410. Nelen MR, Kremer H, Konings IB, et al. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. *Eur J Hum Genet* 1999;7:267-273. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10234502>.
411. Pilarski R, Eng C. Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. *J Med Genet* 2004;41:323-326. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15121767>.
412. Bennett KL, Mester J, Eng C. Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome. *JAMA* 2010;304:2724-2731. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21177507>.
413. Starink TM, van der Veen JP, Arwert F, et al. The Cowden syndrome: a clinical and genetic study in 21 patients. *Clin Genet* 1986;29:222-233. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/3698331>.
414. Brownstein MH, Wolf M, Bikowski JB. Cowden's disease: a cutaneous marker of breast cancer. *Cancer* 1978;41:2393-2398. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/657103>.
415. Pilarski R, Burt R, Kohlman W, et al. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. *J Natl Cancer Inst* 2013;105:1607-1616. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24136893>.
416. Bubien V, Bonnet F, Brouste V, et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. *J Med Genet* 2013;50:255-263. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23335809>.
417. Riegert-Johnson DL, Gleeson FC, Roberts M, et al. Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients. *Hered Cancer Clin Pract* 2010;8:6. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20565722>.
418. Tan MH, Mester JL, Ngeow J, et al. Lifetime cancer risks in individuals with germline PTEN mutations. *Clin Cancer Res* 2012;18:400-407. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22252256>.
419. Tan MH, Mester J, Peterson C, et al. A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. *Am J Hum Genet* 2011;88:42-56. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21194675>.
420. Zbuk KM, Eng C. Hamartomatous polyposis syndromes. *Nat Clin Pract Gastroenterol Hepatol* 2007;4:492-502. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17768394>.
421. Hansen-Kiss E, Beinkampen S, Adler B, et al. A retrospective chart review of the features of PTEN hamartoma tumour syndrome in children. *J Med Genet* 2017;54:471-478. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28526761>.



422. Roche AF, Mukherjee D, Guo SM, Moore WM. Head circumference reference data: birth to 18 years. *Pediatrics* 1987;79:706-712. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/3575026>.

423. Zhou XP, Waite KA, Pilarski R, et al. Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositide-3-kinase/Akt pathway. *Am J Hum Genet* 2003;73:404-411. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12844284>.

424. Zhou XP, Marsh DJ, Morrison CD, et al. Germline inactivation of PTEN and dysregulation of the phosphoinositide-3-kinase/Akt pathway cause human Lhermitte-Duclos disease in adults. *Am J Hum Genet* 2003;73:1191-1198. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14566704>.

425. Andres RH, Guzman R, Weis J, et al. Lhermitte-Duclos disease with atypical vascularization--case report and review of the literature. *Clin Neuropathol* 2009;28:83-90. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19353838>.

426. Butler MG, Dasouki MJ, Zhou XP, et al. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. *J Med Genet* 2005;42:318-321. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15805158>.

427. Herman GE, Butter E, Enrile B, et al. Increasing knowledge of PTEN germline mutations: Two additional patients with autism and macrocephaly. *Am J Med Genet A* 2007;143:589-593. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17286265>.

428. Herman GE, Henninger N, Ratliff-Schaub K, et al. Genetic testing in autism: how much is enough? *Genet Med* 2007;9:268-274. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17505203>.

429. Orrico A, Galli L, Buoni S, et al. Novel PTEN mutations in neurodevelopmental disorders and macrocephaly. *Clin Genet*

2009;75:195-198. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18759867>.

430. Black D, Bogomolny F, Robson ME, et al. Evaluation of germline PTEN mutations in endometrial cancer patients. *Gynecol Oncol* 2005;96:21-24. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15589575>.

431. Nelen MR, Padberg GW, Peeters EA, et al. Localization of the gene for Cowden disease to chromosome 10q22-23. *Nat Genet* 1996;13:114-116. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8673088>.

432. Schaffer JV, Kamino H, Witkiewicz A, et al. Mucocutaneous neuromas: an underrecognized manifestation of PTEN hamartoma-tumor syndrome. *Arch Dermatol* 2006;142:625-632. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16702501>.

433. Brownstein MH, Mehregan AH, Bikowski JB, et al. The dermatopathology of Cowden's syndrome. *Br J Dermatol* 1979;100:667-673. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/465314>.

434. Brownstein MH, Mehregan AH, Bilowski JB. Trichilemmomas in Cowden's disease. *JAMA* 1977;238:26. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/577252>.

435. Heald B, Mester J, Rybicki L, et al. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. *Gastroenterology* 2010;139:1927-1933. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20600018>.

436. Stanich PP, Owens VL, Sweetser S, et al. Colonic polyposis and neoplasia in Cowden syndrome. *Mayo Clin Proc* 2011;86:489-492. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21628613>.

437. Stanich PP, Pilarski R, Rock J, et al. Colonic manifestations of PTEN hamartoma tumor syndrome: case series and systematic review. *World J Gastroenterol* 2014;20:1833-1838. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24587660>.



438. Al-Thihli K, Palma L, Marcus V, et al. A case of Cowden's syndrome presenting with gastric carcinomas and gastrointestinal polyposis. *Nat Clin Pract Gastroenterol Hepatol* 2009;6:184-189. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19190598>.

439. Nieuwenhuis MH, Kets CM, Murphy-Ryan M, et al. Cancer risk and genotype-phenotype correlations in PTEN hamartoma tumor syndrome. *Fam Cancer* 2014;13:57-63. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23934601>.

440. Gorlin RJ, Cohen MM, Jr., Condon LM, Burke BA. Bannayan-Riley-Ruvalcaba syndrome. *Am J Med Genet* 1992;44:307-314. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1336932>.

441. Marsh DJ, Coulon V, Lunetta KL, et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. *Hum Mol Genet* 1998;7:507-515. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9467011>.

442. Eng C. Will the real Cowden syndrome please stand up: revised diagnostic criteria. *J Med Genet* 2000;37:828-830. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11073535>.

443. Bayley JP. Succinate dehydrogenase gene variants and their role in Cowden syndrome. *Am J Hum Genet* 2011;88:674-675; author reply 676. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21565294>.

444. SEER Stat Fact Sheets: Thyroid Cancer. 2015. Available at: <http://seer.cancer.gov/statfacts/html/thyro.html>. Accessed May 28, 2015.

445. Apostolou P, Fostira F. Hereditary breast cancer: the era of new susceptibility genes. *Biomed Res Int* 2013;2013:747318. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23586058>.

446. Marabelli M, Cheng SC, Parmigiani G. Penetrance of ATM gene mutations in breast cancer: a meta-analysis of different measures of risk. *Genet Epidemiol* 2016;40:425-431. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27112364>.

447. Easton DF, Pharoah PD, Antoniou AC, et al. Gene-panel sequencing and the prediction of breast-cancer risk. *N Engl J Med* 2015;372:2243-2257. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26014596>.

448. Lu HM, Li S, Black MH, et al. Association of breast and ovarian cancers with predisposition genes identified by large-scale sequencing. *JAMA Oncol* 2018. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30128536>.

449. Broeks A, Urbanus JH, Floore AN, et al. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. *Am J Hum Genet* 2000;66:494-500. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10677309>.

450. van Os NJ, Roeleveld N, Weemaes CM, et al. Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline. *Clin Genet* 2016;90:105-117. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26662178>.

451. Southey MC, Goldgar DE, Winqvist R, et al. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. *J Med Genet* 2016;53:800-811. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27595995>.

452. Goldgar DE, Healey S, Dowty JG, et al. Rare variants in the ATM gene and risk of breast cancer. *Breast Cancer Res* 2011;13:R73. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21787400>.

453. Bernstein JL, Haile RW, Stovall M, et al. Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study. *J Natl Cancer Inst* 2010;102:475-483. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20305132>.

454. Grant RC, Selander I, Connor AA, et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. *Gastroenterology* 2015;148:556-564. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25479140>.



455. Pilie PG, Johnson AM, Hanson KL, et al. Germline genetic variants in men with prostate cancer and one or more additional cancers. *Cancer* 2017;123:3925-3932. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28657667>.

456. Ramus SJ, Song H, Dicks E, et al. Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer. *J Natl Cancer Inst* 2015;107. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26315354>.

457. Rafnar T, Gudbjartsson DF, Sulem P, et al. Mutations in BRIP1 confer high risk of ovarian cancer. *Nat Genet* 2011;43:1104-1107. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21964575>.

458. Fleming GF, Seidman J, Lengyel E. Epithelial ovarian cancer. In: Barakat RR, Markman M, Randall ME, eds. *Principles and Practice of Gynecologic Oncology*, 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2013:757-847.

459. Easton DF, Lesueur F, Decker B, et al. No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing. *J Med Genet* 2016;53:298-309. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26921362>.

460. Kaurah P, MacMillan A, Boyd N, et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. *JAMA* 2007;297:2360-2372. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17545690>.

461. Pharoah PD, Guilford P, Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. *Gastroenterology* 2001;121:1348-1353. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11729114>.

462. Friedrichsen DM, Malone KE, Doody DR, et al. Frequency of CHEK2 mutations in a population based, case-control study of breast cancer in young women. *Breast Cancer Res* 2004;6:R629-635. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15535844>.

463. Iniesta MD, Gorin MA, Chien LC, et al. Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America. *Cancer Genet Cytogenet* 2010;202:136-140. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20875877>.

464. Kuusisto KM, Bebel A, Vihinen M, et al. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. *Breast Cancer Res* 2011;13:R20. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21356067>.

465. Cybulski C, Wokolorczyk D, Jakubowska A, et al. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. *J Clin Oncol* 2011;29:3747-3752. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21876083>.

466. Weischer M, Bojesen SE, Ellervik C, et al. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. *J Clin Oncol* 2008;26:542-548. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18172190>.

467. Naslund-Koch C, Nordestgaard BG, Bojesen SE. Increased risk for other cancers in addition to breast cancer for CHEK2*1100delC heterozygotes estimated from the Copenhagen General Population Study. *J Clin Oncol* 2016;34:1208-1216. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26884562>.

468. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. *Am J Hum Genet* 2004;74:1175-1182. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/15122511>.

469. Schmidt MK, Hogervorst F, van Hien R, et al. Age- and tumor subtype-specific breast cancer risk estimates for CHEK2*1100delC carriers. *J Clin Oncol* 2016;34:2750-2760. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27269948>.

470. Han FF, Guo CL, Liu LH. The effect of CHEK2 variant I157T on cancer susceptibility: evidence from a meta-analysis. *DNA Cell Biol*



2013;32:329-335. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23713947>.

471. Bonadona V, Bonaiti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. *JAMA* 2011;305:2304-2310. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21642682>.

472. Kohlmann W, Gruber S. Lynch Syndrome. GeneReviews at GeneTests: Medical Genetics Information Resource 2014. Available at:

<http://www.ncbi.nlm.nih.gov/books/NBK1211/>.

473. Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. *JAMA* 2006;296:1507-1517. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17003399>.

474. Watson P, Vasen HF, Mecklin JP, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. *Int J Cancer* 2008;123:444-449. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18398828>.

475. Chen LM, Yang KY, Little SE, et al. Gynecologic cancer prevention in Lynch syndrome/hereditary nonpolyposis colorectal cancer families. *Obstet Gynecol* 2007;110:18-25. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17601891>.

476. Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. *N Engl J Med* 2006;354:261-269. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16421367>.

477. Stuckless S, Green J, Dawson L, et al. Impact of gynecological screening in Lynch syndrome carriers with an MSH2 mutation. *Clin Genet* 2013;83:359-364. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22775459>.

478. Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer

syndromes. *Am J Gastroenterol* 2015;110:223-262; quiz 263. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/25645574>.

479. Stoffel EM, Mangu PB, Gruber SB, et al. Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. *J Clin Oncol* 2015;33:209-217. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/25452455>.

480. Auranen A, Joutsiniemi T. A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families. *Acta Obstet Gynecol Scand* 2011;90:437-444. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21306348>.

481. Jarvinen HJ, Renkonen-Sinisalo L, Aktan-Collan K, et al. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. *J Clin Oncol* 2009;27:4793-4797. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19720893>.

482. Renkonen-Sinisalo L, Butzow R, Leminen A, et al. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. *Int J Cancer* 2007;120:821-824. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17096354>.

483. Rijcken FE, Mourits MJ, Kleibeuker JH, et al. Gynecologic screening in hereditary nonpolyposis colorectal cancer. *Gynecol Oncol* 2003;91:74-80. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14529665>.

484. Dove-Edwin I, Boks D, Goff S, et al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. *Cancer* 2002;94:1708-1712. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/11920532>.

485. Harkness EF, Barrow E, Newton K, et al. Lynch syndrome caused by MLH1 mutations is associated with an increased risk of breast cancer: a



cohort study. J Med Genet 2015;52:553-556. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/26101330>.

486. Goldberg M, Bell K, Aronson M, et al. Association between the Lynch syndrome gene MSH2 and breast cancer susceptibility in a Canadian familial cancer registry. J Med Genet 2017;54:742-746. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/28779004>.

487. Bogdanova N, Feshchenko S, Schurmann P, et al. Nijmegen Breakage Syndrome mutations and risk of breast cancer. Int J Cancer 2008;122:802-806. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/17957789>.

488. Zhang B, Beeghly-Fadiel A, Long J, Zheng W. Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Lancet Oncol 2011;12:477-488. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21514219>.

489. Steffen J, Nowakowska D, Niwinska A, et al. Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland. Int J Cancer 2006;119:472-475. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16770759>.

490. Zhang G, Zeng Y, Liu Z, Wei W. Significant association between Nijmegen breakage syndrome 1 657del5 polymorphism and breast cancer risk. Tumour Biol 2013;34:2753-2757. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/23765759>.

491. Uusitalo E, Rantanen M, Kallionpaa RA, et al. Distinctive cancer associations in patients with neurofibromatosis type 1. J Clin Oncol 2016;34:1978-1986. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/26926675>.

492. Rosenfeld A, Listernick R, Charrow J, Goldman S. Neurofibromatosis type 1 and high-grade tumors of the central nervous system. Childs Nerv Syst 2010;26:663-667. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/19937438>.

493. Nishida T, Tsujimoto M, Takahashi T, et al. Gastrointestinal stromal tumors in Japanese patients with neurofibromatosis type I. J Gastroenterol 2016;51:571-578. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/26511941>.

494. Walker L, Thompson D, Easton D, et al. A prospective study of neurofibromatosis type 1 cancer incidence in the UK. Br J Cancer 2006;95:233-238. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/16786042>.

495. Sharif S, Moran A, Huson SM, et al. Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. J Med Genet 2007;44:481-484. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17369502>.

496. Evans DG. Are we ready for targeted early breast cancer detection strategies in women with NF1 aged 30-49 years? Am J Med Genet A 2012;158a:3054-3055. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/22987630>.

497. Seminog OO, Goldacre MJ. Age-specific risk of breast cancer in women with neurofibromatosis type 1. Br J Cancer 2015;112:1546-1548. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25742481>.

498. Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 2007;44:81-88. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/17105749>.

499. Thompson ER, Rowley SM, Li N, et al. Panel testing for familial breast cancer: calibrating the tension between research and clinical care. J Clin Oncol 2016;34:1455-1459. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/26786923>.

500. Casadei S, Norquist BM, Walsh T, et al. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res 2011;71:2222-2229. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/21285249>.



501. Cybulski C, Kluzniak W, Huzarski T, et al. Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. *Lancet Oncol* 2015;16:638-644. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25959805>.

502. Antoniou AC, Casadei S, Heikkinen T, et al. Breast-cancer risk in families with mutations in PALB2. *N Engl J Med* 2014;371:497-506. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25099575>.

503. Kanchi KL, Johnson KJ, Lu C, et al. Integrated analysis of germline and somatic variants in ovarian cancer. *Nat Commun* 2014;5:3156. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24448499>.

504. Tischkowitz M, Xia B. PALB2/FANCN: recombining cancer and Fanconi anemia. *Cancer Res* 2010;70:7353-7359. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20858716>.

505. Loveday C, Turnbull C, Ruark E, et al. Germline RAD51C mutations confer susceptibility to ovarian cancer. *Nat Genet* 2012;44:475-476; author reply 476. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22538716>.

506. Loveday C, Turnbull C, Ramsay E, et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. *Nat Genet* 2011;43:879-882. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21822267>.

507. Song H, Dicks E, Ramus SJ, et al. Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population. *J Clin Oncol* 2015;33:2901-2907. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26261251>.

508. Hearle N, Schumacher V, Menko FH, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. *Clin Cancer Res* 2006;12:3209-3215. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16707622>.